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Summary of Thesis 
Obese adults have a lower risk of hip and vertebral fracture, but a greater risk of lower 
limb and proximal humerus fracture, compared to adults with a normal body mass index 
(BMI). Differences in fracture risk by skeletal site in obesity might be attributed to 
differences in bone mineral density (BMD), bone microstructure and bone strength 
between obese and normal BMI individuals and/or differences in physical function, 
possibly related to fall frequency and/or direction. The role of vitamin D in bone 
metabolism and physical function in obesity is unclear. The effect of obesity on bone 
microstructure and strength in young and older, men and women, has not been 
investigated in a matched case control design. 
 
BMD, microstructure and strength were determined using novel imaging technologies. 
The roles of various adipose compartments and biochemical factors on BMD and 
microarchitecture were investigated. Physical function and vitamin D metabolism of 
obese and normal BMI individuals was compared. 
 
Younger and older obese adults have higher BMD, favourable microstructure and greater 
bone strength, but there is a greater difference in BMD and microstructure between 
obese and normal BMI in older adults than in younger adults. Obese adults have greater 
bone strength than normal BMI adults, regardless of age. Higher BMD in obesity is 
associated with lower resorption, possibly mediated by circulating leptin and oestradiol 
which were, in turn, associated with subcutaneous abdominal adiposity. Obese adults 
have greater muscle mass but poorer physical performance than normal BMI adults. This 
might be associated with greater fall frequency and affect fall direction. Obese adults 
have lower total and free 25OHD and 1,25(OH)2D than normal BMI adults, likely due to 
greater volumetric dilution. Low 25OHD in obesity does not appear to affect BMD, 
microstructure or strength, or physical performance.   
 
Despite greater BMD and bone strength, obese individuals are at greater risk of some 
fractures. This might be due to the effect of poor physical function on fall characteristics 
in obesity.  
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CHAPTER 1: Introduction 
Background 
Fracture 
A fracture is a break in the bone, which occurs when the stress applied to bone results 
in a strain greater than the bone’s capacity to dissipate such energy. This can be a result 
of non-physiological loads applied to normal bone, or of physiological loads applied to 
abnormal bone, such as in tumour or metabolic bone disease states. Fractures are a 
significant economic burden and are associated with morbidity, poor physical function, 
poorer quality of life and greater risk of mortality (1-4). First fracture has been shown to 
be a risk factor for subsequent fracture (5). The identification of novel targets to improve 
bone health, prevent falls and ultimately prevent fractures is likely to have significant 
consequences at both individual and societal levels.  
 
Function of the Skeleton  
The skeleton is a multifunctional organ that provides the body with strucutral support, 
enables movement, protects internal organs, produces blood cells and facilitates the 
storage and release of minerals to maintain calcium homeostasis. The skeleton can be 
divided into two sub-skeletons; axial and appendicular. The axial skeleton consists of the 
skull, spinal column, sacrum, ribs and sternum, whilst the appendicular skeleton consists 
of the bones of the limbs and pelvic and pectoral girdles.  
 
Bone Physiology 
Bone is composed of mineral, collagen, non-collagenous proteins; including binding 
proteins and glycoproteins such as osteocalcin (OC), osteopontin, osteonectin and bone-
sialoprotein, growth factors, glycosaminoglycans, phospholipids and water (6). 
Approximately 90% of bone matrix is collagenous (type I collagen). The mineral 
component of bone is formed from calcium and phosphate deposited as calcium-
phosphate salts, which undergo mineralisation to hydroxyapatite [Ca10(PO4)6(OH)2].  
 
Bone is a highly active tissue and contains multiple cell types. Bone lining cells cover the 
surface of the bone and control the removal of calcium from bone and protect bone from 
external chemical influences. Osteoclasts resorb the bone matrix, while osteoblasts 
produce bone matrix and control osteoclastogenesis. Osteocytes, the most abundant 
bone cells, control bone formation and resorption to govern the skeletal response to 
mechanical forces. These cells communicate directly and also indirectly, through 
signalling mechanisms (6).  
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Bone is formed of two compartments; cortical and trabecular bone (Figure 1). Cortical 
bone makes up approximately 80% of the total body bone content and is found in the 
diaphyses of the long bones and surrounds the trabecular bone. Trabecular bone is 
found in the vertebrae, pelvis and metaphyses of the long bones.  
 
 
Figure 1: Cortical and trabecular compartments of bone 
 
 
Bone Modelling and Acquisition 
Bone modelling is responsible for changes in the shape and size of the bone, such as 
those observed during growth or adaptative responses to a change in mechanical 
loading patterns (7). Increased loading forces cause bone to deform as a result of 
increased strain within the bone tissue. Skeletal response to increased loading depends 
on the frequency, magnitude, rate and duration of these resulting strains, compared to 
the baseline loading condition.  During modeling, bone resorption ocurrs without any 
associated formation at the site of resorption. For example, periosteal apposition 
accompanied by endocortical resorption can occur to increase bone size without an 
increase in cortical thickness, thus adapting the bone to increased loading forces, without 
increasing bone mass.  
 
Young bone has been shown to be more capable of structural adaptations in response 
to mechanical loading than bone in older age (8). Peak bone mass is the amount of bone 
present at the end of skeletal maturation and is typically acquired by 25 to 30 years of 
age (9). Attainment of peak bone mass is predominantly genetically determined, however 
nutrition, physical activity and disease exposure also influence attainment (10). 
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Bone Remodelling and Loss 
Bone remodelling is the process by which bone tissue is continuously renewed in a cycle 
of resorption of old bone and formation of new bone. Bone is remodelled to alter its mass 
or microarchitecture in response to altered mechanical, nutritional and humoral signals 
and to maintain bone strength through the prevention of accumulated micro-damage. 
 
Remodelling takes place within a bone remodelling unit (BRU) which consists of 
osteoclasts, osteoblasts, osteocytes and bone lining cells on trabecular and Haversian 
bone surfaces. In the first phase of bone remodelling, activation, osteoclast precursors 
are activated and stimulate osteoclastogenesis. These osteoclasts resorb bone by 
dissolving bone mineral and breaking down the bone matrix. Osteoclasts remove 
approximately 0.05 mm3 of bone tissue per cycle (11), forming a resorptive cavity in the 
bone and releasing bone matrix components into the bone microenvironment and the 
circulation. This resorption takes approximately one month. In the third stage, reversal, 
osteoblast precursors are activated at the site of the resorption. Finally, over a period of 
approximately five months, osteoblasts fill the resorptive cavity by depositing newly 
synthesized bone matrix. Subsequently, mineralisation of this matrix occurs and a basic 
structural unit (BSU) of new bone is formed. 
 
Due to the greater surface area-to-volume ratio of trabecular bone compared to cortical 
bone, the majority of bone remodelling occurs on the surface of bone in the trabecular 
compartment. In cortical bone, tunnels or cutting cones are formed by osteoclastic 
resorption before closing cones are formed by the osteoblast. The cortical remodelling 
cycle lasts approximately four months, compared to approximately seven months in 
trabecular bone. 
 
After peak bone mass is attained, a very small percentage of bone is lost with each 
remodelling cycle, such that over one year approximately 0.5 to 1% of the total body 
bone mass is lost. Genetic, endocrine, nutritional and disease factors influence the 
amount of bone lost per cycle and may result in states where the osteoblast is 
increasingly unable to refill the resorption pit, resulting in a greater loss of bone per 
remodelling cycle. This resorption-formation imbalance also occurs with increasing age 
and is particularly notable at menopause. Incomplete refilling of cutting cones due to 
increased resorption relative to formation with increasing age, may explain greater 
cortical porosity and greater cortical pore cross sectional area observed with age.  
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Osteoporosis 
Osteoporosis is a deterioration of bone microarchitecture which results in low bone 
density, reduced bone strength, increased fragility and consequently increased risk of 
low-trauma fracture (12, 13). Osteoporosis is associated the ineffective repair of 
microdamage (14). Osteoporosis is defined as a bone mineral density (BMD) T-score at 
least 2.5 SD values below the healthy young adult mean (15). The osteoporotic 
deterioration of bone microarchitecture is illustrated in Figure 2. There are commonly no 
symptoms of osteoporosis until a fracture occurs, often as the result of a fall and so 
osteoporosis is frequently referred to as a ‘silent epidemic’. However, once a fall and/or 
fracture have occurred there is often a significant increase in morbidity, including pain, 
loss of function, physical impairment, fatigue and a decrease in pulmonary function (1, 
2, 16). Physiological implications of osteoporosis are accompanied by the predisposition 
to psychological and social debilitations including anxiety, depression, low self-esteem, 
and an overall reduction in quality of life (1, 12, 16, 17).  
 
 
 
Figure 2: Microarchitecture of normal and osteoporotic bone 
showing decreased bone volume to total volume and the loss of trabecular connectivity in 
osteoporotic bone 
 
Prevalence of Osteoporosis and Osteoporotic Fractures 
It was estimated that ten million Americans over fifty years of age had osteoporosis in 
2004 and the prevalence of osteoporosis is rapidly increasing, partly due to the 
increasing size of the elder population (12). It is currently estimated that worldwide, one 
in three women and one in five men over fifty years of age will sustain an osteoporotic 
fracture during their lifetime (12). The annual incidence of hip fracture worldwide has 
been predicted to reach 8.2 million by 2050 (18). With osteoporotic fractures estimated 
to cost more than $17 billion per year in the US alone, prevention of osteoporotic 
fractures should be a priority (18, 19).  
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Risk Factors for Osteoporosis 
Osteoporosis incidence increases with age and osteoporosis is more common in women 
than men (13). Postmenopausal women are at greater risk of osteoporosis, due to 
increased bone resorption as a result of the depletion of oestrogen. Other risk factors for 
osteoporosis include smoking, high alcohol intake, immobilisation, hypogonadism, 
chronic inflammatory diseases, glucocorticoid treatment, early menopause, family 
history of osteoporosis and low body weight (20).  
 
Relationship Between Body Weight and Osteoporosis 
Low body weight is associated with low BMD (17, 21-23) and bone loss (24) and is an 
established indication for bone densitometry (25, 26). A recent systematic review showed 
that in addition to menopausal status, low body weight, but not other clinical risk factors 
typically associated with osteoporosis in older women, is an important risk factor for low 
BMD in women aged 40 to 60 years (27). Having a Body Mass Index (BMI) below 
25kg/m2 is associated with an increased risk of fracture (17, 21), particularly of hip and 
all osteoporotic fracture, but is protective of lower leg fracture (23, 28-30). Studies 
investigating the effect of anorexia nervosa on BMD have shown a high prevalence of 
osteopenia and osteoporosis in anorexic populations (31, 32), with fracture rates 
significantly greater than in healthy populations (33). However, while low body weight 
may contribute to such skeletal effects, anorexia nervosa is more complex and hormonal 
consequences may also contribute.  
 
Obesity 
Obesity is a physical state resulting from energy imbalance, where the number of calories 
consumed is greater than that expended by physical activity. Obesity is characterised by 
excess body fat and associated with an increased risk of cardiovascular disease, 
hypertension, type 2 diabetes mellitus (T2DM), some cancers, liver and gall bladder 
disease, musculoskeletal conditions, fibromyalgia, unilateral plantar fasciitis and gout 
(34). Metabolic syndrome describes an amalgamation of metabolic abnormalities, 
typically characterised by abdominal obesity, insulin resistance, hyperglycaemia, 
hypertension, dyslipidaemia and hypertriglyceridemia (35). 
 
Social and economic development and urbanisation have increased access to and 
dependence on high fat, energy rich, convenient foods. This has contributed to a 
nutritional transition, with increased consumption of high fat, high sodium, energy dense 
foods and away from traditional high fibre, high protein diets (36). Concurrently, 
technological advances have reduced physical activity demands. In combination, these 
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factors have contributed towards the creation of an obesogenic environment, with 
physiological, physical, psychological and financial consequences, and individual, 
societal and global implications.  
 
The World Health Organisation (WHO) defined overweight as a BMI of 25 to 29.9 kg/m2 
and obesity as a BMI greater than or equal to 30 kg/m2. Global prevalence of obesity has 
rapidly increased and continues to increase (Figure 3) (37).  
 
Figure 3: Prevalence of obesity in 1980 and 2008 
In men (left) and women (right) (37). Reprinted from The Lancet, 377(9765), Finucane MM, et al. 
Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass 
Index), National, regional, and global trends in body-mass index since 1980: systematic analysis of 
health examination surveys and epidemiological studies with 960 country-years and 9.1 million 
participants, 557-567, Copyright (2011), with permission from Elsevier. 
 
The WHO estimates that around 1.2 billion people worldwide are overweight with at least 
300 million of these individuals being obese (38). It is estimated that approximately 25% 
of adults and 15% of children in England are obese (39, 40). Based on current rates and 
trends in the prevalence of overweight and obesity, it has been predicted that 40% of the 
UK population will be obese by 2025 and more than half of the UK adult population will 
be obese by 2050 (39). By this time it is estimated that fewer than 10% of men and 15% 
of women in the UK will be categorised as having a ‘healthy’ BMI (18.5 to 24.9 kg/m2) 
(39). Consequently, the Foresight report estimated that overweight and obesity will cost 
the National Health Service £10 billion per year by 2050 (39).   
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Osteoporosis Prevalence in Obesity 
A recent study reported that 9.4% of obese women attending for routine bone 
densitometry had osteoporosis at the femoral neck (FN) compared to 52.1% of 
underweight individuals and 20.3% of normal weight attendees (41). In the same group 
of women, only 5.9% of obese individuals had a T-score <-2.5 at the lumbar spine (LS) 
compared to 22.8% of underweight individuals and 12% of normal weight individuals 
(41). In the Study of Osteoporotic Fractures (SOF), only 4.6% of obese women who did 
not fracture between baseline and follow up 11 years later were osteoporotic (42). 
Elsewhere, of women with a T-score ≥+2.5 at the LS, FN or total hip (TH), 43.5%, 55.6% 
and 73.1% respectively were obese (43).  
 
In the SOF, of obese women who fractured between baseline and follow up, where BMD 
might be expected to be lower in light of the fracture, the prevalence of osteoporosis by 
FN T-score ≤−2.5 was only 11.7%, whereas 54.4% of non-obese women who fractured 
were osteoporotic (42). Similarly, of individuals presenting to a fracture liaison service in 
the UK, the prevalence of osteoporosis was 13.4% in the obese group compared to 
40.4% in the normal BMI group (44). The use of anti-osteoporosis medication in obese 
women with fracture was found to be significantly lower than the use in non-obese 
women with fracture (4). 
 
Weight Loss, BMD and Bone Microarchitecture 
The existence of a relationship between body mass and BMD is also supported by weight 
loss studies. A large, prospective study of men found that weight loss over three decades 
was associated with lower hip BMD (45). Amongst men in the lowest BMI quartile at 
baseline who lost ≥5% of their body weight, there was a prevalence of osteoporosis of 
31%, while amongst men in the same low BMI quartile at baseline who gained ≥5% of 
their body weight, there was only a 4% prevalence of osteoporosis, demonstrating a 
positive association between body mass and BMD (45). In postmenopausal women, 
body weight was independently associated with both BMD at baseline and the rate of 
BMD change during a ten year follow-up (46). A recent HR-pQCT study of women 
undergoing bariatric surgery showed a significant decrease in total volumetric BMD 
(vBMD) at the tibia at one year post-surgery (47). This was shown to be mostly due to 
decreases in cortical bone, with declines in cortical density and thickness and area, with 
no difference in trabecular vBMD or trabecular microstructural parameters (47). Despite 
the loss of cortical bone, there was no difference in stiffness or the distribution of load 
through the cortical bone (47).   
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Fracture in Obesity 
Given that low BMD is an established risk factor for fracture and that osteoporosis 
appears less prevalent in obesity, lower fracture risk may be expected in obesity. It has 
been reported that for every standard deviation decrease in body weight, the risk of 
incident fracture increases by 19% (48). A meta-analysis of twelve prospective cohorts 
found a BMI of 25 kg/m2 to be the threshold below which the risk of hip and osteoporotic 
fracture was increased (17). Similar conclusions were reached in the SOF at a BMI of 26 
kg/m2 (48). 
 
However, in the Global Longitudinal Study of Osteoporosis in Women (GLOW study), 
fracture prevalence in obese women at baseline was 222 per 1000 compared with a 
similar 227 per 1000 in non-obese women (49). At two year follow up, fracture incidence 
was 61.7 per 1000, again similar to the rate of 66.0 per 1000 in non-obese women (49). 
In the MrOS cohort, after adjustment for BMD and compared to the risk of non-vertebral 
fracture in men with a normal BMI, mild obesity (BMI 30 to 34.9 kg/m2) was associated 
with a hazard ratio of 1.29 and moderate obesity (BMI 35 to 39.9 kg/m2) associated with 
a hazard ratio of 1.94 (30). In a study investigating the prevalence of obesity in 
postmenopausal women presenting with low-trauma fracture to a fracture liaison service, 
an unexpectedly high proportion of obese attendees was observed (50). Recently, data 
collected over 5.5 years from a fracture liaison service in the UK showed that 30% of 
individuals with a low trauma or osteoporotic fracture were obese (44). Overall these 
general findings are conflicting, but indicate that obesity is perhaps less protective 
against fracture as might have been expected given the seemingly positive associations 
between obesity and BMD. 
 
Associations between obesity and fracture risk appear to be site-dependent; protective 
at some sites but a risk factor at other sites, which may help to make sense of the 
conflicting reports of incident fracture described above. High BMI appears protective 
against fractures in the axial skeleton, with obesity widely shown to be protective against 
hip and vertebral fracture (29, 51-56). Just 9% of all postmenopausal hip fractures 
occurred in obese women in the UK Million Women Study, although the percentage of 
obese women in the cohort is unclear (53). A recent meta-analysis found just 19% of 
osteoporotic fractures and 13% of hip fractures occurred in obese women (55). Obesity 
also appears protective against wrist fracture (49, 54). Even with a lower whole body, hip 
and distal forearm BMD, men with abdominal obesity and metabolic syndrome had a 
lower incidence of vertebral and peripheral fragility fractures than men without metabolic 
syndrome (57). 
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However, despite the lower prevalence of osteoporosis in obese populations and 
protective effects against fracture in the axial skeleton, obesity may increase the risk of 
fracture at peripheral sites including the proximal humerus (23, 29, 55, 58) and lower 
limb (23, 52, 55). Specifically, obese individuals appear to have a greater risk of 
displaced ankle fractures and of Weber C fracture (above the level of the ankle joint) 
than Weber A or B ankle fractures (below or at the level of the ankle joint) (59, 60). Others 
have reported no association between BMI and the risk of ankle or wrist fracture (58) 
and that weight may be more strongly associated with ankle fracture in obesity than BMI 
or height (51). 
 
Whether obesity is protective or a risk factor for fracture at some fracture sites is yet to 
be determined, with inconsistent reports at the forearm (52, 57, 58, 61-63) for example. 
While some have reported increased risk of rib fracture in obesity, the difficulty in 
confirming the presence of rib fracture and controlling for environmental factors 
commonly associated with rib fracture (e.g. alcohol intake) may raise questions over 
whether this is a true effect of adiposity on fracture risk (51, 54). 
 
The extent of adiposity may affect fracture risk at certain sites, with some having reported 
lower fracture risk in overweight versus normal weight or obese groups (23). Fracture 
risk in obesity may also differ by gender, with obese men having been reported as at a 
greater risk of fracture than non-obese men (64). 
 
As BMI is factored into the FRAX® tool, when used with or without BMD, there is a lower 
predicted risk of hip and major osteoporotic fracture in obese women compared to non-
obese women (65). However, for predicting both hip and major osteoporotic fracture, 
sensitivity is lower but specificity higher in obese women compared with non-obese 
women (65). Compared to observed incident fracture data from the SOF, FRAX models 
appeared most valuable for predicting hip fracture in obese women at greatest risk of 
fracture (predicted values between 4 and 10%). For major osteoporotic fracture, FRAX 
generated predicted counts were more similar to the observed fracture counts at all 
predicted risk levels, but especially between 10 and 30% (65). 
 
The economic burden of fracture in obese populations was determined in the GLOW 
study (4). Despite protective effects of obesity against hip and vertebral fracture, 
fractures elsewhere in the skeleton in obesity make a significant contribution to the 
burden of fracture on healthcare systems (4). Despite fracture incidence being greater in 
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non-obese individuals, due to the proportion of overweight and obese individuals in the 
overall population, the majority of fractures occur in those with a high BMI (64). 
 
There are consistent reports of no difference in the risk of complications post fracture 
between obese and non-obese adults (60, 66, 67). Although smaller studies have also 
shown no difference between obese and non-obese individuals in length of 
hospitalisation after ankle fracture (60) or after high trauma fracture of the femur or tibia 
(66), in the GLOW study, obese women with a fracture were hospitalised for significantly 
longer than non-obese women (4). After fracture, obese women have a poorer functional 
status and health related quality of life than non-obese women as fracture related 
morbidity is greater in the obese (4, 68). Whether fracture related mortality is altered in 
obesity is unclear. Obesity has been shown to be a significant risk factor for mortality 
post hip fracture (68), but several large cohort studies have shown fracture related 
mortality to be lower in obese than normal weight groups (69-71), or inverse associations 
between BMI and fracture related mortality risk (72).  
 
Determinants of Fracture in Obesity 
Risk factors for fracture in obesity appear to be similar to those in the non-obese 
population (increased age, lower BMD, history of previous fracture, family history etc.) 
(42, 69). However, there may be differences in skeletal and non-skeletal determinants of 
fracture risk in obesity, compared to non-obese individuals. 
 
Skeletal determinants of protective effects of obesity against fracture might include 
greater bone density, favourable cortical and/or trabecular microstructure and greater 
bone strength at sites where obesity is protective against fracture. 
 
Non-skeletal factors may also contribute to the protective effects of obesity against 
fracture. Obese adults may be protected against fracture at central sites due to greater 
soft tissue thickness which acts as ‘padding’ to absorb some of the impact of a fall and 
thus protect the underlying bone from fracture (23, 73). Obese adults may be more 
sedentary and participate in less physical activity, which might limit their exposure to 
outdoor environments which predispose to falls and fractures. 
 
At sites where obesity is associated with greater fracture risk, there may be no difference 
in BMD between obese and normal BMI individuals, or lower BMD in obese individuals. 
Bone structure may be unfavourable and/or bone strength might be lower at sites where 
obesity is associated with increased fracture risk. Alternatively, if bone density, structure 
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and strength are favourable at sites where obesity is associated with greater fracture 
risk, it may be that the bone is insufficiently adapted i.e. parameters are not greater in a 
way that is commensurate to the greater loading effects of obesity. Importantly, the 
relationship between BMI and bone strength may not be linear. 
 
Finally, non-skeletal factors may contribute to greater fracture risk at some sites in 
obesity. Fall patterns may be different in obese individuals compared to non-obese 
individuals. For example, obese people may be more likely to fall due to lower lean mass, 
sarcopenia, sarcopenic obesity or impaired muscle function. Obese people may fall in 
different directions to non-obese individuals and this may be related to the greater risk 
of some fractures in obesity. Pre- and mid-fall reaction times may be slower in obesity, 
such that there becomes the inability to break a fall by outstretching the arms, thus the 
wrist is protected but the proximal humerus at risk of fracture. In the general population 
obesity is associated with other co-morbidities such as diabetes and low vitamin D status, 
both of which are associated with increased fracture risk (64) 
 
Some gender differences in fracture risk in obesity may also be contributed to by the 
factors above, for example gender differences in soft tissue thickness at the hips may 
contribute to gender-specific differences in hip fracture risk, although this has been 
questioned by others (64, 73). The difference in oestrogen between men and women is 
a possible key determinant of gender differences in fracture risk. 
 
Effects of Obesity on Bone Throughout the Life Course 
Whether adiposity affects bone density, structure, strength and fracture risk, in the same 
way throughout the life course is unclear. The literature regarding associations between 
adiposity, bone structure and strength in children and adolescents is conflicting. Most of 
the evidence from studies of obese children and adolescents suggests negative 
associations between body mass, BMD, bone geometry and bone strength and that fat 
mass may have adverse effects on bone in childhood and adolescence (74-77). 
 
At present it is unclear whether obesity affects bone density, structure, strength and 
fracture risk in younger and older adults in the same way. Age or skeletal state at the 
onset of obesity and also the duration of obesity may affect fracture risk, depending on 
the mechanism of the effect of obesity on bone density, structure and strength and may 
explain why some cross sectional studies report results which are inconsistent with the 
wider literature (78). It may be that obesity from adolescence into young adulthood is 
associated with beneficial effects on the attainment of peak bone mass. Obesity in later 
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adulthood may convey beneficial effects on the skeleton through the reduction of bone 
loss.  
 
Obesity and Bone in Murine Models 
Murine models of high-fat-diet (HFD) and high-fat-sucrose diet (HFSD) induced obesity 
have been widely reported to induce bone resorption (19) and are associated with low 
BMD (19, 79), poor microarchitecture (19, 80, 81) and lower bone strength (80-83). Many 
murine studies have demonstrated short-term effects of HFDs on bone, although similar 
results have been observed in long-term studies (19, 84), where HFSDs exacerbated the 
negative effects of adiposity on bone structure and strength (85). The application of 
murine models to human physiology may be limited as inducing short-term obesity may 
not be comparable to the physiological effects of obesity observed in obese human 
populations, where high body mass may be the result of adiposity accumulated over a 
considerable duration. Additionally, most murine studies involve young animals which 
might serve as potential comparators for observations in children and/or adolescents, 
but any variation in the association between obesity and bone between younger and 
older groups may make such models inapplicable to adulthood. 
 
Overview of Mechanistic Links Between Fat and Bone 
Numerous links between adiposity and bone have been proposed. Determining the 
mechanism(s) by which obesity may exert protective effects on bone might be important 
for the identification of novel therapeutic targets for the treatment of disorders of low bone 
mass, such as osteoporosis. The potential key mechanisms by which obesity may affect 
BMD or bone structure are described here. Several of these mechanisms will be explored 
and discussed in more detail in this thesis. 
 
Mechanical Loading 
The mechanostat theory describes how a microarchitectural response is generated by 
bone in order to adapt to mechanical loading (86). When bone is exposed to a load 
beyond the level required to maintain baseline strength, bone formation is stimulated and 
the threshold load required for skeletal maintenance increased (87, 88). The mechanical 
loading effects of high body weight may therefore contribute to protective effects of 
obesity on BMD. However, despite supporting greater BMD in obesity, it is most likely 
that bones adapt to habitual loading forces rather than to infrequent greater fall forces. 
Consequently, fall forces may exceed the adaptation to habitual loading conditions in 
obesity and fracture may still result, despite greater BMD.  
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Osteoblasts and Adipocytes 
Mesenchymal stem cells (MSCs) are able to differentiate into chondrocytes, myocytes, 
osteoblasts or adipocytes as illustrated in Figure 4 (89). MSCs are “regulated by 
endocrine, paracrine and autocrine signals” (90) and their differentiation is mediated by 
oxidative tension and stress (91). As adipocytes and osteoblasts share this common 
origin, MSCs may play a role in the fat-bone relationship. MSCs differentiate to meet the 
demands of tissue growth and repair. Hence, it was hypothesised that in obesity, as 
demand on the skeleton to adapt to high body weight is greater, MSCs may be more 
likely to differentiate into osteoblasts than adipocytes and consequently, obesity is 
associated with greater bone mass (92). Mutually exclusive differentiation of MSCs is 
unlikely to affect the positive relationship between adiposity and bone, as adipocytes are 
able increase in size, thus adiposity can increase simultaneously with osteoblast 
differentiation (61). 
  
Figure 4: Simplified differentiation potential of MSCs  
along adipogenic, chondrogenic, osteogenic and myogenic lineages 
 
Endocrine Links Between Fat and Bone 
Numerous hormones and biochemical factors have been identified which link fat and 
bone through direct or indirect actions. Many of the effects exerted by hormones on the 
skeleton are understood to be evolutionary adaptations which act as an attempt to 
mediate energy metabolism (93, 94). An overview of endocrine links is given here, with 
a more in-depth review in Chapter 4. 
 
Acute Endocrine Links: Hormonal Responses to Feeding  
Feeding results in an acute decrease in bone resorption, mediated by a number of 
hormones (95). Insulin, preptin and pancreatic peptide increase osteoblast proliferation 
(95), while amylin inhibits bone resorption (61, 96). Growth hormone and insulin-like 
growth factor-1 (IGF-I) increase following feeding and IGF-I is positively associated with 
bone formation and BMD (95, 96). Feeding stimulates the secretion of glucagon-like 
peptide 2 (GLP-2) which has been shown to reduce bone resorption without affecting 
bone formation (95).  
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Fat as an Endocrine Organ 
Adipose tissue is a highly active endocrine organ, producing over fifty cytokines and 
other related molecules (90, 97), some of which have been shown to affect bone and are 
summarised below. 
 
Oestrogen 
Oestrogen inhibits bone resorption. Fat mass (FM) is positively associated with 
circulating oestrogen resulting from greater aromatisation of androgens as aromatase is 
expressed in fat tissue. After menopause, the production of oestrogen by aromatisation 
of adrenal androgens is the main source of oestrogen in older women and so FM may 
be a particularly important regulator of BMD in this population (98).  
 
Adipokines 
Fat produced hormones, or adipokines, are produced in proportion to FM and therefore 
concentrations are altered in obesity. Leptin is a hormone product of the OB gene and 
plays an important role in regulating appetite and energy homeostasis via actions on the 
hypothalamus (90, 97, 99). Circulating leptin levels are positively associated with total 
FM and may be affected by sex hormones and inflammatory cytokines (97, 98). 
Associations between leptin and BMD are complex, with human and murine studies 
yielding conflicting results and leptin exerting positive and negative effects on bone 
metabolism, depending on whether it acts directly on bone cells or indirectly (via the 
hypothalamus and autonomic nervous system), respectively (98, 99). Adiponectin is 
reduced in obesity and inversely associated with visceral adipose tissue (VAT) (90, 96, 
100). Adiponectin is involved in glucose synthesis in the liver; increasing insulin 
sensitivity and reducing serum insulin (96). In humans, negative associations between 
adiponectin and BMD have been reported (101-104). Adiponectin may stimulate RANKL 
and inhibit the production of osteoprotegerin (OPG) by osteoblasts, resulting in 
osteoclastogenesis (105, 106). Resistin is up-regulated in obesity and has been shown 
to increase osteoblast proliferation and osteoclastogenesis in-vitro (96). Visfatin levels 
are positively associated with adiposity and increase the production of interleukin (IL) 1β, 
IL-6 and tumour necrosis factor-α (TNF-α). It has been proposed that visfatin may play 
a role in insulin metabolism (97). 
 
Inflammatory Cytokines 
Obesity is considered a low grade pro-inflammatory state, associated with greater 
concentrations of pro-inflammatory but also some anti-inflammatory cytokines, including 
IL-10, IL-6, IL-8 and IL-1 receptor antagonist (IL-1Ra) and TNF-α (97). Pro-inflammatory 
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cytokines are inversely associated with BMD and positively associated with bone 
resorption, with in-vitro studies showing that inflammatory cytokines act on osteoclast 
precursors to up-regulate osteoclastogenesis (107, 108). 
 
Vitamin D 
Vitamin D is a fat soluble pro-hormone, which functions to increase calcium absorption 
in the intestine. BMI is inversely associated with 25OHD (109, 110). Low 25OHD is 
typically associated with higher parathyroid hormone (PTH) and increased bone 
turnover, resulting in bone loss. However as described earlier, obesity seems to be 
associated with higher aBMD and this suggests that the vitamin D axis and metabolism 
might be altered in obesity. At present the cause(s) and consequences of low vitamin D 
in obesity are unclear. There may also be a role of low 25OHD in mediating the risk of 
falls in obesity through effects on muscle function, which could provide a link between 
obesity and greater risk of fractures at some sites.  
 
Bone as an Endocrine Organ 
The skeleton also acts as an endocrine organ, secreting osteokines to regulate 
metabolism (94). Osteocalcin (OC) is “a major non-collagenous protein in the 
extracellular matrix” produced specifically by mature, active osteoblasts (94, 99, 111). 
OC regulates glucose metabolism by increasing expression of adiponectin by adipocytes 
and insulin by β-cells (93, 99) and is involved in the regulation of central adiposity (112). 
OC exists in two forms; undercarboxylated (uOC) and carboxylated. Greater uOC has 
been positively associated with vertebral and hip fracture risk (111, 113, 114). 
Osteoprotegerin (OPG) is released by osteoblasts and inhibits osteoclast differentiation 
and activity through acting as a receptor activator of RANKL; preventing the binding of 
RANKL to RANK (105, 115). OPG has been found to be negatively correlated with body 
weight, BMI, waist circumference and fasting plasma insulin and positively correlated 
with adiponectin (116). 
 
Different compartments of fat 
Body fat distribution may play an important role in the relationship between adiposity and 
bone as different adipose depots express different biochemical factors and in varying 
concentrations. In obesity, VAT expresses more pro-inflammatory cytokines including 
TNF-α and IL-6, but less adiponectin, leptin and aromatase than subcutaneous fat (SAT) 
(100, 117-119). The overall effect of adiposity on bone is likely to be a balance of positive 
and negative influences from different adipose compartments.  
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Limitations of the Current Literature 
Associations between obesity and fracture risk are complex, with indications of age, 
skeletal site and gender specific differences. Interpretation of the current literature is 
challenging due to the majority of findings originating from observational studies or 
longitudinal cohorts not primarily designed to study the association between adiposity 
and skeletal outcomes. Such incidental findings are widely reported but obese groups 
are often poorly represented, resulting in low power to detect significant differences 
between obese and non-obese groups. Opportunistic studies frequently involve 
participants from heterogeneous racial backgrounds, introducing ethnic variation in bone 
phenotypes, FM and fat distribution (120-122). 
 
Much of the current literature describes associations between adiposity and fracture risk 
in postmenopausal women or ageing men. Studying this association throughout 
adulthood could enable the identification of the onset of any effects of obesity on bone, 
and provide information on the progression of any such effects, in turn helping to identify 
potential mechanisms of the effect of obesity on bone. Pre- and postmenopausal women 
should be studied separately, as the pooling of pre- and postmenopausal women may 
confound findings due to the significant skeletal, soft tissue and endocrine differences 
between the two groups. Similarly, pooling the findings of men and women results in 
confounding due to variation in bone density, bone size, endocrine and soft tissue factors 
by gender (100).  
 
A lack of control for potential confounding factors, such as physical activity, the use of 
hormone replacement therapies or the inclusion of individuals with diabetes may also 
distort findings. This is a further consequence of opportunistic analysis of existing data 
sets, avoidable by designing a study specifically to investigate the fat-bone relationship. 
 
The overwhelming majority of previous work investigating effects of obesity on bone has 
involved determining areal BMD (aBMD) by dual energy x-ray absorptiometry (DXA) and 
inferring aBMD to be positively and proportionally associated with bone strength or lower 
fracture risk. As will be discussed in this thesis, there are significant limitations to the use 
of DXA in obesity. As bone strength is not determined by aBMD alone, but contributed 
to by bone structure, geometry and the material properties of bone, this limits current 
findings. Novel, more sophisticated technologies such as High Resolution Peripheral 
Quantitative Computed Tomography (HR-pQCT) are available which enable the study of 
bone microarchitecture in obesity and reduce soft tissue effects. Finite element (FE) 
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models enable more comprehensive assessments of bone strength to be made by 
incorporating data on bone density, geometry and structure. 
 
The widespread use of DXA has meant that much of the current literature is focussed on 
determining aBMD at the hip and lumbar spine and the results are often assumed to be 
applicable throughout the skeleton. Acknowledging the site-dependent associations of 
obesity and fracture risk, studying axial and appendicular, weight bearing and non-weight 
bearing skeletal sites is likely to provide a more thorough understanding of the effect of 
obesity on fracture risk. 
 
A further implication of the reliance on DXA is the restricted ability to determine the effect 
of different soft tissue compartments on bone. Whilst FM and LM, android, gynoid and 
trunk regions can be distinguished by DXA, alternative depots such as subcutaneous, 
visceral, brown fat, bone marrow fat, inter and intra-muscular fat compartments cannot 
be determined. Determining the contributions of these different adipose depots to the 
effect of obesity on bone may be important for the identification of potential mediators of 
the relationship.  
 
At present, there is a limited understanding of fracture patterns in obesity. Greater risk 
of some fractures in obesity may be due to increased risk of falls or specific fall 
kinematics associated with altered physical performance in obesity. The current literature 
surrounding physical performance in obesity is limited, with a paucity of studies involving 
obese individuals and matched non-obese controls.  
 
Until recently, there was a longstanding lack of a consensus definition of sarcopenia 
which made classifying and interpreting muscle mass and function status problematic. 
Now that a consensus definition is in place, determining whether obese individuals are 
at greater risk of sarcopenia could assist with determining falls risk in obesity.  
 
The cause of low 25OHD in obesity is unclear, as are the consequences of low 25OHD 
in obesity. Very few studies have investigated the effect of adiposity on free fractions of 
25OHD and the effect of obesity on free 1,25(OH)2D has not been studied. No study has 
investigated the role that free fractions of vitamin D play in associations between vitamin 
D status and skeletal structure and strength. The majority of studies investigating the 
effect of obesity on 25OHD rely on corrections for seasonality, which could be better 
controlled by designing studies which recruit during specific periods of the year.  
 33 
Thesis Overview 
This thesis seeks to understand why obese people are protected against some fractures 
but at greater risk of fracture at other sites and identify potential drivers of the site-specific 
differences in fracture risk observed in obesity. This study has been designed specifically 
to investigate the effect of obesity on the skeleton and risk factors for fracture in obesity. 
Thus the study will be sufficiently powered to detect differences in skeletal outcomes 
between an obese group and a normal BMI control group. 
 
Firstly this thesis will seek to understand how obesity affects bone density. This will be 
achieved using conventional DXA imaging alongside state-of-the-art imaging by HR-
pQCT and QCT to differentiate total, cortical and trabecular densities. This thesis will 
progress from studying bone density to investigate associations between obesity and 
bone structure using HR-pQCT and QCT. Understanding patterns of cortical and 
trabecular microarchitecture in obesity may give an insight into skeletal determinants of 
fracture in obesity previously masked by studying aBMD. 
 
Subsequently, FE models will be used to investigate whether any observed differences 
in bone density and structure between obese and normal BMI individuals affect bone 
strength, improving on strength estimates derived from aBMD alone. Employing a range 
of technologies to asses bone density, structure and strength enables the investigation 
of effects of obesity at a range of skeletal sites; central and peripheral, weight bearing 
and non-weight bearing. This will eliminate assumptions that imaging outcomes at made 
central sites reflect those at peripheral sites. 
 
Bone turnover markers, hormones and biochemical factors will be measured to identify 
potential mechanisms by which fat mediates any effect on bone outcomes. Detailed 
assessments of body composition will be undertaken using anthropometry, DXA and CT 
to determine the effects of LM, FM, SAT, VAT and subcutaneous peripheral depots on 
bone density and bone microstructure. 
 
Bone is more likely to be adapted to everyday loading conditions than to loads 
experienced upon falling. Upon falling significant forces associated with high body weight 
may be exerted. Where greater bone strength is not commensurate to the loading forces 
applied, fracture will occur. This thesis will investigate whether obese people might 
fracture at sites where bone density and strength are greater compared to normal BMI 
individuals because they have low LM or poor physical function, which could affect fall 
frequency and/or fall kinematics.  
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Finally, this thesis will investigate vitamin D levels in obesity to better understand why 
low circulating 25OHD levels are observed in obese adults. This work will provide a 
comprehensive assessment of possible causes of low vitamin D in obesity and establish 
whether low vitamin D levels have any association with bone density, bone or 
microstructure, LM or physical performance. 
 
Long Term Research Goals 
The ultimate aim of this area of research is to prevent fracture. By improving current 
understanding of the pathogenesis of fracture in obesity, effective and appropriate 
fracture prevention strategies can be established for this growing subset of the 
population. Identification of obese individuals at highest risk of fracture is important and 
there might be the need to increase awareness of the potential for fracture in obesity 
despite the recognised protective effect of high BMI on BMD. 
 
Understanding how obesity affects bone density and/or structure may enable the 
identification of biochemical factors which mediate the association between fat and bone. 
Ultimately this may lead to the identification of novel therapeutic targets for the treatment 
of conditions characterised by low bone density, such as osteoporosis. 
 
Thesis Aims 
To identify associations between obesity and bone density, bone structure and 
bone strength across the skeleton (Chapter 3). 
1. To compare BMD measured by DXA and QCT at the hip and lumbar spine in 
normal BMI and obese individuals, to determine associations between obesity 
and BMD.  
2. To compare BMD and bone microarchitecture at the distal tibia and distal radius, 
measured by HR-pQCT in normal BMI and obese individuals, to determine 
associations between obesity and each of these outcomes.  
3. To compare bone strength determined by FEA at the hip, lumbar spine, distal 
radius and distal tibia, in normal BMI and obese individuals, to determine 
associations between obesity and bone strength.  
4. To compare the magnitude of the differences in BMD, bone microarchitecture, 
bone geometry and bone strength at different skeletal sites to establish whether 
the effects of obesity on these outcomes are site-specific.  
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5. To determine whether the associations between obesity, BMD, bone 
microarchitectural parameters and bone strength appear commensurate to 
greater body weight in obesity. 
 
To investigate potential mechanisms of the associations between obesity, bone 
density, structure and strength (Chapter 4). 
1. To ascertain which fat compartment(s) are most strongly associated with BMD, 
geometry and microarchitecture, in normal BMI and obese individuals.  
2. To test associations between the proposed key fat compartment, biochemical 
markers of bone turnover and biochemical factors to identify potential mediators 
of the associations between obesity, BMD, bone microarchitecture and bone 
strength. 
 
To determine whether physical performance is impaired in obesity such that 
despite greater BMD, greater risk of ankle and proximal humerus fracture in 
obesity could be explained by greater falls risk (Chapter 5). 
1. To identify whether obesity is associated with greater number of falls. 
2. To compare LM, muscle strength and physical performance in normal BMI and 
obese individuals to determine associations between obesity and physical function. 
3. To compare the prevalence of sarcopenia in the normal BMI and obese groups 
and asscertain any associations between sarcopenia and fall history. 
4. To identify potential biochemical mediators of the association between adiposity 
and physcial performance. 
 
To investigate causes and consequences of low circulating vitamin D in obesity 
(Chapter 6). 
5. To establish whether obese adults have low total and/or free 25OHD and 
1,25(OH)2D. 
6. To determine the potential cause(s) of low 25OHD in obesity. 
7. To investigate associations between levels of 25OHD and BMD, bone structure and 
bone strength to establish whether there are skeletal consequences of low 25OHD 
in obesity. 
8. To investigate whether total and/or free 25OHD and 1,25(OH)2D are associated with 
physical performance in obesity. 
 
To conclude whether the fracture patterns observed in obesity are attributable to 
skeletal inadequacy, non-skeletal determinants of fracture or both and to suggest 
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the most appropriate direction for fracture prevention to take in obesity; for 
example; increased utilisation of anti-osteoporotic therapies, improved fall 
prevention strategies or increased supplementation of vitamin D (Chapter 7). 
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CHAPTER 2: 
 
METHODS   
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CHAPTER 2: Methods 
Study Design 
The Fat and Bone Study (FAB Study) was a single centre, observational, cross-sectional, 
case-control study.  
 
Cases were obese individuals (BMI greater than or equal to 30 kg/m2) and controls were 
individuals with a normal BMI (BMI 18.5 to 24.9 kg/m2). Cases and controls were 
individually and prospectively matched (each control was recruited to match a specific 
obese participant) by age (±3 years), gender, height (±5 cm), first part of postcode (e.g. 
S5) and smoking status (current or non-smoker). This was done to control for potential 
confounding factors by ensuring that cases and controls were as similar as possible. 
Participants were matched by age to control for decreases in BMD and alterations in 
body composition (lower LM and greater FM) which occur with age. As men have a 
greater BMD than women, mixed-sex paring was avoided. Participants were matched on 
height as BMC by DXA  is affected by skeletal size. Postcode matching was performed 
as socioeconomic status can affect lifestyle factors such as diet, physical activity 
participation and healthcare attendance (123) which could affect bone density (124-129), 
fracture risk (130, 131) and incidence of obesity (132). Finally, matching based on current 
smoking status was performed as cigarette smoking has been shown to reduce aBMD 
(133-135), vBMD (136), Tb.vBMD (135-137) and Ct.Th (135) and increase fracture risk 
(138-141). 
 
All participants provided written informed consent prior to enrolment, in accordance with 
Good Clinical Practice guidelines. Ethical approval was obtained from Sheffield 
Research Ethics Committee. 
 
We used data sets from a previous study of healthy women in Sheffield to estimate the 
variability and difference in hip BMD between normal BMI and obese pairs. The mean 
paired difference was 0.085 g/cm2 and the standard deviation of the paired differences 
was 0.136. The effect size was set at 7.5% as this was likely to represent a clinically 
significant difference. A sample size of 240 has 80% power to detect a 7.5% difference 
at p<0.05 based on a paired sample t-test.  
 
Following study completion, a sample size of 200 (mean 25 normal BMI-obese pairs per 
younger/older, male/female group) was obtained. As the effect size was estimated from 
a different population, the power calculation was repeated with data from the FAB study 
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to check that the FAB study had adequate power. The SD of the paired differences in 
total hip BMD was 0.16. For 80% power for a paired samples t-test, the standardised 
difference is 1.125, therefore (1.125 x 0.16) /2 = 0.09. The final sample size of 200 had 
80% power to detect a 0.09 g/cm2 difference in total hip aBMD. 
 
Inclusion and Exclusion Criteria 
Inclusion Criteria: 
Aged 25 to 40 Years or 55 to 75 Years  
Women aged 25-40 years were premenopausal, defined as having regular menstrual 
cycles and at least 8 menstrual cycles per year. Women aged 55-75 years were 
postmenopausal, defined as at least 5 years since their last menstrual period. These age 
groups capture individuals post-peak bone mass and exclude perimenopausal and 
menopausal women who undergo increased bone resorption and decreased bone mass. 
Similar group sizes enabled age group comparisons. 
 
BMI of 18.5 to 24.9 kg/m2 or Greater Than 30 kg/m2  
The WHO BMI classifications were used to group normal BMI and obese individuals. No 
upper BMI limit was enforced but a maximum body weight of 159 kg was applied in 
accordance with guidelines from Hologic for using the DXA scan-bed. 
 
Caucasian Ethnicity 
Only Caucasian individuals were recruited to avoid confounding due to ethnic differences 
in skeletal acquisition, bone density, bone structure and fracture risk (15, 120, 121, 142-
146). Ethnic differences in adiposity and fat distribution may also confound the results. 
Asian individuals have greater percentage body fat and abdominal FM than Caucasians 
matched for age gender and BMI, and differences in SAT and VAT exist by geographic 
region (122, 147, 148). White and Hispanic adults have lower SAT and higher VAT than 
African American and Black African adults (149-152). Relationships between FM and 
BMD may also vary by ethnicity (153). 
 
Sufficiently Mobile 
All participants were sufficiently mobile to undergo scanning and able to remain 
motionless for the duration of the scans, ensuring acquisition of acceptable quality scans 
from all imaging modalities within the approved radiation exposure constraints. 
  
 40 
Exclusion Criteria 
Previous Orthopaedic Surgery, Fractures or Conditions Which Preclude Imaging 
Individuals with joint replacements or osteoarthritis at measurement sites, or other 
conditions which prevent the analysis or interpretation of DXA scans were ineligible. This 
ensured the acquisition of reliable, interpretable and complete scan data. 
 
History of Long Term Immobilisation  
Defined as no weight bearing functionality for longer than three months. Immobilisation 
leads to decreases in total, trabecular and cortical densities and alterations in cortical 
and trabecular structure, with the greatest changes observed at weight bearing sites, 
(154-161). Suppression of bone formation and accelerated resorption is observed after 
30 days of bed rest and appears more rapid in the initial phase of immobilisation (158, 
162). Evidence suggests that one year post bed rest, recovery is incomplete (154, 160, 
161), however time to full recovery is unclear (155, 160, 161). 
 
Fracture Less Than One Year Prior to Recruitment 
As bone remodelling facilitates fracture repair, recent fractures are associated with 
higher bone turnover (163, 164), resulting in elevated circulating BTMs from 1 to 2 weeks 
post-fracture (163, 165). Most of the changes in BTMs occur within six months of 
fracture, after which BTMs might remain only slightly elevated up to one year post-
fracture (163, 166), although only formation markers may remain elevated (165, 167, 
168). Fracture can also affect bone turnover indirectly, through immobilisation or altered 
physical activity. 
 
Current Pregnancy or Trying to Conceive 
A urinary pregnancy test was carried out for all premenopausal women prior to imaging 
to prevent the unethical exposure of a foetus to x-ray radiation. 
 
Delivery of Last Child Less Than One Year Prior To Recruitment  
Changes in BMD occur during pregnancy in response to demands for calcium, as 
required for foetal growth and for the production of breast milk (169). As a result, BMD 
decreases during pregnancy (170, 171), with increased bone resorption and formation 
(172-174). At one year postpartum, adolescent mothers have been shown to have similar 
BMDs to those of nulliparous adolescents (175). 
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Lactation Less Than One Year Prior To Recruitment  
Bone turnover is increased during lactation, (176, 177). Three to six months after the 
onset of lactation, decreased BMC and altered bone structure are observed, with 
average decreases in BMC of five percent observed at the spine and hip (170, 178, 179). 
An increase in BMC occurs in later lactation (180), possibly linked to increasing 
oestrogen. Bone turnover decreases after six to twelve months (177, 181) and BMD 
returns to baseline levels by 3 to 6 months (169) or 12 months post-parturition (179).  
 
Diabetes Mellitus 
Type 1 diabetes mellitus (T1DM) is associated with low BMD and higher fracture risk, 
possibly as a consequence of reduced bone formation and low insulin, amylin and preptin 
during skeletal growth (182-185). Type 2 diabetes mellitus (T2DM) is associated with 
higher BMD, vBMD and trabecular BMD but a greater fracture risk than in non-diabetic 
individuals (186-188). Greater fall risk may contribute to greater fracture risk in diabetic 
individuals, although greater fracture risk persists after adjustment for fall frequency 
(189). Accumulation of advanced glycation endpoints (AGEs) increases bone stiffness 
and might reduce bone strength in T2DM (190).  
 
History of a Diagnosed Restrictive Eating Disorder 
Restrictive eating disorders, such as anorexia nervosa and bulimia, are associated with 
low BMD and increased bone marrow fat (191-193). Individuals who develop eating 
disorders prior to attaining peak bone mass can have skeletal consequences persisting 
into adulthood (194). Although weight gain and recovery may stabilise or restore BMD 
(195), this is not always the case (196-198).  
 
Alcohol Intake of Greater Than 21 Units (168 grams) Per Week  
Whilst light consumption of alcohol may have no effect or a positive effect on BMD, heavy 
alcohol consumption has a deleterious effect on bone, being inversely associated with 
BMD, trabecular volume and cortical thickness across the skeleton (199, 200). High 
alcohol intake also increases the risk of falls and fractures (199, 201). 
 
History of, or Current Conditions Known to Affect Bone Metabolism 
Participants with diagnosed skeletal disease, rheumatoid arthritis, chronic renal disease, 
endocrine disorders (e.g. hyperthyroidism, hypo- or hyper-calcaemia), polycystic ovarian 
syndrome, malabsorption syndromes (e.g. Inflammatory Bowel Disease, Crohns) or a 
history of malignancy were ineligible. Participants with markedly abnormal clinical 
laboratory parameters at visit 1 were excluded.  
 42 
Use of Medications or Treatment Known to Affect Bone Metabolism  
Individuals who used hormone replacement therapy (HRT) for longer than ten years or 
within the year prior to recruitment were ineligible (202). Individuals using any form of 
hormonal contraception were ineligible. Individuals with a history of using depot 
medroxyprogesterone acetate for longer than six months were excluded. Participants 
were eligible to participate one year from stopping the combined oral contraceptive pill 
or four months from stopping progesterone-only contraception (mini-pill, sub-dermal 
implant, intrauterine device) if regular menses had resumed. Participants with a history 
of bisphosphonate, steroid, glucocorticoid or anticonvulsant use were ineligible, although 
those using inhalers for asthma were included. 
 
Competitive Athlete 
Individuals participating in competitive sport at amateur or professional level or 
participating in moderate intensity physical activity for greater than seven hours per week 
were excluded. This ensured that participants were not recruited with a high BMI due to 
high LM and reduced confounding due to differences in physical activity levels between 
normal BMI and obese participants. 
 
Significant Weight Loss Prior to Recruitment 
Dietary energy restriction has been shown to induce neuroendocrine changes such as 
reduced circulating concentrations of thyroid hormones, sex hormones and IGF-I, which 
accelerate bone loss (74). 
 
 
Study Procedures 
Participants attended the Clinical Research Facility, Northern General Hospital, Sheffield 
for three visits (Table 1): 
 
Table 1: FAB Study Visits 
Visit Timeframe Procedures 
1 
Premenopausal women: 
within follicular phase 
Consent, lifestyle questionnaire, height, weight, 
waist and hip circumference, triceps skinfold, 
blood sampling, physical function tests 
2 Within 28 days of Visit 1 Height, weight, DXA, HR-pQCT, QCT, CT 
3 
September to October 
2012 or April to May 2013 
Diet questionnaire, UVB questionnaire, height, 
weight, waist and hip circumference, triceps 
skinfold, blood sampling 
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Questionnaires 
Lifestyle Questionnaire  
A lifestyle questionnaire was used to collect data on demographics, diet, 
supplementation, physical activity, smoking, alcohol consumption, medical history, 
cardiovascular risk, drug history, current medication, fracture history, family history of 
osteoporosis, and weight history. The questionnaire was an adapted version of the 
skeletal health questionnaire used in the Sheffield Metabolic Bone clinical service.  
 
Dietary Vitamin D Intake 
Dietary calcium and vitamin intake were determined with DIETQ (Tinuviel Software, 
Warrington, UK), a food intake questionnaire with a computerised analysis programme 
which assesses the consumption frequency and quantity of a variety of foods. This 
method of dietary analysis has been validated for energy and macronutrient intake. 
 
UVB Exposure Questionnaire 
Participants completed a UVB questionnaire to determine annual and summer sunlight 
exposure (Appendix 1). As no standard questionnaire could be identified for this purpose, 
a questionnaire previously cited (203) was recommended by Professor Lanham-New, 
University of Surrey. Sunbed use and sun protection factor habits (factor, area applied, 
frequency applied) were also recorded. Sunlight exposure was quantified using the rule 
of nines method to estimate the surface area of skin exposed to sunlight (Appendix 2). 
As the rule of nines method did not discriminate hand exposure without full arm 
exposure, a score of 0.2 was given for this purpose. 
 
Anthropometry 
Height (cm) was measured to the nearest 0.1 cm using an electronic, wall-mounted 
stadiometer (Seca 242, Seca, Birmingham, UK). Participants were measured shoeless. 
Participants stood with their feet together, heels against the wall and their head was 
positioned so that the Frankfort Plane was horizontal. Weight (kg) was measured to the 
nearest 0.1 kg using an electronic balance scale (Seca, Birmingham, UK). Participants 
were weighed in lightweight clothing and shoeless.  
 
Anthropometric Assessment of Adiposity 
Body Mass Index 
Although it is unable to distinguish between FM and LM, BMI provides a quick and 
unobtrusive surrogate for adiposity. BMI was calculated using Quetelet's index:  
BMI = (weight (kg) / (height (m)2))  
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Waist-to-Hip Ratio (WHR) 
WHR is an indicator of trunk fat and a more accurate predictor of obesity related co-
morbidity than BMI (204-208). Waist and hip circumferences were measured in cm to the 
nearest 0.1 cm, using a flexible tape measure. Participants stood erect with their feet 
approximately 30 cm apart. Waist circumference (cm) was measured horizontally, at the 
midpoint between the lowest rib and the uppermost aspect of the iliac crest. The 
measurement was made at the end of a regular expiration and directly on the skin. Hip 
circumference was measured horizontally at the level of the greatest protrusion of the 
buttocks when viewed from the side. Fatty aprons were excluded from the measurement; 
with the participant instructed to raise the apron above the region of interest. Hip 
circumference (cm) was measured over loose, lightweight clothing. Waist-to-hip ratio 
was calculated and used as a marker of central adiposity.  
 
Triceps Skinfold Thickness 
Triceps skinfold thickness (mm) was measured using a Harpenden skinfold calliper (Baty 
International, West Sussex, UK) and used as a marker of peripheral subcutaneous 
adiposity. Skinfolds were taken on the right-hand side of the body. Skinfolds were 
measured as a vertical fold on the posterior midline of the upper arm, half way between 
the acromial and olecranon processes, with the elbow extended and the arm relaxed. 
The dial was read to the nearest 0.20 mm, two seconds after the grip was fully released. 
Time was allowed for the skin to regain normal thickness between measurements to 
prevent fat compression.  
 
All anthropometric measurements were taken by a single investigator to eliminate inter-
investigator variability and were measured three times and the mean value determined 
to reduce intra-observer error (207, 209).  
 
Skeletal Imaging 
Dual-Energy X-ray Absorptiometry 
DXA was used to determine aBMD (g/cm2) of the whole body (minus the head), total hip 
and lumbar spine (L1-L4). DXA is currently the standard technique for the measurement 
of BMD, providing a two-dimensional projection from which BMC, bone area and BMD 
can be determined. BMD by DXA has been shown to predict fracture risk (210-212) and 
for this reason is commonly used as a surrogate for bone strength.  
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Principles of DXA 
A DXA system is shown in Figure 5. The x-ray tube produces x-ray beams of two different 
energies; one high the other low, by alternating the voltage of the x-ray tube (kV 
switching). A fan shaped beam is generated by passing the beam through a collimator. 
As the beam passes through the body, some photons are absorbed and some scatter 
(Compton scattering) but the remaining photons pass through the body and are detected 
by a linear array of x-ray detectors. 
 
Figure 5: Components of the DXA Scanner 
 
 
The detector uses a scintillation detector array system to convert the attenuated 
emerging high and low energy x-ray beam intensities to light energies, which are 
detected by a photo diode and converted into electrical signals for image generation. An 
R-value, or attenuation coefficient, is calculated for each pixel as the ratio of the 
attenuation at the low keV to the attenuation at high keV, which depends on the 
composition and density of the tissue. Low density materials, such as air, allow more 
photons to pass through than high density materials, such as bone. For a mono-energetic 
beam passing through a homogeneous tissue, a pattern of attenuation can be 
represented by the following formula (213):  
I = I0exp-(µM) 
Where I= the intensity of the beam after it has passed through the body, I0= the incident 
beam intensity, µ = the linear mass attenuation coefficient of the tissue (cm2g–1) and M= 
the area density (g/cm2) (213).  
 
As the body is not made up of a single homogeneous tissue, a series of two compartment 
models (bone and soft tissue) are used to calculate bone density values. Different tissues 
have different attenuation coefficients, with bone having a constant attenuation 
coefficient at a given energy. Therefore, for a given energy (213):  
I = I0exp–(µBMB + µSMS), where B= bone and S= soft tissue 
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As the attenuation coefficient varies depending on the beam energy, separate equations 
are determined for the low and high-energy beams (213): 
IL = IL0exp (–µBLMB – µSLMS) and IH = IH0exp (-µBHMB – µSHMS) 
Where L= low-energy photons and H= high-energy photons. 
The area density of bone (MB) can then be described as (213): 
MB = [Ln (IL0 / IL) – k Ln (IH0 / IH)] / (µLB - kµHB), where k = µLS / µHS 
 
Ratio k can be derived from the patient measurement by measuring the transmitted 
intensity of the beam at points at which there is no bone (MB = 0). Once ratio k is 
determined, the equation can be solved to calculate the area bone density, MB. Bone 
density is then calculated as the average MB across the bone profile (213). 
 
The software sums the number of pixels containing bone to calculate the bone area (BA) 
that was scanned. Using the mean BMD value and the BA, it is possible to calculate the 
BMC within the image (213): 
BMC (g) = BMD (g/cm2) x BA (cm2) 
 
Gender specific Z and T-scores are determined to report an individual’s BMD. A Z score 
quantifies in SDs how different an individual’s BMD value is from the population mean 
for the individual’s age, whereas a T-score quantifies how far the BMD value departs 
from the mean value for ‘young normal’ adults (age 20-39 years). Again, the difference 
is expressed in terms of SDs. 
Z score = (subject BMD – age matched mean) / age-matched SD 
T score = (subject BMD – young normal mean) / young normal SD 
 
DXA Procedure 
Participants were scanned in the posterior-anterior (PA) projection, using a Hologic 
Discovery A densitometer (Hologic Inc., Bedford, MA, USA). This scanner uses a 
switched-pulse dual-energy (low 100kVp / high 140kVp) x-ray system with a maximum 
current of 10mA and has a multi-element detector array. Scans of the whole body, lumbar 
spine and right (or non-fractured) hip were performed.  
 
DXA Procedure: Whole Body 
The subject was positioned supine, in a straight and central position on the scan table, 
with the head placed towards the top of the table. The operator ensured the body was 
within the scan line limits indicated on the scan table, with the anterior superior iliac 
spines equidistant from the table top to prevent rotation of the pelvis and the feet within 
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the scan limit border. Participant’s arms were placed by their sides, palms flat on the 
table (normal BMI) or palms facing inwards (obese) and slightly separated from the 
thighs (Figure 6). Sub-region defining lines were positioned in accordance with the 
Hologic QDR User’s Guide instructions (Figure 6). 
 
Figure 6: Positioning and sub-region defining lines for the whole body DXA scan 
of an obese (left) and non-obese (right) individual 
 
DXA Procedure: Hip 
Participants adopted a supine, straight and central position on the scan table, with the 
head in the head positioner and feet placed either side of the hip positioner. The 
participant’s arms were placed on the chest, away from the scan field (Figure 7A). The 
operator ensured the proximal femur was within the scan line limits indicated on the scan 
table, with the anterior superior iliac spine equidistant from the table top to prevent 
rotation of the pelvis. The hip was internally rotated by approximately 25° and the leg 
abducted (Figure 7B).  
A  B  
Figure 7: Positioning for the hip DXA scan 
 
An express scan ensured correct positioning. From this, the operator ensured correct 
positioning of the image within the scan field; with at least 3 cm of femoral shaft below 
the lesser trochanter included and the femoral shaft straight within the scan field. The 
array mode was used for the final scan, which extended from at least 3 cm below the 
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lesser trochanter to the pelvis above the femoral head. All scans included at least 5 scan 
lines of adequate soft tissue around the greater trochanter and femoral head. 
 
The image was then analysed. The global region of interest was positioned with the 
upper and right borders at least 5 scan lines away from the edge of the femoral head, 
the left border 5 scan lines from the edge of the greater trochanter and the bottom border 
10 scan lines below the lesser trochanter. The bone map was then identified. The midline 
was placed on the central axis of the hip, the neck box close to the greater trochanter 
and the trochanteric line below the curve of the greater trochanter, with equal amounts 
of soft tissue included within the neck box on either side of the femoral neck (Figure 8). 
The Ward’s triangle box was positioned automatically (Figure 8).  
 
Figure 8: Application of the bone map to a DXA hip scan 
image, indicating the midline, neck box and Ward's Triangle box 
  
DXA Procedure: Lumbar Spine 
The participant was positioned in a supine, straight and central position, head in the head 
positioner and legs elevated over the spine scan positioning block, which was placed 
with the lowest side perpendicular to the table (Figure 9).  
 
Figure 9: Positioning for the lumbar spine DXA scan 
 
The operator ensured that the lumbar spine was within the scan line limits indicated on 
the scan table. The anterior superior iliac spine was equidistant from the table to prevent 
rotation of the spine. An express scan ensured correct positioning. The operator ensured 
the scan image was straight and central within the scan field and extended from mid-L5 
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to mid-T12 so as to image the full L1 to L4 region. There were equal areas of soft tissue 
at either side of the spine. The array mode was used for the final scan. The image was 
then analysed. The global region of interest was positioned with the top border within the 
T12-L1 intervertebral space and the bottom border within the L4-L5 intervertebral space, 
angled to accommodate the shape of the vertebrae. Right and left borders were not 
altered. The bone map was then identified with vertebral lines placed within the L1-2, L2-
3 and L3-4 intervertebral spaces (Figure 10). 
 
Figure 10: Lumbar spine DXA scan with global region of interest and bone map 
 
As prior vertebral fracture may falsely increase BMD, participants aged 55 to 75 years (it 
was unlikely that fractures would be observed in younger participants) underwent a 
vertebral fracture assessment to identify prevalent vertebral fractures between T4 and 
L4, in the PA and lateral projections using the single energy scan mode. Scans were 
visually assessed using the algorithm-based qualitative definition of vertebral fracture 
(214). Vertebrae with evidence of fracture were excluded from the calculation of aBMD. 
A minimum of 2 analysable vertebrae were required for analysis of LS aBMD; 
participants with 3 or more fractures between L1 and L4 were excluded from the study.  
 
DXA Outcomes 
Bone area (cm2), BMC (g) and mean areal BMD (g/cm2) were determined for the whole 
body (minus head), total hip and lumbar spine (mean L1 to L4).  
 
DXA Calibration 
All scans were performed by two highly trained operators with standardised protocols for 
acquisition and analysis; minimising inter-operator error. The DXA scanner underwent 
daily quality control (QC) to ensure stability and precision, in accordance with the 
manufacturer’s recommendations. QC was performed by scanning the Hologic device-
specific anthropomorphic spine phantom, containing four semi-hydroxyapatite vertebrae 
of a single density (Figure 11A). The step phantom, made up of 6 fields of acrylic and 
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aluminium of different thicknesses and known absorptive properties was scanned weekly 
to calibrate the DXA scanner to enable distinction of soft tissues during the whole body 
scan (Figure 11B). A European Spine Phantom (QRM—Quality Assurance in Radiology 
and Medicine, Moehrendorf, Germany) was scanned weekly (Figure 11C). 
 
A  B  C  
Figure 11: Phantoms for the calibration of the DXA device 
Hologic anthropomorphic spine (A), step (B) and European spine (C) phantoms 
 
The resulting bone area (Figure 12), BMC (Figure 13) and BMD (Figure 14) values were 
plotted against pre-specified acceptable limit lines. The scanner is programmed to 
automatically inform the operator of whether the QC has passed or failed. 
 
Figure 12: DXA quality control plot for bone area throughout the FAB Study 
 
 
Figure 13: DXA quality control plot for BMC throughout the FAB Study 
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Figure 14: DXA quality control plot for BMD throughout the FAB Study 
 
A previous departmental study of normal weight adults showed precision (CV) at L1-L4 
to be 1.2% for area, 2.2% for BMC and 1.0% for BMD. Others have reported significant 
differences in precision error between normal and obese adults for LS (0.99% normal 
and 1.68% obese); and WB BMD (0.66 to 0.77% normal and 0.91% obese) by DXA (215, 
216). When the European Spine Phantom was layered with bags of semi-solid 
hydrogenated vegetable oil to simulate overlying adipose tissue, precision error of the 
change in DXA BMD was 3.1% for the PA spine and 3.7% for TH (217). DXA precision 
is also lower in obese adults than those of normal BMI for measures of FM (2.98% normal 
BMI, 1.55% obese) and LM (1.42% normal BMI and 1.68% obese) (216). 
 
Limitations of DXA 
The Hologic Discovery A has a scan table weight limit of 159kg, therefore participants 
heavier than 159 kg were not recruited. It can be difficult to position obese participants 
on the table, with the limited size of the scanning area leading to soft tissue being 
excluded from the scan. Half body scanning can be used; however this method can 
introduce error if the two midlines are misaligned, or where there are anatomical 
differences between the two sides of the body (218).  
 
As DXA is based on a series of two compartment models, a constant level of hydration 
is assumed throughout the LM, which is not always true. DXA is also affected by the 
inhomogeneity of fat distribution (219). In pixels containing both bone and soft tissue, the 
composition of the soft tissue element of the pixel is estimated from ‘bone free’ pixels 
situated adjacent to the bone. By assuming the same percentage of fat to lean mass 
within the soft tissue portion, error can be induced. For the same reason, bone marrow 
fat may also affect measurements of BMD by DXA. In those with osteoporosis, 
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accompanied by increased bone marrow fat, DXA may “widen the difference in BMD 
results” when compared with normal individuals (220, 221). 
 
As BMC is affected by bone size, this must be adjusted or controlled for to ensure 
accurate determination of BMD. DXA has a limited ability to assess bone geometry and 
the positioning of cut planes used to identify regions of interest can affect the accuracy 
and precision of such observations (222). Measurements of BMD are confounded by 
greater soft tissue thickness, which absorbs the x-ray beam such that the resulting 
attenuation is increased. Studies involving fat layering of phantoms have shown aBMD 
by DXA to be increased with increasing fat layering relative to baseline measurements 
(217, 223, 224). 
 
Errors in determining BMC, bone area and proximal femur geometry can arise using fan 
beam DXA due to magnification effects due to proximity to the x-ray source (225). In 
obese individuals with increased posterior soft tissue thickness, the distance of the 
skeleton from the x-ray source is decreased and so the distance from the apex of the fan 
beam is decreased, leading to magnification effects as the observed width of scanned 
bone increases (226). Although this does not significantly affect BMD measurements, 
computational input is required to correct magnification errors in BMC, area and 
geometry outcomes. 
 
Quantitative Computed Tomography 
Principles of QCT 
QCT involves the use of x-rays and computational input to reconstruct a greyscale image 
of a section or slice of the body. X-rays are passed from the radiation source through the 
body and the resulting intensity is detected by a detector on the opposite side. This 
generates an attenuation profile, or projection, which is then reconstructed into an image 
by computing the spatial distribution of the attenuation onto a blank matrix (227). QCT 
allows the visualisation of a range of tissue densities and of within-tissue density 
gradations. Attenuation values within a voxel are compared to the attenuation of water 
and the mean attenuation within the voxel is converted into Hounsfield units (HU); an 
arbitrary scale to determine the derived density of tissues, where water has a HU of zero 
and each value represents a shade of grey on the image (Figure 15) (228). The resulting 
image is made up of pixels of varying gradations of HU. 
 
HU = 1000 x ((µ tissue - µ water) / µ water), where µ= attenuation coefficient 
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Figure 15: Scale of attenuation in Hounsfield Units of various tissues 
adapted from (227, 229) 
 
The peak tube voltage (kilovolts peak (kVp)), controls the quality of the x-ray beam, and 
inversely affects image contrast.  The tube current (mA or mAs (Ma x sec)), controls the 
quantity of x-ray photons produced and affects the image density. The patient dose is, 
therefore, directly proportional to the tube current. The noise index is chosen from 
several options to define the level of acceptable noise in the image. The scanner adjusts 
the mA according to the noise index selected, so patient dose is inversely related to 
image noise. Using the pre-specified noise index rather than altering the scan 
parameters contributing to noise ensures a consistent level of noise across the study 
sample (230). Slice thickness must be consistent to ensure reproducibility of repeated 
scan sections. 
 
QCT Procedure 
Participants aged 55 to 75 years underwent a QCT scan of the right hip and lumbar spine 
(L1-L3). Due to the effective radiation dose to the axial skeleton, premenopausal women 
and men aged 25 to 40 years were excluded from QCT scanning. QCT scans were 
obtained using a LightSpeed VCT-XT scanner (General Electric Healthcare, 
Buckinghamshire, UK) in the Medical Imaging Department, Northern General Hospital, 
Sheffield. This scanner has 64 detector elements along the z-axis and uses a solid state, 
scintillation detector array system to convert the incident x-ray intensities to light 
energies, which are detected by a photo diode and converted into electrical signals for 
image generation (227). All QCT scans were performed in the axial plane, with a helical 
rotation and rotation time of 0.8 seconds and a table height of 155. The scan pitch, (pitch 
= d / (M x S)) or “the ratio of the table feed (d) [in mm per 360° rotation] to total slice 
collimation (M.S)”, where M= the number of slices and S= the slice width (227), was 
0.969 for each scan. All scans had a noise index of 30.  
 
Participants were placed in the AP position; with the upper part of a Mindways phantom 
(Mindways Software Inc., Austin, TX, USA) positioned level with the iliac crest. Gel bags 
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were used to fill any gaps under the participant as necessary. Scout scans were 
performed initially to ensure accurate positioning of the phantom and to select 
subsequent scan regions  
 
QCT scans of the proximal femur were performed with a slice thickness of 0.625mm, 
beginning 3 cm above the femoral head to 3 cm below the lesser trochanter. The tube 
current (modulated Ma) was at a maximum 200, minimum 100, with a mean assumed 
tube current of 120mA and a tube voltage of 120 kilovolt peak (kVp).  
 
QCT scans of the lumbar spine (L1-3) were attained from 5mm above the superior end 
plate of L1 (inclusive of the T12-L1 joint space) to 5mm below the end plate of L3 
(inclusive of the L3-4 joint space). Scans had a slice thickness of 0.625mm. The tube 
current (modulated Ma) was at a maximum 140, minimum 80, with a mean assumed 
tube current of 120mA and a tube voltage of 80 kilovolt peak (kVp). 
 
3D reconstruction and analysis of the proximal femur and lumbar spine QCT scans was 
performed using the Mindways QCT Pro™ software version 5.0.3 (Mindways Software, 
Inc., Austin, TX, USA). The results for L1-3 were averaged for each participant. The 
CTXA application of QCT Pro was used to determine total hip and femoral neck 
outcomes. Default threshold values of 100 mg/cm3 and  350 mg/cm3 were applied  to 
distinguish bone from soft tissue and cortical from trabecular bone, respectively. QCT 
scans were analysed by a single operator blinded to BMI, although due to the nature of 
the analytical process, blinding could not be considered true. 
 
QCT Outcomes 
QCT was used to determine L1-3 vBMD. Bone mass (g), area (cm2), volume (cm3) and 
vBMD (mg/cm3) were determined for the total, cortical and trabecular compartments at 
the TH and FN. FN angle, FN width and hip axis length were also determined. 
 
QCT Calibration 
Quality assurance was performed once per month using a Mindways phantom 
(Mindways Software, Inc., Austin, TX, USA). 
 
Advantages of QCT over DXA  
QCT enables 3D volumetric measurements to be acquired, rather than 2D areal 
measurements by DXA. QCT enables the assessment of trabecular and cortical bone 
compartments and enhances ability to determine geometric properties of bone. QCT has 
 55 
been shown to be less affected by soft tissue thickness than DXA (217, 231). Being less 
affected by soft tissue thickness, differences in bone density by DXA and QCT imaging 
have been reported. Women with a BMI >27 kg/m2 had a mean DXA T-score 1.45 units 
greater than that of age and height matched controls, but the mean QCT T-score was 
not different between obese and non-obese groups (Weigert and Cann 1999. Cited in 
(224)). Therefore QCT may provide a more accurate assessment of bone density in 
obesity than is possible by DXA.  
 
Limitations of QCT 
Generally QCT is associated with higher cost than DXA, is less widely available, and 
requires more specialist analysis and interpretation than DXA, restricting its use. As a 
result, QCT is less validated for fracture risk prediction than DXA, with a range of analysis 
packages and in-house FE models being used to analyse scans and estimate vBMD and 
bone strength. Some previous studies have shown positive associations between QCT 
derived vBMD and fracture risk (232-235), although adding QCT parameters to DXA 
based estimate of fracture risk was not advantageous (236).  
 
The scanner gantry is of a fixed width which can lead to obese participants exceeding 
the field of measurement. QCT scanning involves a higher radiation dose than DXA 
scanning and the radiation exposure associated with QCT of the spine and proximal 
femur in this study was considered too high for the 25 to 40 years group and was not 
performed. A balance must be struck between the necessary radiation exposure and the 
image resolution required (228).  
 
QCT is affected by inhomogeneity of soft tissue distribution and bone marrow fat, 
although to a much lesser degree than DXA. Artifact on QCT images can result from 
patient movement, beam hardening, scattered radiation or partial volume effects. 
 
High Resolution Peripheral QCT 
Principles of HR-pQCT 
High resolution peripheral QCT (HR-pQCT) involves the same principles as QCT, but 
enables high resolution scanning of the distal appendicular skeleton. A 360° rotating x-
ray tube generates x-rays which are passed through a section of the distal radius or distal 
tibia, and detected by a static 2D detector array. This generates an attenuation profile, 
which is reconstructed into an image by computing the spatial distribution of the 
attenuation onto a blank matrix (227). This simultaneous acquisition of a series of 2D 
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parallel image slices, is then computed into a high resolution 3D image (isotropic 
resolution = 82 µm). 
 
Total, cortical and trabecular densities are determined from a pre-calibration step. The 
scanner is calibrated using a phantom with five hydroxyapatite-resin compartments of 
densities from 0 mgHA/cm3 (a soft tissue equivalent with no mineral content) to 800 
mgHA/cm3 (Figure 16). Image slices are taken of the phantom and the mean attenuation 
for each of the compartments calculated. From this pre-calibration data the attenuation 
values of the scan can be converted into measures of BMD (mgHA/cm3). 
A   B  
Figure 16: Scan images of the HR-pQCT phantoms 
 
HR-pQCT Procedure 
Scans were acquired using the XtremeCT Device (Scanco Medical AG, Zurich, 
Switzerland)in the high resolution mode (image matrix= 1536x1536) using a source 
potential of 60 kVp, a tube current of 900 mA and an integration time of 100 ms. 110 
slices were acquired over a scan length of 150mm, diameter of 125mm and stack height 
of 9.8mm. Scans were performed using the non-dominant limb, with the dominant limb 
used if the participant had sustained prior fracture of the non-dominant limb. 
 
HR-pQCT Procedure: Distal Radius 
With the participant seated, the operator placed the hand and lower arm into the forearm 
cast and used an arm pad to stabilise the arm within the cast (Figure 17A). The chair 
was positioned so that the arm rest of the chair was level with the gantry opening and 
the arm was placed into the device and secured (Figure 17B). A scout scan was 
performed to determine the measurement area. 
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A)   B)  
Figure 17: Positioning for the distal radius HR-pQCT scan 
illustrating the arm within the cast (A) and positioning of the participant (B) 
 
A reference line was placed on the notch on the articular surface of the distal radius on 
the scout image to indicate the position of the first measurement slice (9.5 mm from the 
reference line) (Figure 18). The participant was instructed to remain motionless and the 
scan was performed. Upon completion, the cast was removed and the scan quality 
evaluated. The operator visually inspected random slices to check consistent quality. 
The operator drew a contour around the cortical perimeter on the first image, before 
running the automatic contouring detection program which iterated the contouring 
process through the slice stack. Images were then analysed using the ‘Evaluation 3D’ 
option.  
 
Figure 18: Reference line and measurement area on a distal radius scout scan 
 
HR-pQCT Procedure: Distal Tibia 
The subject seated, the operator placed the foot and lower leg into the tibia cast and 
used a foot insert and pad to secure the leg within the cast (Figure 19A).   
Reference line 
} Measurement stack 
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A)   B)  
Figure 19: Positioning for the distal tibia HR-pQCT scan 
illustrating the leg within the cast (A) and positioning of the participant (B) 
 
The leg was rested on the leg support and the chair positioned with the leg at the same 
height as the gantry. The leg was placed into the device and secured (Figure 19B). A 
scout scan was performed to determine the measurement area; with a reference line 
placed at the endplate of the distal tibia on the scout image to indicate the position of the 
first measurement slice (9.5 mm from the reference line) (Figure 20). The measurement 
scan and analysis was completed as per the distal radius procedure. 
 
Figure 20: Positioning of the reference line on a distal tibia scout scan 
 
HR-pQCT Outcomes 
Volumetric BMD, cortical and trabecular bone structures and bone microarchitectural 
parameters at the distal radius and distal tibia were determined. HR-pQCT outcomes are 
described in Table 2, supported by Figure 27. 
 
HR-pQCT Calibration 
The XtremeCT device was calibrated daily using the manufacturer device-specific 
phantom (Scanco Medical AG, Zurich, Switzerland) to monitor the stability of the 
machine and pre-calibrate the scanner. Weekly measurements of the phantom were 
performed to monitor the assessment of bone microstructural properties.  
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Table 2: HR-pQCT outcomes, units, definitions and abbreviations 
Outcome Units Abbrev. Definition 
Total area mm2 Tot.Ar 
Mean surface area of the cortical and 
trabecular compartments 
Cortical area mm2 Ct.Ar 
Mean surface area of the cortical 
compartment 
Trabecular area mm2 Tb.Ar 
Mean surface area of the trabecular 
compartment 
Total vBMD mgHA/cm3 Tot.vBMD 
Total mineral mass divided by the total 
bone volume 
Cortical vBMD mgHA/cm3 Ct.vBMD 
Cortical mineral mass divided by the 
cortical volume 
Trabecular 
vBMD 
mgHA/cm3 Tb.vBMD 
Trabecular mineral mass  divided by the 
volume inside the cortical bone 
Cortical 
thickness 
mm Ct.Th 
Mean thickness between the periosteal 
and endosteal surfaces  
Cortical 
perimeter 
mm Ct.Pm 
Distance covered by the perimeter of 
the periosteal surface 
Cortical porosity % Ct.Po 
Percentage of cortical area occupied by 
pores 
Cortical pore 
diameter 
µm Ct.Po.Dm 
Mean diameter of pores within the 
cortical bone 
Cortical tissue 
mineral density 
 
mgHA/cm3 
 
Ct.TMD 
 
Cortical mineral mass divided by the 
cortical volume after excluding cortical 
pore space 
 
Trabecular 
number  
mm-1 Tb.N 
Mean number of trabeculae per mm 
within the trabecular compartment 
Trabecular 
thickness  
mm Tb.Th 
Mean thickness of trabeculae within the 
trabecular compartment 
Trabecular 
spacing 
mm Tb.Sp 
Mean distance between trabeculae 
within the trabecular compartment 
Trabecular 
heterogeneity 
mm Tb.N.SD 
SD of the intra-individual distribution of 
trabecular separation 
Bone volume 
fraction 
% BV/TV 
Derived by dividing Tb.vBMD by an 
assumed 100% mineralisation of 1200 
mgHA/cm3 
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Advantages of HR-pQCT Over DXA and pQCT 
Unlike DXA, HR-pQCT enables the distinction between cortical and trabecular bone 
compartments, allowing the study of bone microstructure. HR-pQCT enables high 
resolution imaging of the non-weight bearing distal radius which is a common fracture 
site and of the weight bearing tibia (237). There is less soft tissue present at distal sites 
and therefore HR-pQCT is likely to be less affected by soft tissue confounding than DXA 
or axial QCT scanning. In contrast to axial QCT, radiation exposure from HR-pQCT is 
low, with a typical scan effective dose of 3 µSv (237) and areas particularly sensitive to 
radiation exposure (e.g. the reproductive organs) are excluded from the scan area. 
 
Limitations of HR-pQCT 
It is unknown how well peripheral measurements at the distal radius and tibia reflect 
those of the axial skeleton.  A recent study found that skeletal stiffness, density and 
microarchitecture at peripheral sites assessed by HR-pQCT, was significantly associated 
with that of the proximal femur and lumbar spine, as measured by QCT (238). Moderate 
correlations have also been reported elsewhere (239).  
 
Whilst some outcomes, e.g. Tb.N, are directly measured, the majority of trabecular 
outcomes are derived, including Tb.Th and Tb.Sp (240). Despite HR-pQCT technology 
vastly improving resolution compared to previous technologies, resolution issues remain 
a challenge when defining the cortical and trabecular compartments, particularly when 
the cortical region is porous(241) . The 82μm resolution achieved with the HR-pQCT 
scanner is close to the thickness of a trabecula. Assessments of Ct.Po are also limited 
by the resolution of HR-pQCT, with Ct.Po assessments confined to detection of 
Haversian canals and larger resorption cavities resolvable by HR-pQCT (237). 
 
Where trabeculae are between 1 to 2 voxels in thickness, soft tissue is included in the 
voxel volume and so partial volume effects result, lowering the threshold for the voxel to 
be identified as trabecular bone. 
 
Defining the cortex from the trabeculae at the transitional zone can be difficult; 
particularly when the cortex is porous or when Ct.Th is low. This can be an issue both 
for the operator identifying the periosteal surface before the scan analysis is run and for 
the software during the automated analysis (237). 
 
Movement artefact is common, and “measures of micro-architecture are more sensitive 
to movement artefact compared with geometric or densitometric measures” (237). A 
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single repeat scan was factored into the radiation protection assessment for HR-pQCT 
scanning to allow for a repeat scan to be taken in the event of movement on the first 
image.  
 
Some participants report discomfort relating to positioning within the cast or difficulty 
refraining from movement for the scan duration and large individuals may present with 
limbs greater than the width of the cast or than the width of the scanner gantry. Our 
department has considerable experience with positioning participants of all ages and of 
a range of body sizes, having performed validation studies involving the HR-pQCT 
device previously.  
 
As HR-pQCT has only been commercially available since 2004, with the first publications 
involving the use of HR-pQCT arising in 2005 (242) there is currently limited reference 
population data and little data on prospective fracture rates or treatment effects relating 
to outcomes determined by HR-pQCT. 
 
Micro Finite Element (µFE) Analysis 
Bone strength was determined directly from the HR-pQCT scans using the extended 
µFE software (version 1.13; FE-solver included in the Image Processing Language, 
Scanco Medical AG, Zurich, Switzerland) which simulates strength-determining 
biomechanical tests through mathematical modelling, taking into account trabecular and 
cortical microarchitecture. This software is fully automated and validated for the 
assessment of in-vivo bone strength (243, 244). A compression test was used to simulate 
a fall from standing height onto an out-stretched hand. Each voxel was converted into 
equally sized elements and the elements connected by a mesh. A Young’s modulus of 
20 GPa and 17 GPa was applied to cortical and trabecular bone elements respectively. 
A Poisson’s ratio of 0.3 was applied to all elements. A 1000 N load was applied in the 
axial direction at the distal site, while the proximal bone was constrained in all directions 
(Figure 21) (245). Failure was said to occur when 2% of the bone tissue was strained 
beyond a critical level of 3500 strain. This was based on a previously defined criterion 
by Pistoia et al. (246) but modified to reflect the elastic properties assigned in the present 
study in relation to those used by Pistoia et al. (245, 246). A similar model was also used 
to determine tibial strength.  
 
Outcomes of the µFE analysis are listed in Table 3. 
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Figure 21: The principle of the determination of bone strength from µFEA 
adapted from (235) 
 
FEA Limitations 
µFE models which simulate direct compression at the tibia may be of limited value due 
to the more common sideways, twisting nature of falls leading to ankle fracture. Variation 
in the extent of mineralisation may affect µFE measurements, as inhomogeneous 
mineralisation is likely to affect the distribution of strains throughout the compartment, 
but this is not taken into consideration in the present software. 
 
 
Table 3: µFE analysis outcomes from HR-pQCT scanning 
Outcome Units Abbrev. Definition 
Stiffness kN/mm Stiffness Resistance to deformation when 
applying a load; total reaction 
force divided by displacement  
Estimated ultimate 
failure load 
kN Est.Fail.Load Maximum load the bone can 
bear before fracture; when 2% 
of the bone is strained beyond 
3500 strain 
Mean trabecular Von 
Mises stress  
MPa Tb.VM Indicates whether combined 
stresses in the x, y and z 
directions in the trabeculae will 
cause failure 
Mean cortical Von  
Mises stress 
MPa Ct.VM Indicates whether combined 
stresses in the x, y and z 
directions in the cortex will 
cause failure 
Proximal trabecular load 
All % 
 
The distribution of the load 
between the cortical and 
trabecular compartments 
Proximal cortical load   
Distal trabecular load  
Distal cortical load  
 
Assessment of Adiposity by Imaging 
Whole Body DXA 
From the whole body DXA scan previously described, body composition with sub-region 
analysis software was used to determine FM (kg) of the total body, trunk, android/gynoid 
regions, arms and legs (from which appendicular FM was calculated). Despite 
advantages over anthropometrical techniques, such as a lower influence of inter and 
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intra-operator effects, DXA measurements of FM are confounded by greater body 
thickness. The assessment of abdominal adiposity may be less reliable than 
assessments at peripheral sites due to confounding influences of other organ systems 
within the region of interest. A further key limitation of using DXA to estimate FM is its 
inability to distinguish between visceral and subcutaneous abdominal fat compartments. 
 
Computed Tomography (CT) 
Five-slice CT scans were taken at the mid-level of the L3 vertebra in all participants, to 
estimate subcutaneous abdominal (SAT) and visceral (VAT) adipose tissue. CT scans 
were taken using the LightSpeed VCT-XT (General Electric Healthcare, 
Buckinghamshire, UK) in the Medical Imaging Department, Northern General Hospital. 
Participants were placed in the AP position; with a Mindways phantom (Mindways 
Software Inc., Austin, TX, USA) in the midline and the umbilicus central to the phantom. 
Gel bags were used to fill gaps under the participant as necessary. AP and lateral 
topograms of the abdomen were taken at the level of L3 to ensure accurate positioning 
of the phantom. CT scans were performed in the axial plane, with a helical rotation and 
rotation time of 0.8 seconds and a table height of 155. The scan pitch was 1.375 for each 
scan, with a noise index of 46. The tube current (modulated Ma) was at a maximum 400 
mA, minimum 100 mA, with a tube voltage of 120 kilovolt peak (kVp). 
 
Total, SAT and VAT volumes were determined using the Volume Viewer imaging 
software (General Electric Healthcare, Buckinghamshire, UK) on an AW Workstation 
(General Electric Healthcare, Buckinghamshire, UK). The mid (third) slice in the image 
sequence was selected with the image in the axial format. To identify adipose tissue, a 
threshold of -30 to -130 HU was applied. The total volume of adipose tissue was 
calculated using the histogram function. A manual trace function was applied inside the 
SAT inner border and the ‘cut outside’ function applied to remove SAT from the image 
(Figure 22). The histogram function was re-applied to quantify the remaining VAT and 
SAT was determined as total minus VAT.  
 
Figure 22: Manual trace to distinguish SAT and VAT on a CT abdomen scan 
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Assessment of Muscle Mass by Imaging 
Whole body LM (WBLM) was determined by DXA. Appendicular LM (ALM) was 
calculated as the sum of the DXA determined LM of the arms and legs. Limitations to the 
use of DXA for determining LM include confounding by greater soft tissue thickness in 
obesity and the inability to account for fat infiltration of muscle. 
 
Radiation Exposure 
The radiation exposure (effective dose) for each scan was:  
 DXA: WB= 8.4 µSv, proximal femur= 8.6 µSv, LS= 14.9 µSv, VFA= 24.0 µSv. 
 CT/QCT: Abdomen= 430 µSv, LS = 980 µSv, proximal femur = 2500 µSv. 
 HR-pQCT: Distal radius= 6 µSv, distal tibia= 6 µSv. 
The overall effective dose: 
 25 to 40 years age group = 474 µSv, equivalent background dose: 11 weeks.  
 55 to 75 years age group = 3978 µSv, equivalent background dose: 22 months. 
 
 
Physical Performance Assessments 
Physical function was determined using a short physical performance battery (SPPB) 
adapted from that described by Guralnik et al. (247). Batteries typically include 
assessments of balance, walking speed and a chair stand test, which have been shown 
to associate with falls risk and morbidity (247, 248). The SPPB in this study comprised a 
balance assessment from a narrow walk test, walking speed assessment and a chair 
stand test: 
 
Chair Stand Test 
The chair stand test determines an individual’s ability to stand from a chair without using 
their arms; reflecting lower limb strength. Participants were seated with feet on the floor, 
squarely in front of them, knees flexed slightly greater than 90°. Participants kept their 
arms folded across their chest throughout. Participants were asked to stand and sit once 
to determine their capability to continue to the repeated test. If able to continue, 
participants were instructed to stand and sit five times continuously, as quickly as 
possible. Time taken to complete the five stand-and-sit cycles was recorded to the 
nearest 0.01 seconds. 
 
Gait and Balance Assessment 
Walk tests were used to determine usual walking speed and assess balance. To assess 
usual walking speed (m/s), participants walked a six metre marked course (Figure 23) at 
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their normal pace. The number of steps and time taken, to the nearest 0.01 seconds, 
were recorded. This was repeated and the average determined. The course was then 
narrowed to 20cm wide (Figure 23). Participants were asked to walk the course, keeping 
their feet within the marked lines whilst looking ahead. Time taken to complete the narrow 
walk test was recorded to the nearest 0.01 seconds. This was repeated three times and 
the average time taken and number of deviations recorded.  
 
Figure 23: Six metre walk and narrow walk course 
 
 
SPPB Score 
A SPPB score was calculated out of a maximum of 12 points to provide an overall 
measure of physical performance. Quartile of repeated chair stand time and gait speed 
were determined by gender. Participants in the top quartile (Q4) were awarded 4 points, 
through to the poorest performing quartile (Q1) awarded 1 point. As balance was 
measured on an ordinal scale, participants deviating from the lines on 0 to 3 occasions 
were classed as ‘within the lines’ and awarded 4 points, participants completing the 
course but deviating more than 3 times were classed as ‘not within the lines’ and awarded 
2 points and those unable to complete the assessment were awarded 0 points for that 
test  
 
Grip Strength 
Hand grip strength was measured using a digital hand dynamometer (Saehan 
Corporation, Masan, Korea) to determine muscle strength. Participants were seated, feet 
flat on the floor, and instructed to hold the dynamometer with their upper arm in line with 
their body, forearm at approximately 90º and their wrist un-rotated. Participants were 
instructed to grip the dynamometer as tightly as possible for 5 seconds and the result 
recorded. No encouragement was given whilst the participant was executing the test. 
Grip strength was assessed 3 times on each hand, starting with the right hand. At least 
30 seconds rest was given between each repetition.  
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Assessment of Sarcopenia 
Sarcopenia was defined using the European Working Group on Sarcopenia in Older 
Persons (EWGSOP) definition (249). Individuals were categorised as: 
1) Not sarcopenic (Normal ALM) 
2) Pre-sarcopenic (Low ALM) 
3) Sarcopenic (Low ALM and either weakness or poor SPPB score) 
4) Severely sarcopenic (Low ALM, weakness and poor SPPB score) 
 
Low ALM was defined as an ALM corrected for height (ALM/(height (m)2), (or Skeletal 
muscle index (SMI)), <7.23 kg/m2  for men or <5.67 kg/m2  for women (249). Weakness 
was defined as a maximal hand grip strength <30 kg (men) or <20 kg (women).  
A poor SPPB score was defined as a SPPB score ≤8. 
 
 
Biochemistry 
Blood samples were collected at visit 1, following an overnight fast. Samples were taken 
between 08:00 and 10:00 to minimise the effect of inter-individual variability and 
circadian rhythms on circulating concentrations (250). To confirm eligibility, screening 
biochemical analysis was performed prior to visit 2 by the Clinical Chemistry Laboratory, 
Sheffield Teaching Hospitals. Participants were screened for creatinine, calcium, 
albumin and PTH (Cobas c701 auto-analyser, Roche Diagnostics, Mannheim, 
Germany), glucose (Cobas c702 auto-analyser, Roche Diagnostics, Mannheim, 
Germany), TSH (Cobas e602 auto-analyser, Roche Diagnostics, Mannheim, Germany) 
and full blood count (Sysmex XN Series, Sysmex, Norderstedt, Germany). In participants 
aged 55 to 75 years, screening bloods were assessed for TC, HDL, LDL and triglycerides 
(Cobas c701 auto-analyser, Roche Diagnostics, Mannheim, Germany). The 
manufacturer’s reported inter assay precision is <2.0% for each test. 
 
FAB Study Biochemistry 
Blood samples were taken to assess hormones, BTMs and other biochemical factors 
which may mediate the relationship between obesity and bone. Samples were allowed 
to clot at room temperature for 30 minutes before being centrifuged at 3000rpm for 10 
minutes. Serum samples were aliquoted and stored at -80ºC until analysis.  
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Assay Principles 
Manual Sandwich Enzyme Immunoassay (ELISA) 
Serum samples and standards were diluted as necessary (100 fold for leptin and 
adiponectin, 3 fold for OPG) and added to 96 well microplates, pre-coated with analyte-
specific monoclonal antibody (Figure 24).  
 
Figure 24: Example ELISA well-plate set-up 
  
 
Any analyte contained in the sample binds to the antibody. Following an incubation 
period, the wells were washed to remove all unbound substances. An enzyme-linked 
antibody specific to the analyte was added (leptin and adiponectin: monoclonal antibody, 
OPG: biotin labelled polyclonal antibody)*. After further incubation, the wells were 
washed to remove unbound antibody-enzyme reagent**. Colourless substrate solution 
was added and the plate kept in darkness. Colour developed in proportion to the quantity 
of analyte contained in the sample. After a final incubation, colour development was 
stopped with the addition of acidic solution, and the colour changed. Final colour intensity 
was measured using a microplate reader. An illustrated overview of this process is given 
in Figure 25.  
 
*In the sclerostin ELISA, biotin labelled monoclonal antibody was added to the microplate 
with the samples, incubated, aspirated and washed before a streptavidin-HRP conjugate 
was added at this point.  
 
**In the OPG ELISA, streptavidin-HRP conjugate was added at this point, incubated and 
washed before the subsequent steps.  
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Figure 25: Overview of the stages of an ELISA 
 
Chemiluminescence Immunoassay (CLIA) 
The IDS-iSYS (ImmunodiagnosticSystems, Boldon, UK) uses CLIA to detect and 
quantify sample analytes. The serum sample is loaded onto the autoanalyser and two 
antibodies are added; an anti-analyte antibody labelled with biotin and an acridinium 
labelled antibody. Magnetic micro-particles coated with streptavidin are added and bind 
to the biotin in the complex. The mixture is incubated and the magnetic particles become 
bound to a magnet. A wash step occurs to remove any unbound substances. Reagents 
are added to stimulate the acridinium conjugate to emit light, with the amount of light 
produced being proportional to the concentration of the analyte. 
 
ElectroChemiLuminescence Immunoassay (ECLIA) 
The Cobas e411 autoanalyser (Roche Diagnostics, Mannheim, Germany) uses an 
ECLIA to detect small analyte concentrations. The serum sample is loaded onto the 
autoanalyser and two antibodies added; one labelled with biotin and the other labelled 
with ruthenium, which form a complex with the analyte. The mixture is incubated before 
microbeads coated with streptavidin are added, which interact and bind to the biotin in 
the complex. The mixture is aspirated into a measuring cell. When a magnetic force is 
applied, the microbeads bind to the surface of the oxide film-coated electrode. A solution 
containing tripropylamine (TPA) is added to remove any unbound substances. When a 
specified voltage is given by the electrode, the ruthenium and TPA excite and the TPA 
releases a proton which acts as a reactant to the ruthenium. As the ruthenium decays 
from its excited state to its lower energy basal state, it emits light. This luminescence is 
detected by a photomultiplier and the intensity over a period of time is subsequently 
quantified against a calibration curve, with the amount of light proportional to the analyte 
concentration.  
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Biochemical Tests 
Bone Turnover Markers 
Changes in BTMs reflect acute alterations in bone metabolism which may not be 
detectable from BMD by imaging. High bone turnover is associated with bone loss and 
so may help to identify individuals at high risk of fracture (251). BTMs are either by-
products of collagen formation or breakdown, or cell proteins that reflect osteoclastic or 
osteoblastic activity. Serum and urinary CTX is proportional to the mass of the resorbed 
bone matrix, while serum concentrations of OC and BAP are proportional to bone 
formation activity assessed by histomorphometry. 
 
Despite there being a range of BTMs available to measure, serum CTX and serum PINP 
were measured in this study in line with the recommendations of the International 
Osteoporosis Foundation and International Federation of Clinical Chemistry and 
Laboratory Medicine (252). βCTX is a product of type I bone collagen degradation and 
used as a marker of bone resorption. Collagen is degraded into long peptides of CTX 
and N-terminal crosslinks before further degradation into smaller molecules such as 
deoxypyridinoline, pyyridinoline, hydroxylyzine and hydroxyproline. CTX circulates in 
native (α) and β-isomerized forms. The degradation of mature type-I collagen is 
determined from the β-isomerized form which will be measured in this study, rather than 
the degradation of immature collagen (α form). During bone formation osteoblasts 
secrete procollagen to be incorporated into the bone matrix. PINP is a matrix protein 
derived when the N-terminal of the procollagen molecule is cleaved from the type I 
procollagen molecule. The PINP molecule is released into the circulation whilst the 
remainder of the procollagen molecule is incorporated into the bone matrix. PINP can 
therefore be used as a marker of bone formation. OC, a non-collagenous protein specific 
to osteoblast activity, and BAP, a glycoprotein found on the surface of osteoblasts, are 
also markers of bone formation and reflect osteoblastic activity.  
 
CTX, PINP and OC were determined by automated ECLIA (Cobas e411, Roche 
Diagnostics, Mannheim, Germany). BAP was determined by automated CLIA (IDS-iSYS, 
Immunodiagnostic Systems, Boldon, UK). The inter assay CV for CTX was 2.9%, PINP 
5.7%, OC 2.9% and BALP 3.9%. 
 
Adipokines 
Leptin and adiponectin were determined by manual ELISA (Human Leptin Quantikine 
ELISA, Human Total Adiponectin Quantikine ELISA, R&D Systems, UK). The minimum 
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detectable dose for the leptin assay was <7.8 pg/ml. The mean minimum detectable dose 
for the adiponectin assay was 0.246 ng/ml. Samples above the range of detection of the 
adiponectin assay were diluted appropriately with calibrator diluent and the analysis 
repeated with the result multiplied according to the dilution factor. The inter assay CV for 
leptin was 3.8% and adiponectin 2.8%. 
 
Further Biochemistry 
PTH, 25OHD, totE2 and insulin were determined by automated ECLIA (Cobas e411, 
Roche Diagnostics, Mannheim, Germany). The inter assay CV for PTH was 2.8%, 
25OHD 5.7%, totE2 5.4% and insulin 5.0%. IGF-I was measured by automated CLIA 
(IDS-iSYS, Immunodiagnostic Systems, Boldon, UK). The inter assay CV for IGF-I was 
4.3%. Sex hormone binding globulin (SHBG) was measured by automated ECLIA 
(Cobas e602, Roche Diagnostics, Mannheim, Germany). The manufacturer’s inter assay 
precision is <5.6%. HsCRP was measured by automated nephelometry (BNII System, 
Siemens, Siemens Healthcare Diagnostics, Surrey, UK). The inter assay CV for HsCRP 
was 3.3%. IL-6 was measured by automated immunoassay (Cobas e601, Roche 
Diagnostics, Mannheim, Germany). The manufacturer’s inter assay precision is <8.5%. 
 
OPG was measured by manual ELISA (Biovendor, GmbH, Heidelberg, Germany). The 
minimum detectable dose for this OPG assay was 0.03 pmol/L. Samples above the 
range of detection of the OPG assay (>60 pmol/L) were diluted appropriately with 
calibrator diluent and the analysis repeated with the result multiplied according to the 
dilution factor. The inter assay CV for OPG was 1.6%. Sclerostin was measured by 
manual ELISA (Biomedica, Vienna, Austria). The minimum detectable dose for this 
sclerostin assay was 2.6 pmol/L. The inter assay CV for sclerostin was 9.1%. 
 
Biochemical Calculations 
Free and Bioavailable E2 
E2 circulates bound to SHBG or albumin. Free E2 (fE2) was determined using the 
simplified calculation cited in Rinaldi et al. (253), based on the mass action law and taking 
into account the affinity constants of albumin and SHBG for E2: 
fE2 (mol/L) = (-b + √(b2 – 4ac)) / 2a 
Where:  N= 1+ affinity constant of albumin for E2 x albumin 
  a = N * affinity constant of SHBG for E2 
  b = N + affinity constant of SHBG for E2 * (SHBG - Total E2) 
  c = -Total E2  
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Affinity constant of albumin for E2 = 4.21 × 104 L/mol  
Affinity constant of SHBG for E2  = 3.14 × 108 L/mol 
 
Bioavailable E2 (bioE2) is that which is unbound or bound to albumin, as unlike SHBG, 
albumin dissociates readily to enable E2 to cross the cell membrane and bind to its 
receptor (253). BioE2 was calculated as:  
 bioE2 (mol/L) = (1+ affinity constant of albumin for E2 x albumin)* fE2 
The affinity constants used were those stated in Rinaldi et al. (253). It was not possible 
to use the more complex equation which takes into account competition for binding sites 
by testosterone, E2 and dihydrotestosterone, as no testosterone or dihydrotestosterone 
measurements were available.  
 
Insulin Resistance 
Insulin resistance was determined using the homeostasis model assessment of insulin 
resistance (HOMA-IR); calculated as: 
(Fasting serum glucose (mmol/L) * fasting serum insulin (µU/ml) / 22.5) 
 
Kidney Function 
Kidney function was estimated from calculation of estimated glomerular filtration rate 
(eGFR), using the Modification of Diet in Renal Disease (MDRD) equation: 
eGFR = 175 * (serum creatinine (µmol/L) * 0.0113)-1.154 * age-0.203 [* 0.742 if female] 
 
Vitamin D Sub-study Biochemistry 
At the vitamin D visit, blood samples were taken between 08:00 and 10:00 after an 
overnight fast. Serum and whole blood samples were kept frozen at −80°C until analysis, 
with the exception of CK samples which were analysed in real-time. 
 
Total 25OHD  
Total 25OHD was measured by automated ECLIA (Cobas e411, Roche Diagnostics, 
Mannheim, Germany). The inter assay CV was 4.6% 
 
25OHD2 and 25OHD3 
As immunoassays may fail to discriminate between 25OHD2 and 25OHD3, total 25OHD3 
was also measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) 
in the laboratory of the Institute of Human Development, University of Manchester. 200µl 
of sample and deuterated internal standard (d6-25OHD) were prepared using 100µl 
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methanol;isopropanol (80:20) then extracted with 1ml hexane. The extracted 25OHD in 
the hexane supernatant was blown down and reconstituted in 150µl of 66% methanol. 
37.5µl of this extract was injected onto a Waters Phenyl column attached to the mass 
spectrometer and eluted with an isocratic gradient over 5 minutes. Analysis was carried 
out in positive ion mode using the transitions m/z 401>159 and Mm/z 407>159 for 
25OHD and d6-25OHD respectively. Run time injection to injection was 5.1 minutes. 
Between batch CV (SD) was 7.4% (2.7), 7.1% (6.5) and 6.3% (8.8) at concentrations of 
37, 91, and 140 nmol/L respectively. 
 
Free 25OHD 
Free 25OHD was measured by immunoassay (Future Diagnostics BV, Wijchen, 
Netherlands) in the laboratory of Future Diagnostics (Wijchen, Netherlands) (254). 
Serum samples and calibrators were pipetted into the wells of a microtiter plate coated 
with anti-25OHD antibody. Free 25OHD was captured by the antibody during an 
incubation. After washing, a biotin-labelled 25OHD analog was allowed to react with the 
non-occupied antibody binding sites in a second incubation. After a second wash and 
incubation with a streptavidin-peroxidase conjugate, bound enzyme is quantitated using 
a colorimetric reaction. Signal intensity is inversely proportional to the concentration of 
free 25OHD in the sample. The assay was calibrated against a symmetric dialysis 
method. The calibrator range was 0.0 to 35.0 pg/ml. The limit of the blank, from 60 
replicates, was 0.7 pg/ml and the limit of detection, determined from the pooled SD from 
12 measurements of five low samples, was 1.9 pg/ml, both determined according to the 
Clinical Laboratory and Standards Institute EP17-A guideline. Precision was determined 
over 20 consecutive days with two runs per day according to the CLSI- EP5 protocol. 
Assay CVs were <15.7%.  
 
Calculated Free 25OHD 
Free 25OHD was also calculated from the concentration of DBP and albumin and their 
binding affinities for 25OHD using the formula (255): 
Free 25OHD = Total 25OHD/(1+(6*105 x albumin) + (7*108 x DBP))  
 
Total 1,25(OH)2D 
Total 1,25(OH)2D was measured by manual immunoassay (Immunodiagnostic Systems, 
Boldon, UK). The inter assay CV was 6.0%.  
 
Free 1,25(OH)2D  
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Free 1,25(OH)2D was calculated from the concentration of DBP and albumin and their 
binding affinities for 1,25OHD using the formula (256):  
Free 1,25(OH)2D= Total 1,25(OH)2D / (1+(5.4*104M-1 x albumin) + (3.7*107M-1 x DBP)) 
 
Vitamin D Binding Protein 
DBP was measured by manual immunoassay (Human Vitamin DBP Quantikine ELISA, 
R&D Systems, UK). The inter assay CV was 3.3%. 
 
Vitamin D Binding Protein Genotyping 
DBP genotyping was performed in the laboratories of the Sheffield Diagnostic Genetics 
Service, Sheffield Children’s Hospital. The pyrosequencing assay was developed in 
house, using PSQ assay design software version 1.0.6 (Qiagen), to detect DBP rs4588 
and rs7041 polymorphisms. PCR reactions contained 1μl (10 to 20 ng) of human 
genomic DNA, 5 pmol of forward and reverse primers, 7.5μl of OneTaq® 2X Master Mix 
with standard buffer (NEB) and H2O up to a final volume of 15µl. Table 4 shows the 
primer sequences.  
 
Table 4: Primer sequences for the genotyping of DBP 
Allele PCR primers (5'→3') 
Pyrosequencing primer 
(5'→3') 
VDBP 
rs4588+ 
rs7041 
F: 5'- ATCTGAAATGGCTATTATTTTG -3' 
R: 5' Btn- ACAGTAAAGAGGAGGTGAGTT -3' 
AAAAGCTAAATTGCCTG 
 
PCR conditions consisted of an initial denaturation at 94ºC for 3 min; 47 cycles of 
denaturation at 94ºC for 30 seconds, annealing at 57ºC for 30 seconds and extension at 
68ºC for 30 seconds; followed by a final extension at 68ºC for 4 minutes. PCRs were 
performed using a 9700 Gene Amp® PCR system (Applied Biosystems, CA). For each 
genotype determination, single-stranded DNA was purified from 5μl of PCR products 
using PyroMark Q96 Vacuum Prep Workstation (Qiagen). PCR products were bound to 
streptavidin Sepharose beads (GE Healthcare, UK), washed with 70% ethanol, 
denatured using a 0.2mol/L NaOH solution and washed again with 10mM Tris Acetate. 
Single stranded DNA was eluted in 12µl of sequencing buffer containing 0.3μmol/L 
pyrosequencing primer, denatured at 80ºC for 2.5 minutes and cooled to room 
temperature to allow annealing of the sequencing primer. Pyrosequencing was 
performed (PyroMark Q96 MD , Qiagen) according to the manufacturer's instructions. 
Nucleotide dispensation order was: VDBP rs4588+rs7041 CATGTCACACACTG. SNP 
analysis was carried out using the SNP analysis software provided (Qiagen). 
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Biochemical Markers of Bone Turnover 
CTX, PINP and OC were measured by automated ECLIA (Cobas e411, Roche 
Diagnostics, Germany). The inter assay CVs were: CTX 4.0%, PINP 4.1%, OC 2.2%. 
BAP was measured by automated CLIA (IDS-iSYS, ImmunoDiagnostic Systems, 
Boldon, UK). The inter assay CV for BAP was 4.5%.  
 
Vitamin D Sub-study Further Biochemistry 
Albumin, creatinine, calcium, phosphate, PTH, CK, triglycerides, TC, HDL and LDL were 
measured by automated ECLIA (Cobas c701, Roche Diagnostics, Mannheim, Germany) 
in the Chemical Chemistry laboratory, Sheffield Teaching Hospitals. The manufacturer’s 
reported inter assay precision was <2.0% for each test. IGF-I was measured using by 
automated CLIA (IDS-iSYS, ImmunoDiagnostic Systems, Boldon, UK). The inter assay 
CV was 3.2%. HsCRP was measured by automated nephelometry (BNII System, 
Siemens, Siemens Healthcare Diagnostics, Surrey, UK) in the Immunology laboratory, 
Sheffield Teaching Hospitals, UK. The inter assay CV was 3.1%.  
 
In an associated study, TNF-α, IL-1 and IL-6 were found to be frequently below the 
detection limit of the available assay and therefore were not measured. 
 
Biochemistry Quality Control 
All assays were undertaken by, or under the supervision of, an experienced technician, 
to minimise technician variability. For all manual assays a standard curve was produced 
using a range of standards from a stock solution (Figure 26). High and low QC standards 
were determined for OPG. Blank wells were included for sclerostin. An in-house QC 
sample was used for each plate. Samples were analysed in duplicates, where possible.  
 
Figure 26: Example manual assay standard curve plot 
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Calibration of the Cobas e411 and IDS-iSYS was performed prior to using reagents from 
a new lot. Further calibration of the IDS-iSYS was performed on an analyte dependent 
weekly or fortnightly basis, as recommended by the manufacturer. All samples 
underwent a maximum of two freeze-thaw cycles. Where repeated freeze-thaw cycles 
were indicated as unsuitable in the manufacturer’s guidelines, a fresh sample was used.  
 
Analyte measurement method can affect variability. Most of the auto-analysers used in 
the study involve a monoclonal antibody which ensures specific measurements of the 
analyte (251). Manual ELISAs are subject to greater operator error than automated 
methods. ECLIA and CLIA methods are highly sensitive, simple to perform, quick, and 
do not require radioisotopes (251). A further source of analyte variability is pre-analytical 
variability. Whilst some elements of pre-analytical variability can be easily modified, other 
causes are less modifiable, as shown in Table 5 (251). 
 
Table 5: Sources of analyte variability  
and attempts to control such variability in the FAB study 
 Source of variability How variability was controlled for  
M
o
d
if
ia
b
le
 
Circadian variation Samples taken between 08:00-10:00 
Menstrual variation Samples from pre-menopausal women taken 
in the follicular phase 
Fasting Overnight fasted blood samples taken 
Physical activity Participants instructed not to participate in 
vigorous activity for 24 hours prior to sampling 
Seasonal variation Not controlled for in FAB. All samples taken in 
two one month periods for the vitamin D sub-
study  
L
e
s
s
 e
a
s
il
y
 m
o
d
if
ia
b
le
 
Age Normal BMI/obese pairs matched by age 
Gender Normal BMI/obese pairs matched by gender 
Menopausal status Older women ≥5 years postmenopausal 
Diseases characterised by 
accelerated bone turnover 
e.g. Primary hyperparathyroidism, bone 
metastases; participants ineligible/ excluded 
Diseases characterised by 
dissociation of bone 
turnover 
e.g. Cushing’s disease, multiple myeloma; 
participants ineligible/ excluded 
Diseases characterised by 
low bone turnover  
e.g. Hypoparathyroidism; participants 
ineligible/ excluded 
Chronic diseases associated 
with limited mobility 
Participants ineligible/ excluded 
Recent fracture Participants with a fracture 12 months prior to 
recruitment ineligible 
 76 
Medications known to affect 
bone turnover 
e.g. oral corticosteroids, aromatase inhibitors, 
hormonal contraceptives; participants taking 
such medications ineligible  
Day-to-day variation Not controlled for 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: 
 
BONE DENSITY, STRUCTURE AND 
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CHAPTER 3: Bone Density, Structure and Strength in Obesity 
Background 
Obesity and aBMD 
BMI is positively associated with areal bone density in younger (15, 257), older (23, 43, 
45, 48, 105, 258-261) and elderly (262, 263) men and women. Body weight and BMI are 
positively associated with aBMD of the lumbar spine (48, 258, 259, 261), femoral neck 
(48, 258) distal radius (261), proximal femur and leg (23, 48, 259, 260, 263). 
Concordantly, a retrospective cohort study found that low body weight and low BMI were 
associated with osteoporosis at the lumbar spine, proximal femur, total hip, femoral neck 
and trochanter (48).  
 
Despite the majority of the literature indicating a positive association between body 
weight and aBMD, a number of studies have reported conflicting results. Such findings 
commonly result from opportunistic studies with insufficient power to detect differences 
in aBMD between normal BMI and obese groups, or from adjustment for body 
composition outcomes without acknowledgment of their covariance. Whether there is a 
threshold BMI above which aBMD ceases to be positively associated with BMI is unclear 
but has been proposed in response to findings of greater LS aBMD in overweight 
individuals versus normal BMI controls, but lower LS aBMD in obese than overweight 
individuals (264).  
 
Although obese adults may have higher aBMD than normal BMI adults, as discussed in 
Chapter 1, obese individuals are not exempt from fracture. There are several reports of 
a high prevalence of obese individuals presenting to fracture clinics even though these 
individuals were shown to have mean T-scores of +2.5 or greater at the lumbar spine, 
femoral neck or total hip (43, 44, 50). This suggests that aBMD may be a particularly 
poor indicator of fracture risk in obese individuals. 
 
Obesity and vBMD 
The principal outcomes of HR-pQCT imaging are illustrated in Figure 27 and described 
in more detail in Chapter 2. 
 
Obesity and Total vBMD 
Few studies have investigated associations between obesity and measures of vBMD. 
Obesity was associated with greater vBMD at the distal tibia by pQCT in pre and 
postmenopausal women (265) and was positively associated with vBMD by HR-pQCT 
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in a study of chronic kidney disease patients (266). Obese postmenopausal women in 
the OFELY cohort had a 13% greater vBMD at the distal radius and a 15% greater vBMD 
at the distal tibia than non-obese postmenopausal women (261). Another recent study 
found positive associations between total body FM and vBMD at the FN and LS by QCT 
and at the distal radius by HR-pQCT (267). 
 
Figure 27: Principal microstructural outcomes of HR-pQCT imaging 
 
 
Associations between BMI and total vBMD at the distal radius by HR-pQCT in young 
obese men were not presented by Bredella et al. (268). As there was no non-obese 
control group in this study, the limited BMI range may have been insufficient to detect 
such an association, particularly if the hypothesis of there being a threshold BMI above 
which increases in vBMD are disproportionate to increases in BMD holds true.  
 
Obesity and Tb and Ct vBMD 
At the distal tibia, high BMI (BMI>35 kg/m2) was positively associated with Tb.vBMD in 
two studies, with 15% greater Tb.vBMD in the obese than the non-obese women in the 
OFELY cohort (261, 265). However, the two studies yielded conflicting results in terms 
of Ct.vBMD, with lower Ct.vBMD by pQCT observed in obese premenopausal American 
women (265) but a 7% greater Ct.vBMD reported in obese women from the OFELY study 
(261). 
 
Positive associations between BMI and compartmental vBMD have also been reported 
at the distal radius, with obese women having a 14% greater Tb.vBMD and a 3% greater 
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Ct.vBMD, compared to non-obese women (261). Associations between BMI and Tb and 
Ct.vBMD at the distal radius were assumed not significant in young obese men (268). 
 
When L4 Tb.vBMD was investigated by QCT in obese premenopausal women, no 
significant associations between BMI and Tb.vBMD were found, although there was no 
non-obese control group to refer to in this study (269). 
 
Obesity and Bone Microarchitecture  
Only one study has presented bone microarchitectural findings in obesity compared to a 
non-obese control group. As already mentioned, greater total vBMD was observed in 
obesity and this was due to there being greater Ct.Th, Ct.Ar and Ct.vBMD and greater 
Tb.vBMD due to greater Tb.N with a lower Tb.Sp.SD (261). At the tibia, Ct.Th was not 
significantly greater in obesity, but trended positively. At the tibia Ct.Po was 21% lower 
in the obese group, whilst no differences in Ct.Po were observed at the radius (261). 
Tot.Ar and Tb.Ar were no different in obesity (261). Greater percentage differences in 
microarchitectural parameters between the obese and non-obese group were observed 
at the distal tibia compared to the distal radius (261).  
 
Similar to these findings, BMI was positively associated with Tb.N and inversely 
associated with Tb.Sp and Tb.Th in young obese men (268). Positive associations 
between BMI and Tb.N and Ct.Th were reported in chronic kidney disease patients, with 
an inverse association between BMI and Tb.Sp (266).  
 
A recent study examined the effect of FM and LM on HR-pQCT derived bone 
microarchitecture in obese individuals with metabolic syndrome (270). The study 
reported positive associations between LM and Tb.N and Tb.Sp at the radius, and  
vBMD, Tb.vBMD, BV/TV, Tb.N, Tb.Sp and Ct.Th at the distal tibia (270). No significant 
associations between FM and microarchitectural outcomes were observed (270). 
Whether associations between high BMI and bone microarchitecture are due to greater 
FM or greater LM in ‘healthy’ obese adults is unclear.  
 
Obesity and Bone Strength 
Bone strength describes “the force required to produce mechanical failure under a 
specific loading condition” (222). Historically, bone strength has been assessed using 
ex-vivo, mechanical strength testing methods such as the three point bending test (271). 
aBMD by DXA has become a conventional surrogate for bone strength in-vivo, however 
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it is widely appreciated that bone strength is influenced by not only aBMD and bone 
quantity, but also by bone geometry and structure.  
 
True assessment of bone strength would require quantification of both the structural and 
material properties of bone (222). Although we are unable to non-invasively quantify the 
material properties of bone tissue, novel in-vivo assessments of bone strength by FEA 
have been developed which take into account the density, geometry and 
microarchitectural components of bone. By converting each image voxel into equally 
sized elements connected by a mesh, applying a simulated load and observing the bone 
response, more accurate predictions of fracture risk can be made (222).  
 
In pre- and postmenopausal women with a BMI >35kg/m2, bone strength from pQCT at 
the distal tibia, was not higher than in normal weight women (265). Stiffness and 
estimated failure load were investigated in young obese men at the distal radius by HR-
pQCT (268). Although there was no control group in the aforementioned study, stiffness 
and estimated failure load were higher than those given elsewhere for men aged 20 to 
78 years (BMI 17-39kg/m2) (272), although the comparable literature is lacking. 
 
As only one study has presented results from HR-pQCT imaging in obese versus non-
obese adults, only that data is available to infer the effect of obesity on bone strength 
determined by µFEA of HR-pQCT images. At both the distal radius and distal tibia there 
were no differences in load distribution, but there were lower Ct. and Tb. Von Mises 
Stresses (the combination of the stresses from the x, y and z directions and all shear 
stresses within the cortical or trabecular compartment) and higher stiffness and 
estimated failure load in the obese women compared to the non-obese controls (261). 
Further research clearly is needed to support these findings and to understand 
associations between obesity and bone strength in younger women and in men. Whether 
differences in bone strength are proportional to differences in body weight in obese 
people compared to those with a normal BMI is unclear. 
 
Background Summary 
In summary, obesity is associated with greater aBMD at weight bearing sites as 
determined by DXA and may also be associated with greater aBMD at non-weight 
bearing sites such as the forearm. More recent studies have begun to use HR-pQCT to 
assess vBMD and initial findings suggest that vBMD and compartmental vBMD are 
indeed greater at both weight bearing and non-weight bearing sites in obesity. 
Microarchitecture may be favourable in obesity, but more studies are required to better 
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understand such associations. Whether the extent of adiposity affects relationships 
between BMI and vBMD remains unclear (23). Recent work has begun to study the effect 
of obesity on bone in men and in both pre- and postmenopausal women, to investigate 
whether age, gender and/or menopausal state affect the relationship between obesity 
and bone. A single study is yet to address relationships between obesity, vBMD and 
microarchitecture by age, menopausal status and gender. It may be that obesity 
promotes greater BMD in younger adults and/or that obesity is protective against bone 
loss in older adults. 
 
Research Questions, Aims and Hypotheses 
Research questions: 
1. Does obesity affect BMD, bone geometry, bone microarchitecture and bone 
strength of the hip, lumbar spine, distal radius and distal tibia?  
2. Are the effects of obesity on BMD, bone geometry, bone microarchitecture and 
bone strength site- specific or consistent throughout the weight-bearing and non-
weight-bearing skeletal sites of the axial and appendicular skeleton?  
3. Are the effects of obesity on BMD, microstructure and strength commensurate to 
the greater body weight? 
 
Aims: 
1. To compare BMD measured by DXA and QCT at the hip and lumbar spine in 
normal BMI and obese individuals, to determine associations between obesity 
and BMD at central sites.  
2. To compare BMD and bone microarchitecture at the distal tibia and distal radius, 
measured by HR-pQCT in normal BMI and obese individuals, to determine 
associations between obesity and the peripheral skeleton.  
3. To compare bone strength determined by FEA at the distal radius and distal tibia, 
in normal BMI and obese individuals, to determine associations between obesity 
and bone strength.  
4. To compare the magnitude of the differences in BMD, bone microarchitecture, 
bone geometry and bone strength at different skeletal sites in order to establish 
whether associations between obesity and these outcomes are site-specific. 
5. To compare differences in body weight with the differences in bone density, 
microstructure and strength to determine whether bones are proportionally 
adapted to the greater loading conditions of obesity. 
 
Hypotheses: 
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1. Obesity is associated with higher aBMD and vBMD at the hip and lumbar spine, 
with mechanically favourable bone geometry and bone microarchitecture and 
resultant greater bone strength, compared to normal BMI individuals. This might 
explain the lower risk of vertebral and hip fracture in obese individuals compared 
to non-obese individuals. 
2. Obesity is associated with higher vBMD at the distal tibia and distal radius, but 
mechanically unfavourable differences in bone geometry and bone 
microarchitecture, with resultant lower bone strength, compared to normal BMI 
individuals of similar age and height. This might explain the greater incidence of 
ankle fracture in obesity despite higher BMD. 
3. In obese individuals, bone density, structure and strength at the lumbar spine and 
total hip are adapted in proportion to body weight, but this is not the case at the 
distal tibia. This might explain site specificity of fracture patterns in obesity. 
4. Greater soft tissue thickness at central sites might contribute to site specific 
fracture patterns in obesity. 
 
Methods 
200 individuals were recruited to the study according to the inclusion criteria detailed in 
Chapter 2. Participants were recruited in individually-matched, normal BMI and obese 
pairs, as described in Chapter 2. 
 
Height (cm) was measured using an electronic, wall-mounted stadiometer (Seca 242, 
Seca, Birmingham, UK). Weight (kg) was measured to the nearest 0.1 kg using an 
electronic balance scale (Seca, Birmingham, UK). BMI was calculated as (weight (kg)/ 
(height (m)2)). 
 
Whole body, lumbar spine and total hip aBMD were determined by DXA (Discovery A, 
Hologic Inc., Bedford, MA, USA). Total vBMD, cortical and trabecular vBMD and bone 
microstructural parameters at the distal radius and distal tibia were determined by HR-
pQCT (XtremeCT, Scanco Medical AG, Zurich, Switzerland) (Chapter 2). 
 
Bone strength at the distal radius and distal tibia was estimated using micro finite element 
analysis (version 1.13; FE-solver included in the Image Processing Language, Scanco 
Medical AG, Zurich, Switzerland) (Chapter 2). 
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Statistical Analysis 
Radial images from one pair of older women were excluded due to movement artifact. 
Tibial images from two pairs of older women were excluded due to movement and data 
loss. Radial extended cortical measures outcomes from one pair of older men were 
excluded due to outlying results (Ct.Po =0.737, Ct.Po.Dm =2.388, compared to the 
sample mean of 0.033 and 0.160).  
 
Mean (SD) age, height and BMI of the study sample were calculated by age, gender and 
BMI group. All variables were assessed for normality and log transformed where 
necessary. Paired samples t-tests were used to determine significant differences 
between normal BMI and obese groups, for the entire sample, by age group and by age 
and gender. Independent samples t-tests were used to determine significant differences 
between genders in the magnitude of the difference between normal BMI and obese 
groups.  
 
Univariate general linear models were used to identify whether age group, gender and 
BMI had an effect on bone outcomes and to identify interactions between age or gender 
and the effect of BMI on bone outcomes.  
 
Standard deviation scores were calculated by standardising the mean difference 
between normal BMI and obese groups for each variable against the standard deviation 
of the normal BMI, gender and age matched group. Percentage difference between 
normal BMI and obese individuals for each bone outcome was calculated.  
 
To determine whether bone outcomes were proportionally adapted to greater body 
weight in obesity, bone outcomes were normalised to body weight and the percentage 
difference between the normal BMI and obese individual’s normalised value was 
calculated. Mean percentage differences were expressed as a percentage of the mean 
of the normal BMI group.  
 
Analysis was performed using IBM SPSS Statistics for Windows (Version 21.0. Armonk, 
NY: IBM Corp.). Significance was accepted when p<0.05. 
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Results 
The total sample consisted of 200 individuals. The 25 to 40 years group was made up of 
18 male and 22 female pairs and the 55 to 75 years group of 30 male and 30 female 
pairs. Characteristics of the study population are shown in Table 6. Obese and normal 
BMI individuals were closely matched on age with no significant difference between 
normal BMI and obese groups (Table 6). Participants were well matched on height; no 
difference in height was observed between 55 to 75 years normal BMI and obese groups. 
Whilst women aged 25 to 40 years with a normal BMI were statistically significantly taller 
than the obese group (p<0.001) and younger men with a normal BMI were statistically 
significantly shorter than the obese men (p<0.05), the mean paired differences (-2.65 
cm, +2.61 cm respectively) were comfortably below the ±5 cm matching criterion and 
thus were not considered clinically significant. BMI was greater in the obese groups (all 
p<0.001). 
 
Table 6: Characteristics of the study population by age and BMI group; mean (SD) 
 
 
Areal BMD in Obesity 
Obese individuals had a greater aBMD at the WB (p<0.001), TH (p<0.001) and LS 
(p<0.001) than normal BMI individuals (Figure 28).  
 
Men had greater WB and TH aBMD than women (both p<0.001). There was no 
interaction between gender and the effect of BMI on WB, TH or LS aBMD. The magnitude 
of the difference in aBMD between normal BMI and obese groups was not significantly 
different between the sexes in either age group, at any site. 
  
 Women (n=104) Men (n=96) 
 25 to 40 Years 
(n=22 pairs) 
55 to 75 Years 
(n=30 pairs) 
25 to 40 Years 
(n=18 pairs) 
55 to 75 Years 
(n=30 pairs) 
 Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Age, 
years 
34.6 
(4.16) 
34.8 
(4.6) 
65.4 
(5.8) 
65.1 
(5.6) 
33.2 
(4.2) 
33.9 
(3.7) 
65.9 
(5.3) 
65.5 
(5.7) 
Height, 
cm 
167.1 
(6.8) 
164.5 
(7.3) 
161.1 
(4.3) 
160.6 
(4.0) 
178.4 
(7.0) 
180.4 
(6.7) 
175.5 
(6.4) 
176.1 
(7.5) 
BMI, 
kg/m² 
22.4 
(1.5) 
35.4 
(4.2) 
22.9 
(1.5) 
35.9 
(5.0) 
23.0 
(1.3) 
32.9 
(2.6) 
23.4 
(1.2) 
34.6 
(4.0) 
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Figure 28: Whole body (A), total hip (B) and lumbar spine (C) aBMD  
of normal BMI versus obese individuals. All ages and genders combined.1,2 
A B C  
 
 
 
 
 
Figure 29: Whole body aBMD of normal BMI and obese individuals by group: 
young (A), older (B), young women (C), young men (D), older women (E), older men (F).1,2 
A B C  
D E F  
 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half times the interquartile range above or below the box boundary) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Figure 30: Total hip aBMD of normal BMI and obese individuals by group: 
young (A), older (B), young women (C), young men (D), older women (E), older men (F)1,2 
A B C   
D E F  
 
Figure 31: Lumbar spine aBMD of normal BMI and obese individuals by group: 
young (A), older (B), young women (C), young men (D), older women (E), older men (F)1,2 
A B C   
D E  F  
 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Young adults had greater WB, LS and TH aBMD than older adults (all p<0.05) (Figure 
29, Figure 30, Figure 31). The effect of obesity on WB and LS aBMD was greater in older 
adults than young adults (both p<0.01). There was no difference in the effect of BMI on 
total hip aBMD by age group. In younger adults, aBMD was 0 to 1 SD scores greater in 
the obese group than in the normal BMI group (Figure 32). In older adults, aBMD was 1 
to 2 SD scores greater in the obese group than in the normal BMI group (Figure 32). 
 
 
 
Figure 32: aBMD of obese individuals as SD scores 
of the mean of the normal BMI group, for total hip and lumbar spine and whole body. (Mean 
(95%CI).  
Reproduced with permission: Evans AL et al. Bone Density, Microstructure and Strength in Obese and 
Normal Weight Men and Women in Younger and Older Adulthood, 2014 Journal of Bone and Mineral 
Research, John Wiley and Sons. © 2014 American Society for Bone and Mineral Research 
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vBMD and Bone Microarchitecture in Obesity 
Obese individuals had greater vBMD at the distal tibia than normal BMI individuals 
(p<0.001) (Figure 33). Older obese adults had greater vBMD at the distal radius than 
older adults with a normal BMI (p<0.001) (Figure 34). There was a greater effect of 
obesity on vBMD at the distal radius in older adults than younger adults (p<0.01). 
 
Figure 33: Tibia vBMD of normal BMI and obese individuals 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C  
D E F  
 
 
 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Figure 34: Radius vBMD of normal BMI and obese individuals 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C  
D E F  
 
 
Microstructure measurements showed the higher vBMD in obesity was due to greater 
Tb.vBMD in the young adults (p<0.05 radius, p<0.001 tibia) and greater Tb.vBMD and 
Ct.vBMD in the older adults (all p<0.001) (Figure 35, Figure 36). The higher Tb.vBMD in 
the obese groups was due to greater Tb.N (p<0.001 all ages, all sites) and lower Tb.Sp 
(p<0.001 all ages, all sites) with no difference in Tb.Th at the radius or the tibia (Figure 
35, Figure 36). 
  
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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The higher Ct.vBMD in older obese adults was due to higher cortical tissue mineral 
density (Ct.TMD) (p<0.05 radius, p<0.001 tibia) and lower Ct.Po (NSD radius, p<0.05 
tibia), whereas no differences between normal BMI and obese individuals were observed 
for any of these parameters in the younger adults (Figure 35, Figure 36). Obese 
individuals had greater Ct.Th at the distal tibia (p<0.01 younger, p<0.001 older) (Figure 
35) and at the distal radius in the older adults (p<0.001) (Figure 35Figure 36). 
 
The difference in Ct.vBMD (p<0.05 radius, p<0.01 tibia) and Ct.TMD (p<0.05 radius, 
p<0.01 tibia) between normal BMI and obese groups was greater in older women than 
older men. At the tibia, the difference in Ct.Th and Ct.Ar was also greater in older women 
than older men (both p<0.05). In the younger adults, differences in cortical and trabecular 
properties between normal BMI and obese groups were similar by gender. 
 
No difference was observed in bone size (Tot.Ar, Ct.Pm) between normal BMI and obese 
individuals (Figure 35, Figure 36).  
 
Figure 35: Tibia vBMD, microarchitecture and strength of obese individuals  
as SD scores of the mean of the normal BMI group (mean (95% CI)).  
Reproduced with permission: Evans AL et al. Bone Density, Microstructure and Strength in Obese and 
Normal Weight Men and Women in Younger and Older Adulthood, 2014 Journal of Bone and Mineral 
Research, John Wiley and Sons. © 2014 American Society for Bone and Mineral Research 
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Figure 36: Radius vBMD, microarchitecture and strength of obese individuals 
as SD scores of the mean of the normal BMI group (mean (95% CI)) 
Reproduced with permission: Evans AL et al. Bone Density, Microstructure and Strength in Obese and 
Normal Weight Men and Women in Younger and Older Adulthood, 2014 Journal of Bone and Mineral 
Research, John Wiley and Sons. © 2014 American Society for Bone and Mineral Research 
 
 
Lumbar Spine vBMD by QCT 
Obese women had greater LS.vBMD than women with a normal BMI (p<0.01) (Figure 
37). There was no effect of gender on LS.vBMD but there was an interaction between 
gender and the effect of obesity on LS.vBMD with a greater effect of obesity on vBMD in 
women (compared to a smaller negative effect in men) (p<0.01). In women, the 
difference in LS.vBMD between normal BMI and obese groups was significantly greater 
than in men (p<0.01).  
 
Figure 37: vBMD of obese individuals at the lumbar spine 
as SD scores of the mean of the normal BMI group (mean (95% CI)) 
 
Bone Strength in Obesity 
Obese adults had greater bone stiffness at the distal tibia (p<0.01 younger, p<0.001 
older) (Figure 35) and at the distal radius in older adults (p<0.001) (Figure 36). In both 
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age groups, obesity was associated with greater bone strength determined by greater 
estimated failure load at the radius (p<0.05 younger, p<0.001 older) and tibia (p<0.01 
younger, p<0.001 older) (Figure 35, Figure 36, Figure 38, Figure 39). There were no 
interactions between age or gender and the effect of obesity on bone stiffness or 
estimated failure load, in either age group. Therefore, although younger adults may 
exhibit less significant effects of obesity on bone density and microarchitecture at the 
distal radius, the differences observed appear to add up to an overall greater bone 
strength compared to normal BMI individuals. 
 
Figure 38: Radius estimated failure load of normal BMI and obese individuals 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C   
D E F   
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Figure 39: Tibia estimated failure load of normal BMI and obese individuals. 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C   
D E F  
 
 
Are Greater BMD and Strength Sufficient for Greater Body Weight? 
Although the results of this Chapter suggest that obese individuals may be at lower risk 
of fracture due to higher BMD and greater bone strength, whether the magnitude of the 
difference in bone density, structural parameters and bone strength ultimately conveys 
a protective effect given the magnitude of the difference in loading forces from high body 
weight is unclear. Others have suggested that BMD and bone structural outcomes might 
scale linearly with increasing body weight (261) and therefore linear scale comparisons 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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were made between body weight and bone outcomes. Mean percentage difference (as 
a percentage of the normal BMI group) between normal and obese individuals in body 
weight compared to mean percentage difference in aBMD, vBMD, bone 
microarchitectural properties and bone strength are presented in Table 7. Despite 
favourable bone microarchitecture in obesity, relative to the excess of weight bone 
parameters were lower than in normal BMI individuals. Percentage differences in bone 
outcomes normalised to body weight are presented in Table 7.  
 
Table 7: Mean percentage difference in skeletal outcomes between obese and normal BMI 
individuals before and after normalising for body weight 
 
Outcome 
Mean % difference 
between obese and 
normal BMI adults 
Mean % difference 
between obese and 
normal BMI adults 
normalised for weight 
 Body weight 52.12  
 WB aBMD 7.91 -26.37 
TH aBMD 19.84 -20.39 
LS aBMD 16.20 -22.72 
 LS vBMD 12.87 -24.67 
R
a
d
iu
s
 
Tot.vBMD 19.93 -20.31 
Tb.vBMD 23.04 -18.37 
Ct.vBMD 5.47 -29.69 
Tot.Ar 4.65 -30.63 
Ct.Ar 35.53 -10.58 
Tb.Ar 3.39 -31.47 
Ct.Th 35.03 -10.65 
Ct Pm 2.31 -31.90 
Tb.N 17.60 -21.86 
Tb.Th 5.05 -29.93 
Tb.Sp -13.66 -42.00 
Stiffness 21.42 -19.86 
Est. failure load 20.96 -20.21 
T
ib
ia
 
Tot.vBMD 19.03 -20.68 
Tb vBMD 18.58 -21.28 
Ct vBMD 4.52 -29.99 
Tot.Ar 1.97 -32.04 
Ct.Ar 30.36 -13.26 
Tb.Ar -0.82 -33.90 
Ct.Th 30.40 -13.03 
Ct Pm 0.73 -32.65 
Tb.N 21.37 -19.52 
Tb.Th -1.33 -33.82 
Tb.Sp -15.65 -42.74 
Stiffness 16.53 -22.64 
Est. failure load 16.48 -22.70 
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Summary of Results 
A summary of the key messages of this Chapter is given in Table 8. 
Table 8: Summary of results Chapter 3 
The effects of BMI and age, gender and BMI interactions on BMD, structure and strength  
 
Variable 
Effect of 
BMI 
Age/BMI 
Interaction 
Gender/BMI Interaction 
 WB aBMD ↑ (older) ↑effect in older - 
 TH aBMD ↑ - - 
 LS aBMD ↑ ↑effect in older - 
 LS vBMD ↑(women) NA ↑effect in women 
D
IS
T
A
L
 T
IB
IA
 
Total vBMD ↑ - - 
Tb vBMD ↑ - - 
Ct vBMD ↑ (older) ↑effect in older ↑effect in women (older) 
Ct TMD ↑ (older) ↑effect in older ↑effect in women (older) 
Total area - - - 
Ct area ↑ ↑effect in older ↑effect in women (older) 
Tb area - - - 
Ct.Th ↑ - ↑effect in women (older) 
Ct Pm - - - 
Ct Po ↓ (older) ↑effect in younger - 
Tb N ↑ - - 
Tb.Th - - - 
Tb.Sp ↓ - - 
Stiffness ↑ - - 
Est. failure load ↑ - - 
D
IS
T
A
L
 R
A
D
IU
S
 
Total vBMD ↑ (older) ↑effect in older - 
Tb vBMD ↑ ↑effect in older - 
Ct vBMD ↑ (older) ↑effect in older ↑effect in women (overall) 
Ct TMD ↑ (older) ↑effect in older ↑effect in women (overall) 
Total area - - - 
Ct area ↑ ↑effect in older - 
Tb area - - - 
Ct.Th ↑ (older) ↑effect in older - 
Ct Pm - - - 
Ct Po - - - 
Tb N ↑ - - 
Tb Th - - - 
Tb Sp ↓ - - 
Stiffness ↑ (older) - - 
Est. failure load ↑ - - 
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Discussion 
The results presented in this Chapter are consistent with the existing literature which 
shows greater aBMD in obesity. BMI has previously  been positively associated with 
aBMD in adults (15, 23, 43, 45, 48, 105, 257-261) and older adults (262, 263) of both 
genders. Body weight and BMI have been positively associated with aBMD of the lumbar 
spine (48, 258, 259, 261), femoral neck (48, 258), distal radius (261), proximal femur and 
leg (23, 48, 259, 260, 263). This is the first study to address relationships between 
obesity, bone microarchitecture and micro FEA derived bone strength in an individually-
matched case control study of younger and older men and women.  
 
Obese individuals have greater vBMD at the lumbar spine, distal tibia and, in older adults, 
at the distal radius. Greater vBMD in obese individuals is due to there being greater 
Tb.vBMD as a result of greater Tb.N and lower Tb.Sp without a difference in Tb.Th. The 
greater vBMD in older adults is also contributed to by greater Ct.vBMD as a result of 
greater Ct.TMD and lower Ct.Po. Obese individuals have greater Ct.Th at the distal tibia, 
and at the distal radius in older adults. There is no difference in bone size at the distal 
radius or tibia between obese and normal BMI individuals, indicating that there is no 
difference in periosteal apposition in obesity. As periosteal apposition typically occurs in 
response to greater loading conditions, it may be hypothesised that there are no effects 
of greater loading per se on bone in obesity and that the differences in bone density and 
structure observed are attributed to the altered hormonal milieu associated with greater 
adiposity. As there is no difference in bone size but greater Ct.Th, obese individuals may 
exhibit greater endosteal apposition. 
 
As expected, there is greater aBMD and vBMD at the distal radius and distal tibia in 
younger adults than older adults. As shown by the interaction terms, there is a greater 
effect of obesity on LS and WB aBMD and distal radius vBMD in older adults. This 
indicates that high body weight may be of particular skeletal benefit in older age, possibly 
through the reduction of bone loss with age in obesity. Although obesity in younger adults 
appears to afford some clear skeletal benefits, the dominant effect of obesity on the 
skeleton appears to be to reduce bone loss in older adulthood. Whether older adults who 
have been obese since younger adulthood will have benefited from both mechanisms of 
obesity on the skeleton is unclear and warrants further study. 
 
Sornay-Rendu et al. (2013) have reported an assessment of bone microarchitecture in 
obese postmenopausal women, compared with a non-obese control group (261). In 
agreement with the current study findings, they reported greater vBMD at the distal 
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radius and distal tibia in obesity. This greater vBMD resulted from greater Tb.vBMD, due 
to greater Tb.N and lower Tb.Sp, and greater Ct.vBMD, due to greater cortical area and 
Ct.Th and lower Ct porosity. Also in agreement with the results of this Chapter, the 
authors reported no difference in total area or Tb area in obesity (261). Sornay-Rendu et 
al. reported greater percentage differences in microarchitectural parameters at the distal 
tibia compared to the distal radius in the obese group versus the non-obese group, 
whereas in the present study the mean percentage differences in microarchitectural 
parameters were higher at the radius than the tibia (261). 
 
Similar to our findings, BMI was positively associated with Tb.N and inversely associated 
with Tb.Sp in a study of young obese men (268).  
 
A recent study examined the effect of FM and LM on HR-pQCT derived bone 
microarchitecture in obese individuals with metabolic syndrome (270). The study 
reported positive associations between LM and Tb.N and Tb.Sp at the radius, and vBMD, 
Tb.vBMD, BV/TV, Tb.N, Tb.Sp and Ct.Th at the distal tibia (270). No significant 
associations between FM and microarchitectural outcomes were observed (270). 
However as there was no control group, and metabolic syndrome may have effects on 
bone metabolism through effects on glucose metabolism in addition to the effects of 
greater adiposity, it is difficult to compare these findings directly with our results. 
 
Fat distribution may affect associations between adiposity and bone microarchitecture 
(267-269, 273). Premenopausal women with greater central adiposity have been shown 
to have higher cortical porosity with lower trabecular bone volume, bone stiffness and 
bone formation (12). The inverse relationship between trunk fat and trabecular bone 
volume by bone biopsy remained significant after controlling for age and BMI (12).  
 
As expected, aBMD at all sites measured and vBMD at the distal tibia were greater in 
men than in women. There was no difference in vBMD by gender at the distal radius or 
lumbar spine. In younger adults, gender did not alter the effect of obesity on bone 
microstructure at the distal radius or tibia. However, in older adults, the effect of obesity 
on LS.vBMD and Ct.vBMD and Ct.TMD at the radius and tibia was greater in older 
women than in men. Gender differences in the distribution of adiposity and/or endocrine 
profile could explain this difference and are an area for further investigation. 
 
While patterns of bone density and structure are consistent between the distal tibia and 
distal radius in older adults, younger people show less significant effects of obesity at 
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the radius. However, despite this, bone strength is greater at the radius and the tibia in 
both older and younger obese individuals. The differences in bone density and 
microstructure observed are associated with greater estimated failure load at the distal 
radius and distal tibia. However, differences in bone parameters between obese 
individuals and those with a normal BMI show that bone adaptations are not 
commensurate to greater body weight. This was first shown by Sornay-Rendu et al., who 
suggested that the greater BMD observed in obesity does not appear to be sufficiently 
great in proportion to the greater body weight (261). Fractures often occur in obese 
individuals despite normal or high aBMD (49, 50). In particular, tibial vBMD and 
estimated failure load are greater in obese people, so lower bone density is not the cause 
of the increased risk of lower limb or ankle fracture observed in obesity (23, 44, 52, 55). 
Simple scaling such as that used by both in this Chapter and by Sornay-Rendu et al. 
may not be sophisticated enough to fully determine appropriate bone strength for body 
size. Further development of finite element models that account for body weight in the 
forces acting may provide a better understanding of fracture risk in obesity. Bone is more 
likely to adapt to the exposure to daily forces and loads, which differ from forces acting 
upon fall impact. Therefore it may not be surprising that obese individuals continue to 
fracture despite greater BMD than normal weight individuals.   
 
Whilst findings of greater BMD at the hip and lumbar spine support reports of obesity 
being protective against hip and vertebral fracture, non-skeletal determinants of fracture 
may also contribute to fracture risk in obesity. Greater soft tissue thickness at the greater 
trochanter may be protective of hip fracture (73, 274, 275) and this has begun to be 
incorporated into novel finite element models simulating the risk of hip fracture from a 
sideways fall (Figure 40) (274, 275). 
 
Figure 40: Anterior view of the 3D FE model of the pelvis-femur-soft tissue complex 
by Majumder et al. (2008), (275).  Permission to reproduce granted by Elsevier 
http://www.elsevier.com (license number 3345380469871) 
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Non-skeletal determinants of fracture may also explain increased risk of lower limb and 
proximal humerus fracture in obesity. Obese individuals may be at greater risk of falls 
due to impaired muscular function, sarcopenic obesity, and/or fat infiltration of skeletal 
muscle (276-278). Different fall direction and fall forces may also increase fracture risk. 
 
The cross-sectional design of this study must be acknowledged as a limitation. 
Determining adiposity by BMI may be considered a limitation as body fat distribution may 
be an important determinant of bone density and microarchitecture, but the obese group 
did have significantly higher fat mass than the normal BMI group, as shown in Figure 43. 
Whilst the possible confounding differences between obese and normal BMI individuals 
(age, body size, smoking and socioeconomic status) were controlled for as much as 
possible, any remaining differences may have affected the results. DXA and CT density 
measurements may be affected by the soft tissue thickness effects of increasing BMI, 
however this is unlikely to affect microarchitectural outcomes by HR-pQCT. The HR-
pQCT finite element analysis model used in this study does not take into account 
individual loads upon falling and adopting this approach would increase the validity of 
the model. The current model simulates a direct compression force on the distal tibia 
which may not be the most suitable strength test for the prediction of ankle fracture which 
is affected by torsion forces and contribution of ligaments. Finally, the resolution of the 
HR-pQCT scanner may limit the reliability of measurements of cortical porosity and 
cortical pore diameter. 
 
Results of the hip QCT scans were not presented in this Chapter. The analysis of these 
scans has proved troublesome, due to the need to ‘trim’ the soft tissue from the image 
without compromising the bone compartment of the image before the analysis is run. 
This has been difficult in the obese group where a greater thickness of soft tissue must 
be removed. Where soft tissue is left untrimmed, the density of the bone derived from 
the subsequent analysis is affected. Advice on analysing these scans has been sought, 
but the issue not yet resolved. Hip QCT scans will also be analysed using alternative in-
house software which does not require soft tissue trimming and the results of the two 
analyses will be compared. 
 
In conclusion, this Chapter has confirmed that aBMD is greater in obesity, and for the 
first time has demonstrated relationships between obesity, bone microarchitecture and 
micro finite element analysis derived bone strength in younger and older, men and 
women. Obese individuals have greater bone density than their normal BMI 
counterparts, at all sites measured. The greater density in trabecular bone is due to 
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greater trabecular number, but trabecular thickness does not differ between obese and 
normal weight people. Cortical thickness and cortical tissue mineral density were also 
higher in obese people, and cortical porosity was lower. Bone size at the radius and tibia 
did not differ between obese and normal BMI individuals. The magnitude of the difference 
in bone density observed between obese and normal BMI individuals using DXA was 
comparable to that observed using HR-pQCT, suggesting that greater bone density in 
obesity is a true biological effect and not solely an artefact of DXA imaging linked to 
greater soft tissue thickness. The greater differences between obese and normal BMI 
individuals in the older adults suggest obesity may be associated with reduced bone loss. 
Reduced bone loss might be associated with greater circulating E2 in obesity as a result 
of increased aromatisation of androgens which could confer a greater advantage in older 
adulthood where adipose tissue is the main source of E2. Alternative mechanisms might 
include age-related differences in the effects of mechanical loading, greater leptin, lower 
adiponectin and altered glucose metabolism on bone outcomes in obesity. 
 
The identification of mechanisms responsible for greater bone density in obesity will 
improve our understanding of the pathophysiology of osteoporosis and could lead to new 
therapeutic targets. The results of this Chapter do not explain the greater risk of some 
fractures in obesity, as described in Chapter 1. At these sites, aBMD and/or vBMD may 
be poor indicators of fracture risk. Understanding why some fractures are increased in 
obesity may require more sophisticated models, which may lead to further insights into 
the site-specific mechanisms of fractures. 
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CHAPTER 4: Potential Mechanisms of Associations Between Obesity, 
Bone Density and Bone Microstructure 
 
Background 
The work in Chapter 3 has identified differences in aBMD, vBMD, cortical and trabecular 
microarchitecture and bone strength between obese individuals and those with a normal 
BMI. What causes these differences in density and structure is unknown. The 
identification of potential mediators of the effect of obesity on bone outcomes might 
improve current understanding of why and how such differences arise. This might 
eventually enable the identification of potential therapeutic targets for the treatment of 
conditions characterised by low bone mass, such as osteoporosis.  
 
There are multiple potential mechanisms which may contribute to positive associations 
between obesity and bone, some of which might also help to explain the greater 
differences in BMD and microstructural properties between obese and normal weight 
individuals in older adults, compared to younger adults. There are also differences in the 
hormonal milieu in obesity which might negatively affect bone density. As the overall 
effect of obesity on bone is most likely determined by the combination of positive and 
negative influences, the distribution of adipose tissue may be an important factor in the 
associations between biochemical influences and bone outcomes. 
 
Mechanical Loading Effects of High Body Weight 
Previously it was considered that the protective effects of obesity on BMD were due to 
mechanical loading effects of high body weight on bone. Bone modelling occurs in 
response to changes in mechanical loading to maintain skeletal competence (7). Frost’s 
mechanostat hypothesis proposed that strain magnitudes could stimulate bone 
modelling following tissue deformation in response to mechanical loading thresholds, so 
it is logical that in obesity, bone mass at weight bearing sites would be greater than in 
non-obese individuals (279). However, a single mechanostat does not control the entire 
skeleton; rather the strain magnitude required for skeletal maintenance is site-specific 
and varies within individual units of bone (87). This may contribute to understanding why 
obese adults have greater bone mass at load bearing sites which are not weight bearing, 
such as the radius. The magnitude of the difference in vBMD between obese and normal 
BMI individuals at the distal radius and distal tibia, was similar (Chapter 3). As the radius 
is a less frequently loaded, non-weight bearing bone, this might suggest that the strain 
magnitude required at the radius is lower than that of the tibia for a BMD difference of 
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equal magnitude. As the skeletal response to increased loading dependends on the 
frequency, magnitude, rate and duration of the resulting strains, compared to the 
baseline loading conditions, duration of obesity may also be a factor. Young bone has 
been shown to be more capable of structural adaptations in response to mechanical 
loading than in bone in older age (8). Whether the contribution of mechanical loading to 
the effect of obesity on bone changes with age is unknown. 
 
Body Composition 
Fat Mass and Lean Mass Contributions to BMD 
Both LM and FM contribute to body mass and affect bone density (257, 280-283). There 
is evidence both for (61, 284-287) and against (257, 280, 281) FM being the stronger 
determinant of bone density. While “passive loading from fat mass is less anabolic to 
bone than the active dynamic loads from muscle contraction”, the endocrine actions of 
FM make it a likely determinant of BMD irrespective of the loading effects high BMI (288). 
The relationship between LM, FM and BMD might be affected by menopausal status. In 
premenopausal women LM was the significant determinant of lumbar spine BMD, 
whereas in postmenopausal women, FM and both LM and FM were significant 
determinants of BMD (284, 289). 
 
Body Fat Distribution 
Many studies have shown relationships between BMI or total body FM and BMD. 
However, total body FM is comprised of multiple fat depots, which not only differ in their 
anatomical location, but also in their production and expression of hormones, cytokines 
and inflammatory factors which can affect bone. The effect of adiposity on BMD may be 
highly dependent on the distribution and relative proportions of adipose tissue 
compartments, rather than overall adiposity.  
 
Peripheral Adiposity 
Peripheral adiposity (PAT) describes subcutaneous fat deposited away from the trunk 
(290, 291). There is evidence to support there being a protective effect of PAT on aBMD 
at the whole body (292), FN (293), femur, spine and forearm (294), although others have 
found no association with arm aBMD (295, 296).   
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Central Adiposity 
Abdominal Adiposity  
Much of the available evidence supports a negative association between abdominal 
adiposity and BMD and bone microstructure. Total abdominal FM was inversely 
associated with vBMD at the lumbar spine and distal radius (267-269). At the distal 
radius, abdominal FM was associated with lower Tb.Th and lower bone strength, despite 
greater Tb.N lower Tb.Sp (268). In young women divided into tertiles based on trunk FM, 
although aBMD by DXA and vBMD by QCT were no different or lower in those with the 
highest trunk FM, µCT of transiliac biopsies taken from the same subjects showed 
inferior bone microarchitecture; with lower Tb.vol, Tb.N, Tb.Th, and stiffness and higher 
Ct.Po) with greater trunk FM (273). Markers of bone formation (bone formation rate, 
cancellous bone formation rate and mineralising surface) were also lower in the highest 
tertile of trunk FM (273). 
 
Subcutaneous Abdominal and Visceral Adiposity 
Subcutaneous abdominal fat (SAT) is the fat beneath the skin of the abdomen but above 
the abdominal muscle wall, while visceral fat (VAT) is that which accumulates beneath 
the abdominal muscle wall, around the organs (Figure 41). Subcutaneous adipocytes 
are smaller, less metabolically active, less sensitive to lipolysis and less insulin-resistant 
than visceral adipocytes (297). Associations between SAT and BMD appear mostly 
positive (118, 119), SAT being associated with greater vBMD, Tb.vBMD and Ct.vBMD 
at the FN, LS, and radius and with trabecular microarchitecture at the radius (267). A 
recent study, however, reported no associations between L4 Tb.vBMD and SAT in obese 
women (269). Positive, though non-significant, correlations between SAT and Tb.N and 
an inverse correlation between SAT and Tb.Sp were reported in obese men (268).  
 
Figure 41: Location of subcutaneous and visceral fat compartments 
in relation to the abdominal wall on an abdominal CT image 
 
VAT contains more inflammatory cells and macrophages and is more vascularised and 
innervated than SAT (297). VAT is associated with an increased risk of obesity related 
complications such as insulin resistance, hyperlipidaemia and coronary heart disease 
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(117, 118). VAT appears to be negatively associated with BMD (118, 119, 268, 298, 
299). In young obese men, inverse associations were observed between VAT and 
Tb.vBMD and Tb.Th, and VAT trended toward an inverse association with vBMD and 
Ct.Ar (268). Similarly, in young obese women, VAT was inversely associated with L4 
Tb.vBMD, although VAT was not a significant predictor of Tb.vBMD (269). As a result, 
negative associations were found between VAT and stiffness and estimated failure load 
at the radius, with VAT explaining 17% and 20% of the variability in these variables, 
respectively (268). µCT of transiliac biopsies showed inverse associations between VAT 
and trabecular bone formation rate (273).  
 
It has been suggested that a critical amount of VAT may be required before the 
deleterious effects on bone are observed (118). This seems logical when the proposed 
positive effects of SAT and PAT are considered; with the overall effect of high adiposity 
dependent on the distribution of FM throughout various compartments. Some studies 
have attempted to address the issue of conflicting effects of SAT and VAT 
compartmental effects on bone by using a VAT:SAT ratio. VAT:SAT ratio was negatively 
associated with FN and LS vBMD in postmenopausal women, supporting a negative 
effect of VAT on BMD (267). 
 
Waist Circumference and Waist-to-Hip Ratio 
Waist circumference and WHR are surrogates for VAT and consequently have been 
inversely associated with WB, LS and TH aBMD (57, 300-303). Although other authors 
report positive correlations with BMD at the hip (304), spine (305) and radius (306), this 
may be reflective of the positive contribution of SAT to measurements of waist 
circumference and WHR.  
 
Android and Gynoid Adiposity  
Android fat patterning, defined as increased fat deposition around the trunk, is associated 
with increased risk of metabolic disease compared to gynoid fat patterning, where the 
majority of FM is deposited in the gluteo-femoral region (290, 291, 307, 308). Android 
FM comprises both SAT and VAT and might have a negative effect on BMD, possibly 
depending on the ratio of VAT to SAT within the android region (283, 300). In 
postmenopausal women, android:gynoid ratio was negatively associated with total body, 
arm and leg BMD (283). As there was no association in premenopausal women, this 
relationship may depend on menopausal status (283).  
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Bone Marrow Fat 
Bone marrow fat content increases with age as fatty yellow marrow replaces functional, 
hematopoietic red marrow. Marrow fat has also been shown to accumulate in cortical 
pores (309). Adipose infiltration of the marrow compartment varies by skeletal site; 
beginning at peripheral sites and progressing into central sites (310). Whether the 
increase in bone marrow fat with age reflects marrow adipocyte hypertrophy or 
hyperplasia is unclear (311). Bone biopsies have shown marrow adipocyte volume to be 
directly associated with WBFM, trunk FM and SAT (273).  
 
Marrow fat content is inversely associated with BMD (91, 220, 311, 312), cortical and 
trabecular microarchitecture (268, 313) and bone strength (91, 220, 221, 311). It is 
unclear whether marrow fat causes, or is a consequence of low bone density. Although 
“an increase in marrow fat may simply represent a compensation for trabecular thinning”, 
this suggests a rather passive role of marrow fat in a relationship driven by bone loss 
(311, 314). Marrow fat possesses characteristics of both white and brown fat, and the 
ability to adapt to changes in systemic energy metabolism, although with age, marrow 
fat exhibits mainly white fat characteristics and has a decreased ability to respond to 
changes in energy metabolism (314). These findings suggest that marrow fat 
accumulation is unlikely a passive filling of the trabecular compartment with age. It may 
be that inverse associations between marrow fat and BMD demonstrate a lineage switch 
of MSCs away from osteoblastogenesis and toward marrow adipogenesis (311). 
Preadipocyte factor-1 (Pref-1) may play a role in the regulation of MSC differentiation 
within the bone marrow, by preventing preadipocyte proliferation and differentiation to 
adipocytes (315, 316) and inhibiting MSCs differentiation along adipocyte and osteoblast 
lineages (317). Obese individuals have lower Pref-1 than those of normal weight (318). 
In anorexia, low BMD, high marrow adiposity and high pref-1 are observed compared 
controls (319, 320). As oestrogen treatment has been shown to decrease pref-1 while 
decreasing marrow fat and increasing BMD in anorexia, adipokines and sex hormones 
may affect the differentiation of MSCs and bone marrow fat content (319) 
 
Current evidence indicates an inverse association between marrow adiposity and bone 
density and microstructure, although the mechanisms for such a relationship are unclear, 
but may involve low IGF-I expression by marrow fat (321). The marrow fat compartment 
might exert negative influences on BMD in obesity, similar to the hypothesised effects of 
VAT. Marrow fat and VAT were positively associated in obese women (321). Marrow fat 
accumulation in cortical pores might exacerbate cortical resorption and the 
trabecularisation of cortical bone.  
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Brown Fat 
Brown fat is predominantly found in neonates and rodents but also appears to be present 
in human adults (322-324). Whereas white fat mainly consists of lipid and has the 
principal role of energy storage, brown fat has a high mitochondrial content and is highly 
metabolically active; the main function of brown fat being to dissipate heat (325). Brown 
fat is located at the bottom of neck and in para-spinal and peritoneal areas, although 
depots change with age (322). Cold exposure can induce white fat to become brown fat 
and others have postulated this ability may hold anti-obesogenic therapeutic potential 
(326). Brown fat activity and volume are inversely associated with BMI, WBFM, 
percentage FM and VAT (324, 327). Brown fat is positively associated with inflammatory 
cytokines, but may exert a less pro-inflammatory effect than white fat (328). Brown fat 
volume was positively associated with BMD in young women (329, 330) and trended 
positively with femoral total and cortical cross sectional area (323). Misty mice, which 
have impaired brown fat function, have recently been shown to have lower aBMD and 
BMC, L5 Tb.vBMD, distal femur Tb.BV/TV, connectivity density and Tb.N, greater Tb.Sp, 
but no difference in Tb.Th compared to wild-type animals (331). Misty mice also have 
accelerated trabecular bone loss with age compared to wild type mice, due to impaired 
bone formation and increased bone resorption as shown by histomorphometry (331). 
The contribution of brown fat to associations between obesity, bone density and bone 
microstructure is unclear and warrants further research. 
 
Gender Differences in Adiposity  
Men and women differ metabolically and hormonally, resulting in differences in the 
amount and distribution of body fat by gender. Women have greater total adiposity and 
greater gynoid adiposity than men, who have greater abdominal fat (291). Within the 
abdominal region, women have greater SAT and lower VAT than men and so a lower 
VAT:SAT ratio (291). However, obesity can induce altered fat patterning, with obese 
women exhibiting high VAT and obese men having large amounts of PAT  (291).  
 
Relationships between fat compartments and skeletal outcomes may vary by both age 
and gender. Ng et al. reported that after adjustment for age, correlations between 
adiposity and vBMD weakened (267). In premenopausal women, associations between 
adiposity and BMD were weak, while in young men, VAT was negatively associated with 
LS and radius total vBMD and FN Ct.vBMD (267). In older men, correlations were again 
weak (267). As associations were strongest in postmenopausal women, this might 
suggest that adiposity, namely SAT in that study, conveys a greater advantage in older 
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women, possibly related to increased aromatisation of androgens with high fat 
mass(267). While VAT:SAT ratio was negatively associated with FN vBMD in young 
men, the opposite was found in older men (267). Such differences highlight the need to 
study the effects of obesity on bone in both genders, pre- and post-menopause and by 
adipose depot.  
 
Biochemical Mechanisms 
Although FM contributes to the loading effect of high body weight on the skeleton, 
adipose tissue is a highly active endocrine organ known to be involved in the production 
and release of more than fifty cytokines and other related molecules (90, 97), some of 
which can affect bone. Previous research has identified biochemical factors associated 
with adiposity which might positively affect bone, as well as other factors which may 
contribute to bone loss.  
 
Positive Biochemical Mechanisms 
Oestrogen 
Greater FM is associated with higher circulating oestrogen due to increased 
aromatisation of androgens. When oestrogen binds to its receptors on the osteoclast, 
suppression of RANKL-induced osteoclast differentiation occurs, accompanied by an 
increase in osteoclast apoptosis (332). Oestradiol (E2) is also able to increase OPG to 
further suppress osteoclastogenesis, while down regulating inflammatory cytokines 
(332). E2 maintains bone formation by inhibiting osteoblast apoptosis (332). The ability 
of E2 to lower resorption and maintain formation implicates it as a major protective 
determinant of BMD (332-334). After menopause, the conversion of androgens to E2 in 
adipose tissue is the main source of E2 in the body. This has led to the hypothesis that 
FM may be an important regulator of bone mass in older adults in particular (98).  
 
In obese young adults, differences in the relationships between E2 and bone 
microstructural outcomes have been reported by gender, such that positive associations 
were observed for vBMD and Tb.Th in men (268), while there was no association 
between E2 and aBMD (334) or L4 Tb.vBMD (269) in premenopausal women. In obese 
women, studies have shown no association between fE2 and BMI, trunk or abdominal 
FM (269, 273).  
 
Aromatase expression is lower in VAT, indicating that body fat distribution might 
influence relationships between adiposity and BMD if E2 is found to be a mediator of the 
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relationship (100, 119). As E2 circulates bound to SHBG and albumin, both of which 
could be affected by adiposity (273), free or bioavailable E2 may be better predictors of 
BMD or bone turnover than total E2.  
 
Leptin 
Leptin is a hormone product of the OB gene. Leptin is produced primarily by white 
adipose tissue and therefore highly associated with FM (335). Leptin plays an important 
role in regulating appetite and energy homeostasis via its actions on the hypothalamus 
(90, 97, 99). Circulating leptin concentrations are influenced by sex hormones, 
inflammatory cytokines and lipopolysaccharides (97, 98, 273). 
 
In vitro work has shown anabolic bone responses to the direct actions of leptin on bone 
cells (96, 98). Leptin receptors (LEPR) are expressed on hemopoietic precursor cells, 
and leptin can act as a growth factor to enhance the development of hemopoietic 
precursor cells (98). Leptin can induce MSC proliferation and the in vitro administration 
of leptin influences MSC differentiation favouring the chondrocyte lineage over the 
adipocyte lineage (Figure 42) (98, 99). Inhibition of adipogenesis might be regulated via 
a negative feedback loop, possibly through the induction of the Mitogen-Activated Protein 
Kinase pathway, which also stimulates osteoblast differentiation (96, 98). As well as 
enhancing osteoblastic differentiation, leptin also regulates osteoclastogenesis by 
inhibiting RANKL (98).  
 
Figure 42: The effects of leptin on bone through peripheral and central actions. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology (99), 
copyright 2009 
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Leptin knockout (ob/ob) mice have low femoral and whole body BMD compared to wild 
type mice, accompanied by greater bone marrow adiposity (336). Subcutaneous leptin 
treatment of ob/ob mice is associated with an increase in BMC and a decrease in the 
number of bone marrow adipocytes (337). A study of recombinant leptin therapy in a 
case of human congenital leptin deficiency showed increased bone mass, despite weight 
loss with treatment, indicating a positive effect of leptin on bone, independent of FM 
(338). 
 
Contrary to the direct effects of leptin on bone, leptin appears to exert catabolic effects 
on bone when it acts via the central nervous system (CNS) (96, 98, 99). In mice, central 
leptin administration reduces appetite and is associated with reductions in caloric intake, 
body weight, adipocyte size and circulating insulin (96). Mouse models show that when 
leptin is administered via the CNS, leptin binds to hypothalamic LEPR, which activates 
the β2-adrenoreceptor (ADRB2) on the osteoblast, decreasing osteoblast activity, 
increasing RANKL production and stimulating trabecular resorption (Figure 42) (90, 96, 
99).  
 
While “antiosteogenic leptin effects are often seen in axial elements but anabolic effects 
are observed in appendicular components” in mice (99, 336), the relationship between 
leptin and bone in humans is more consistent and positive in nature. Most studies report 
positive associations between leptin and aBMD (339-342). There may be differences in 
the relationship between leptin and bone by gender (334, 341, 342), possibly reflecting 
sexual dimorphism in adiposity, leptin production and/or interactions between leptin and 
sex hormones (343, 344). Some authors report a negative association (345-347) and 
others have reported no association (304, 335, 348-350) between leptin and BMD. 
Inconsistency between studies may be attributed to whether associations were adjusted 
for adiposity. After adjustment for BMI, significant associations between leptin and BMD 
are often weaker, reflecting the strong relationship between adiposity and leptin levels 
(342). 
 
Positive associations between leptin and BMD in humans suggest that the positive 
peripheral effects of leptin likely outweigh the adverse central effects of leptin on bone in 
humans. This may partly be because leptin is primarily derived from extraosseous 
adipocytes, bone marrow adipocytes, chondrocytes and osteoblasts in peripheral 
locations and not from the CNS (96). As obesity is associated with reduced transfer of 
leptin across the blood-brain barrier, which might also suggest that peripheral actions of 
leptin on bone would predominate over any central effects in obese humans (96).  
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Adiponectin 
Adiponectin is secreted exclusively by adipocytes and is highly expressed by bone 
marrow adipocytes (335). Circulating adiponectin is lower in obesity and inversely 
associated with VAT (90, 96, 100, 273). Adiponectin is involved in glucose synthesis in 
the liver; increasing insulin sensitivity and reducing serum insulin (96). Adiponectin is 
also involved in fatty acid oxidation (97, 351) and has anti-inflammatory properties (342).  
 
Adiponectin receptors are expressed by osteoblasts (96, 97). Upon binding to the 
adiponectin receptor, adiponectin may stimulate RANKL production and inhibit the 
production of OPG by osteoblasts, driving osteoclastogenesis (105, 106). Consequently 
inverse associations have been observed between adiponectin and aBMD across the 
skeleton, in men and women of various ages (101-104, 335, 340, 342, 348, 350, 352, 
353). Adiponectin also appears to be inversely associated with total vBMD (352, 353), 
Tb.vBMD and Ct.vBMD (352). Others have found no significant association between 
adiponectin and BMD (105, 300, 347, 349, 354).  
 
Bone Turnover 
Nutritional disturbances can lead to imbalances in bone formation and resorption and 
consequently affect bone remodelling and BMD. Having low LM or FM is associated with 
greater bone resorption and bone loss (263, 355). Weight loss is associated with 
increased bone turnover and consequently bone loss (356, 357). Therefore, high FM in 
obesity may be associated with lower bone turnover which is positively associated with 
BMD and might contribute favourable microarchitecture properties of bone. Previous 
studies have shown high body weight to be characterised by lower bone turnover, when 
assessed by markers of resorption (273, 358-361) and formation (269, 273, 358-361). 
Lower rates of bone loss in overweight women were proposed to be due to low bone 
turnover (362).  
 
While there is some evidence to support inverse associations between bone resorption 
(by CTX) and BMI, WBFM and abdominal adiposity determined by trunk FM, SAT and 
VAT (273), associations between adiposity and bone formation (by PINP) in obesity are 
less clear and perhaps more dependent on the degree and distribution of adiposity. In 
women with a range of BMI values, PINP was negatively associated with BMI, total FM, 
trunk FM, SAT and VAT (273). However, in obese women, a positive association was 
observed between PINP and SAT, but there was no association with BMI, WBFM or PAT 
or VAT (269). While positive correlations were reported between PINP and Tb.vBMD at 
the level of L4, PINP was not a significant predictor of Tb.vBMD in young obese women 
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(269). Bone resorption was not measured in this study, but it may have been that bone 
resorption and bone turnover were lower better determinants of BMD than PINP alone. 
 
There is insufficient evidence to conclude the effect of obesity on bone turnover, nor the 
effect of different fat compartments on bone turnover. Associations between adiposity 
and bone turnover are particularly unclear in populations other than postmenopausal 
women, although recent evidence suggests findings in older women may extend to 
premenopausal women (273). Characterising bone turnover in younger and older adults 
might improve current understanding of potential mechanisms driving larger differences 
between normal BMI and obese adults which could be mediated by reduced bone loss 
with advancing age. 
 
Osteocalcin 
OC is a non-collagenous protein produced by mature, active osteoblasts (94, 99, 111), 
with OC transcription stimulated by RunX2 and vitamin D3 (363). OC plays a major role 
in energy metabolism by increasing energy expenditure and adipose, lipid and glucose 
metabolism (364, 365). OC regulates glucose metabolism by increasing the expression 
of adiponectin by adipocytes and insulin by β-cells (93, 99) and is positively associated 
with glucose tolerance and insulin sensitivity (366). Murine models have been studied to 
describe the mechanism by which OC regulates glucose metabolism. When leptin is 
secreted by adipocytes, sympathetic tone is stimulated which increases Esp expression 
in osteoblasts; reducing OC activity and altering insulin secretion from β-cells (99). As 
Esp is not expressed in humans, the applicability of this model in humans may be limited. 
(99). 
 
There are two forms of OC; carboxylated and under carboxylated (uOC). uOC has a low 
affinity for hydroxyapatite and so to increase this affinity, glutamine acid residues of OC 
undergo post-translational γ-carboxylation into γ-carboxyglutamic acid in the presence 
of vitamin K (94, 99). The relationship between adiposity and OC and uOC may differ. 
Total OC has been implicated in the association between central adiposity and insulin 
resistance, with inverse associations between OC and BMI, waist circumference, trunk 
FM and VAT, which may be linked to elevated glucose and triglyceride levels in 
individuals with high central adiposity (112, 261, 273, 365, 367, 368). However, uOC was 
not associated with markers of adiposity (273).  
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Sclerostin 
Sclerostin is a glycoprotein secreted by mature osteocytes at the onset of mineralisation, 
which inhibits the Wnt pathway by binding with LRP; preventing bone formation (369). In 
mice, sclerostin knockout (SOST) animals exhibit increased bone formation and higher 
bone mass than wild type mice (370), whereas overexpression of the SOST gene is 
associated with osteopenia (371). In humans, mutations in the SOST gene cause 
sclerosteosis and van Buchem’s disease, both of which are autosomal recessive 
conditions, characterised by high PINP and high bone mass amongst other clinical 
features (372).  
 
Sclerostin expression is stimulated by mechanical loading, PTH and E2 (373) and levels 
correlate positively adiposity (359, 369, 374). Associations between sclerostin and BTMs 
are inconsistent (359, 375, 376) but sclerostin may be inversely associated with OC 
(369). Sclerostin is positively associated with BMD (369, 374, 376-378) and may also be 
associated with favourable bone microarchitecture (378). Whether sclerostin has a 
causative role in the association between obesity and high BMD is unclear. It may be 
that high sclerostin with high BMI simply reflects the greater osteocyte number 
associated with greater bone mass.  
 
Negative Biochemical Mechanisms 
High adiposity is also associated with several factors which may negatively affect BMD. 
Although the effect of high BMI on BMD and microstructure appears to be positive, it may 
be that the certain adipose compartments exert negative effects on bone, such as VAT.  
 
IGF-I 
IGF-I is a member of the IGF superfamily. Approximately 80% of circulating IGF-I is 
produced by the liver, although both skeletal and adipose tissues produce IGF-I (379). 
IGF-I mediates growth hormone (GH) concentrations through the GH/IGF axis, and 
regulates adipogenesis by impairing the activation of the Mitogen-Activated Protein 
Kinase pathway (379). Relationships between IGF-I and bone depend on whether the 
IGF-I is circulating or local; circulating IGF-I exerts mainly endocrine effects, whereas 
IGF-I produced by skeletal tissue exerts paracrine or autocrine effects associated with 
skeletal acquisition (379). IGF-I has positive effects on osteoblast activity and is 
positively associated with skeletal acquisition, periosteal apposition and bone mass (269, 
273, 379-381). In obesity, IGF-1 is positively associated with Tb.vBMD (269), bone size 
and cortical geometry; predicting cortical area, perimeter and thickness (268, 382).  
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IGF-I is inversely associated with BMI (269). Recent studies have reported inverse 
associations between IGF-I and trunk FM and VAT, while no relationship was observed 
between IGF-I and SAT (269, 273). This suggests that low IGF-I with high BMI could be 
attributed to low IGF-I expression by the VAT compartment, rather than the overall 
abdominal compartment. Whether VAT exerts upregulates bone turnover with 
consequential negative effects on bone density and microstructural compartments 
through low IGF-I expression is unclear.  
 
Pro-Inflammatory Cytokines 
Obesity is a low grade pro-inflammatory state associated with greater circulating pro-
inflammatory cytokines including IL-1, IL-6, TNF-α and IL-8 (97). Pro-inflammatory 
cytokines have roles in the autoimmune and metabolic consequences of obesity, such 
as the regulation of glucose and lipid metabolism by IL-6 (97). IL-6 enhances the 
formation of C-reactive protein (CRP) by the liver which is inversely associated with 
adiponectin (107, 353). Inflammatory cytokines are positively associated with 
osteoclastogenesis (383, 384), osteoclast activity (108) and bone resorption (107, 385). 
IL-1, TNF-α, IL-6 (386, 387) and CRP (388, 389) have been inversely associated with 
total BMD, Tb.vBMD and trabecular microstructure (390). As a result, inflammatory 
cytokines are negatively associated with bone strength (391) and positively associated 
with fracture risk (391-393). 
 
VAT has greater expression of pro-inflammatory cytokines than SAT, once again 
indicating that VAT may be a positive predictor of bone turnover and a negative predictor 
of BMD and bone microstructure (100, 117-119). 
 
Vitamin D 
Serum 25OHD maintains calcium homeostasis by functioning to increase calcium 
absorption in the intestine. Low 25OHD is associated with higher PTH, increased bone 
turnover and bone loss (394). Low 25OHD is typically associated with low BMD (395, 
396) and increased risk of fracture (394, 397-400). Associations between low 25OHD 
and the microarchitectural and mechanical properties of bone are unclear (268). As 
obese individuals have lower 25OHD, but higher bone density than normal BMI 
individuals, it is possible that vitamin D metabolism might be altered in obesity. Low 
25OHD status in obesity may play a role the relationship between obesity and fracture 
risk through effects on physical performance and falls risk (401). This will be discussed 
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in more detail in Chapters 5 and 6. Potential causes and consequences of low 25OHD 
in obesity will be investigated in Chapter 6. 
 
Although it is established that total 25OHD is inversely associated with adiposity (110, 
396, 402-407), associations between 25OHD and different fat compartments are unclear 
(110, 404, 408, 409). It may be that the effect of low 25OHD on bone metabolism in 
obesity is outweighed by the greater positive influences exerted by adiposity on bone 
turnover and bone density.  
 
Summary 
There is evidence to support complex crosstalk between bone, adipocytes, cytokines, 
osteokines and other biochemical factors in obesity. Endocrine influences and the 
mechanical loading effects of high body weight, might drive lower bone turnover and thus 
explain the greater BMD and favourable bone microarchitecture observed in obesity. A 
summary of the potential mechanisms by which obesity might influence bone density is 
given in Table 9. 
 
Table 9: Potential mediators of the effect of obesity on bone density 
Positive Mechanisms Negative Mechanisms 
↑Mechanical loading  
↑WBFM ↑VAT, ↑VAT:SAT 
↑SAT ↑Trunk FM 
↑PAT ↑Android FM 
↑Gynoid FM ↑Bone Marrow fat 
 ↓Brown fat 
↓Bone turnover 
(↓resorption, ↓formation) 
 
↑Osteocalcin  
↑Leptin ↑Inflammatory cytokines 
↓Adiponectin ↓IGF-I 
↑E2 ↓25OHD 
↑Glucose, ↑Insulin  
↑Sclerostin  
 
The varying metabolic profiles of distinct adipose compartments are likely to contribute 
to differing effects of adiposity dependent on body fat distribution. While high total body 
adiposity may be associated with the down-regulation of some biochemical factors which 
are positively associated with bone metabolism (e.g. IGF-I) and the up-regulation of 
factors which are negatively associated with bone metabolism (e.g. inflammatory 
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cytokines), the overall effect of obesity on bone turnover and density will likely result from 
the balance of favourable and unfavourable influences on bone tissue.  
 
Identification of potential mediators of the effects of adiposity on bone turnover, bone 
density and microstructure is required to better understand how adiposity exerts positive 
effects on bone density and microstructure.  In the short term, this knowledge may be 
used to focus further investigations into the effects of adiposity on bone. Longer term, 
identification of novel therapeutic targets for use in conditions characterised by low or 
deteriorating BMD, such as osteoporosis may be possible. 
 
Research Questions, Aims and Hypotheses 
Research questions: 
1. Do certain fat compartments, such as peripheral, subcutaneous abdominal or 
visceral fat, exert greater effects on BMD, bone geometry, bone microarchitecture 
and bone strength than other fat compartments?  
2. What are the potential mediators of the effects exerted by obesity on BMD, bone 
geometry, bone microarchitecture and bone strength?  
 
Aims: 
1. To ascertain which fat compartment is most strongly associated with BMD, 
geometry and microarchitecture, in normal BMI and obese individuals.  
2. To test associations between the proposed key fat compartment, biochemical 
markers of bone turnover and hormones to identify potential mediators of 
associations between obesity, BMD, bone microarchitecture and bone strength. 
 
Hypotheses: 
1. Bone turnover is decreased in obesity and as such, there is a significant difference 
in BTMs between obese and normal BMI individuals. 
2. Peripheral, subcutaneous abdominal and gynoid fat exert a positive effect on BMD, 
bone geometry and bone microarchitecture.  
3. Visceral, android and trunk fat exert a negative effect on BMD, bone geometry and 
bone microarchitecture.  
4. The positive effect of peripheral, subcutaneous abdominal and gynoid fat on bone 
turnover will be greater than the negative effect of visceral, android and trunk fat; 
such that there is an inverse association between adiposity and bone turnover. 
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5. Associations between peripheral, subcutaneous abdominal and gynoid fat and 
BMD, bone geometry and bone microarchitecture are mediated by higher E2 and 
leptin and lower adiponectin, which lower bone resorption. 
6. There is a greater difference in E2 between normal BMI and obese older women 
than between normal BMI and obese younger women and this is associated with 
the greater difference in BMD between normal BMI and obese older adults, 
compared to that of younger adults. 
7. Associations between visceral, android and trunk fat and BMD, bone geometry and 
bone microarchitecture are mediated by higher inflammatory cytokines and lower 
IGF-I. 
 
Methods 
Whole body FM, trunk FM, android FM, gynoid FM and FM on the arms and legs were 
determined by whole body DXA (Discovery A, Hologic Inc., Bedford, MA, USA). 
Appendicular FM was calculated as the sum of the FM on the arms and legs.  
 
Waist circumference (cm) was measured at the midpoint between the lowest rib and the 
uppermost aspect of the iliac crest. Hip circumference (cm) was measured at the level 
of the greatest protrusion of the buttocks. Waist-to-hip ratio was calculated as a marker 
of central adiposity. Triceps skinfold thickness (mm) was measured using a Harpenden 
skinfold calliper (Baty International, West Sussex, UK) as a marker of PAT.  
 
SAT and VAT was determined by five-slice CT, taken at the mid-level of the L3 vertebra 
(LightSpeed VCT-XT, General Electric Healthcare, Buckinghamshire, UK). 
 
Creatinine, calcium, albumin, lipid profile (Cobas c701 auto-analyser, Roche 
Diagnostics, Mannheim, Germany) and glucose (Cobas c702 auto-analyser, Roche 
Diagnostics, Mannheim, Germany) were measured from the screening blood samples in 
the Clinical Chemistry Laboratory, Sheffield Teaching Hospitals .  
 
CTX, PINP and OC were determined by automated ECLIA (Cobas e411, Roche 
Diagnostics, Mannheim, Germany). BAP was determined by automated CLIA (IDS-iSYS 
Immunodiagnostic Systems, Boldon, UK). OPG was measured by manual ELISA 
(Biovendor, GmbH, Heidelberg, Germany). Sclerostin was measured by manual ELISA 
(Biomedica, Vienna, Austria).  
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Leptin and adiponectin were determined by manual ELISA (Human Leptin Quantikine 
ELISA, Human Total Adiponectin Quantikine ELISA, R&D Systems, UK).  
 
PTH, 25OHD, albumin and insulin were determined by automated ECLIA (Cobas e411, 
Roche Diagnostics, Mannheim, Germany). IGF-I was measured by automated CLIA 
(IDS-iSYS, Immunodiagnostic Systems, Boldon, UK).  
 
Insulin resistance was determined using the homeostasis model assessment of insulin 
resistance (HOMA-IR): 
(Fasting serum glucose (mmol/L) * fasting serum insulin (µU/ml) / 22.5) 
 
SHBG was measured by automated ECLIA (Cobas e602, auto-analyser, Roche 
Diagnostics, Mannheim, Germany). Total E2 was determined by automated ECLIA 
(Cobas e411, Roche Diagnostics, Mannheim, Germany). Free E2 (fE2) was determined 
as: 
fE2 (mol/L) = (-b + √(b2 – 4ac)) / 2a 
Where:  N= 1+ affinity constant of albumin for E2 x albumin 
  a = N * affinity constant of SHBG for E2 
  b = N + affinity constant of SHBG for E2 * (SHBG - Total E2) 
  c = -Total E2  
Affinity constant of albumin for E2 = 4.21 × 104 L/mol  
Affinity constant of SHBG for E2  = 3.14 × 108 L/mol 
 
BioE2 was calculated as:  
bioE2 (mol/L)= (1+ affinity constant of albumin for E2 x albumin)* fE2 
 
HsCRP was measured by automated nephelometry (BNII System, Siemens, Siemens 
Healthcare Diagnostics, Surrey, UK). IL-6 was measured by automated immunoassay 
(Cobas e601 auto-analyser, Roche Diagnostics, Mannheim, Germany).  
 
Kidney function was estimated from calculation of estimated glomerular filtration rate 
(eGFR), using the MDRD equation: 
eGFR = 175 * (serum creatinine (µmol/L) * 0.0113)-1.154 * age-0.203 [* 0.742 if female] 
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Statistical Analysis 
Coupling Index was calculated as a SD score, by subtracting the mean of the age and 
gender matched normal weight group from each result and subsequently dividing by the 
SD of the normal weight group. Mean SD scores were then calculated. All variables were 
assessed for normality and log transformed where necessary. As paired t-tests were to 
be used to determine significant differences between normal BMI and obese groups, the 
absolute differences between the matched pairs were assessed for normality. Where the 
difference between the pairs was skewed, the raw data was log transformed and the 
differences re-evaluated for normality.  
 
Paired samples t-tests were used to determine significant differences between normal 
BMI and obese groups, for the entire sample, by age group and by age and gender 
Where transformed values remained non-normal, the Wilcoxon Signed Rank test was 
used. Univariate general linear models were used to identify whether age group, gender 
and BMI had an effect on FM or biochemical outcomes and to identify interactions 
between age or gender and the effect of BMI on FM or biochemical outcomes.  
 
Pearson correlation coefficient was used to determine associations between FM and 
biochemical variables, FM and skeletal outcomes and biochemistry and skeletal 
outcomes. Spearman’s rank correlation coefficient was used where the sample 
distribution remained non-normal. Multiple linear regression adjusting for age and gender 
was used to determine whether FM or LM predicted bone density and microstructural 
outcomes. WBLM and each FM variable separately were entered as dependent variables 
to avoid collinearity. Multiple linear regression models were constructed determine the 
influence of different fat compartments on BMD by testing the working hypotheses. BMD 
or microstructural variables were entered as the independent variable and age, gender, 
and pairs of contrasting fat compartments (SAT and VAT, trunk FM and AFM, android 
FM and gynoid FM) were entered as dependent variables. 
 
To determine the influence of different fat compartments on cortical and trabecular 
outcomes, multiple linear regression with microstructural outcome as the independent 
variable and age, gender, and pairs of contrasting fat compartments (SAT and VAT, trunk 
FM and AFM, and android FM and gynoid FM) as dependent variables was performed. 
Analysis was performed using IBM SPSS Statistics for Windows (Version 21.0. Armonk, 
NY: IBM Corp.). Significance was accepted when p<0.05.   
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Results 
All measures of adiposity except VAT:SAT ratio, were higher in the obese individuals 
than individuals with a normal BMI (all p<0.001) (Figure 43, Figure 44, Figure 45).All 
measures of adiposity (except VAT:SAT ratio) were higher in obese individuals when 
assessed by age group (all p<0.001) or by age and gender (all p<0.001, except WHR in 
older women where p<0.05). There was no effect of age on BMI or WBFM. There was 
no effect of gender on BMI, but women had a higher WBFM than men (p<0.005).  
 
Figure 43: Whole body adiposity of normal BMI and obese individuals 
by BMI (A) and WBFM (B).1,2 
A  B  
 
Central Adiposity 
Older adults had greater trunk FM (p<0.01), android FM (p<0.01), VAT (p<0.001), 
VAT:SAT ratio (p<0.001), waist circumference (p<0.001) and WHR (p<0.001) than 
younger adults. Younger adults had greater gynoid FM than older adults (p<0.001). 
There was no effect of age on SAT or hip circumference. Age associations were 
unchanged by adjustment for WBFM. There was a greater effect of BMI on SAT and VAT 
in younger adults than older adults (SAT: p<0.01, VAT: p<0.05). 
 
Figure 44: SAT, VAT and VAT:SAT ratio of normal BMI and obese individuals.1,2 
 
 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Women had greater trunk FM (p<0.01), gynoid FM (p<0.001), SAT (p<0.001) and hip 
circumference (p<0.01). Men had greater VAT, VAT:SAT ratio, waist circumference and 
WHR (all p<0.001). There was no effect of gender on android FM. There was a greater 
effect of BMI on hip circumference in women than men (p<0.01). There was a greater 
effect of BMI on WHR in men (univariate GLM p<0.05). 
 
Figure 45: Central adiposity of normal BMI and obese individuals 
by trunk (A), android (B) and gynoid FM (D), waist (D) and hip circumference (E) and WHR (F).1,2 
A B C  
D E F  
Peripheral Adiposity 
There was no effect of age on AFM or triceps skinfold thickness. Women had greater 
AFM and triceps skinfold thickness than men (both p<0.001) (Figure 46). 
Figure 46: Peripheral adiposity of normal BMI and obese individuals 
by AFM (A) and triceps skinfold thickness (B) Ages combined (A), young (B), and older (C).1,2 
A  B   
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Are Associations Between Obesity and Bone Due to FM or LM? 
A summary of the effects of WBLM and WBFM is given in Table 10. 
 
aBMD at all sites was positively predicted by WBLM but not by FM variables. 
As there were interactions between age and the effect of FM variables on aBMD, models 
were re-run by age group: 
In young adults: 
 WB aBMD was positively predicted by all FM variables and not by WBLM 
 TH aBMD remained predicted by WBLM not FM 
 LS aBMD remained predicted by WBLM not FM 
In older adults: 
 WB aBMD remained predicted by WBLM and not by FM variables 
 TH aBMD was predicted by all FM variables and not by WBLM  
 LS aBMD remained predicted by WBLM not FM, except for android FM and LM  
 
Tibia vBMD was positively predicted by: 
 WBFM  (adjusted R square .291, beta .302 p<0.001) 
 AFM   (adjusted R square .283, beta .240, p<0.05) 
 Trunk FM  (adjusted R square .311, beta .331, p<0.001) 
 Android FM (adjusted R square .322, beta .349, p<0.001) 
 Gynoid FM  (adjusted R square .291, beta .279, p<0.01) 
 SAT   (adjusted R square .315, beta .291, p<0.01)  
In each of these models, tibia vBMD was not predicted by WBLM. 
Tibia vBMD was predicted by both WBLM and VAT (adjusted R square .293, beta WBLM 
.315, p<0.01, beta VAT .213, p<0.05). 
 
Radius vBMD was positively predicted by: 
 WBFM  (adjusted R square .133, beta .136, p<001) 
 AFM   (adjusted R square .121, beta .297, p<0.01) 
 Triceps skinfold thickness (adjusted R square .116, beta .223, p<0.01) 
 Trunk FM  (adjusted R square .139, beta .335, p<0.01) 
 Android FM (adjusted R square .146, beta .342, p<0.001)  
 Gynoid FM  (adjusted R square .128, beta .322, p<0.01) 
 SAT   (adjusted R square .140, beta.291, p<0.01)  
 VAT   (adjusted R square .123, beta .230, p<0.05) 
In each of these models, radius vBMD was not predicted by WBLM.  
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As there were interactions between age and the effect of FM variables on distal radius 
vBMD, models were re-run by age group. Except for android and gynoid FM in older 
adults, where neither FM nor LM predicted vBMD, FM remained the dominant predictor 
of vBMD  
 
 Lumbar spine vBMD was positively predicted by both WBLM and FM indices, with the 
exception of android, gynoid and AFM where only LM predicted LS.vBMD. 
 
Table 10: LM predicts aBMD at central sites, while FM predicts peripheral vBMD 
Dependent 
variable 
Independent 
variables 
Beta 
p 
value 
Model 
p 
value 
R 
square 
Adj. R 
square 
Age 
Interaction  
WB 
aBMD 
WBLM 
WBFM 
.824 
-.073 
<.001 
.366 
<.001 .496 .485 
WBFM* 
Trunk FM* 
SAT** 
AFM* 
Android FM* 
Gynoid FM*  
TH  
aBMD 
WBLM 
WBFM 
.777 
.120 
<.001 
.134 
<.001 .515 .505 - 
LS 
aBMD 
WBLM 
WBFM 
.654 
.092 
<.001 
.333 
<.001 .303 .289 
WBLM*+ 
VAT* 
Android FM* 
Radius 
vBMD 
WBLM 
WBFM 
-.090 
.336 
.487 
<.001 
<.001 .147 .133 
WBFM** 
Trunk FM** 
AFM** 
Android 
FM** 
Gynoid FM** 
Tibia 
vBMD 
WBLM 
WBFM 
.039 
.302 
.741 
<.001 
<.001 .302 .291 - 
LS vBMD 
WBLM 
WBFM 
.517 
-.304 
<.05 
<.05 
.088 .056 .031  
*p<0.05, **p<0.01, + when entered with WBFM, AFM, triceps skinfold or gynoid FM 
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Which Fat Compartment Has the Greatest Influence on BMD? 
Results of the linear regression models to determine which FM variable has a dominant 
effect on BMD are presented in Table 11, Table 12 and Table 13. aBMD was predicted 
by SAT, gynoid FM and AFM, whereas vBMD was predicted by SAT, android FM and 
trunk FM. 
 
Table 11: Prediction of BMD by SAT and VAT 
Dependent 
variable 
Independent 
variables 
Beta p value 
Model p 
value 
R square 
Adjusted 
R square 
WB aBMD SAT 
VAT 
.356 
-.026 
<.001 
.815 
<.001 .356 .341 
TH aBMD SAT 
VAT 
.418 
.096 
<.001 
.387 
<.001 .351 .336 
LS aBMD SAT 
VAT 
.328 
.088 
.004 
.480 
<.001 .173 .155 
Radius vBMD SAT 
VAT 
.288 
.079 
.012 
.530 
<.001 .158 .139 
Tibia vBMD SAT 
VAT 
.342 
.058 
.001 
.607 
<.001 .321 .306 
 
 
Table 12: Prediction of BMD by gynoid FM and android FM  
Dependent 
variable 
Independent 
variables 
Beta p value 
Model p 
value 
R square 
Adjusted 
R square 
WB aBMD Android FM 
Gynoid FM 
-.068 
.474 
.588 
<.001 
<.001 .374 .361 
TH aBMD Android FM 
Gynoid FM 
.230 
.341 
.061 
.010 
<.001 .398 .386 
LS aBMD Android FM 
Gynoid FM 
.065 
.433 
.636 
.004 
<.001 .241 .225 
Radius vBMD Android FM 
Gynoid FM 
.299 
.059 
.039 
.704 
<.001 .164 .147 
Tibia vBMD Android FM 
Gynoid FM 
.407 
-.015 
.002 
.915 
<.001 .334 .320 
 
 
Table 13: Prediction of BMD by AFM and trunk FM  
Dependent 
variable 
Independent 
variables 
Beta p value 
Model p 
value 
R square 
Adjusted 
R square 
WB aBMD AFM 
Trunk FM 
.553 
-.140 
<.001 
.303 
<.001 .383 .370 
TH aBMD AFM 
Trunk FM 
.300 
.263 
.036 
.050 
<.001 .396 .384 
LS aBMD AFM 
Trunk FM 
.279 
.188 
.087 
.217 
<.001 .218 .202 
Radius vBMD AFM 
Trunk FM 
.015 
.326 
.929 
.041 
<.001 .156 .139 
Tibia vBMD AFM 
Trunk FM 
-.083 
.452 
.582 
.002 
<.001 .324 .310 
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Which Fat Compartment Has the Greatest Influence on Bone Microstructure? 
Results of the linear regression models to determine which FM variable has a dominant 
effect on bone microstructure are presented in Table 14.  
 
Bone microarchitectural outcomes (Ct.vBMD, Ct.Th, Tb.vBMD and Tb.N at the distal 
radius and Ct.Th, Tb.vBMD and Tb.N at the distal tibia) were best predicted by SAT 
(Table 14). Although bone microarchitectural outcomes were also predicted by android 
FM and trunk FM (Table 14), both android FM and trunk FM incorporate SAT and may 
therefore be acting through the dominant effect of SAT.  
 
Due to the highly collinear nature of SAT, android FM and trunk FM it was not possible 
to run accurate paired models to determine the dominant FM from these variables. SAT 
was therefore chosen as the fat depot with the greatest influence on bone microstructure 
for subsequent analysis. 
 
Table 14: Adipose compartment predictors of bone microstructure 
 Dependent 
variable 
Significant 
predictors 
Beta 
p 
value 
Model 
p value 
R 
square 
Adjusted 
R square 
Radius Ct.vBMD SAT .245 .035 <.001 .138 .119 
 Ct.Ar SAT .350 .001 <.001 .333 .318 
 Ct.Th SAT .303 .009 <.001 .144 .125 
 Ct.Pm Gynoid FM 
Android FM 
AFM 
.331 
-.214 
-.137 
.003 
.038 
.225 
<.001 
<.001 
<.001 
.578 
.578 
.571 
.570 
.570 
.562 
 Tb.vBMD SAT 
Android FM 
Trunk FM 
.253 
.258 
.350 
.014 
.047 
.015 
<.001 
<.001 
<.001 
.322 
.326 
.313 
.307 
.312 
.299 
 Tb.N SAT 
Gynoid FM 
.428 
.309 
<.001 
.032 
<.001 
<.001 
.257 
.284 
.241 
.270 
Tibia Ct.vBMD - - - - - - 
 Ct.Ar SAT .302 .001 <.001 .483 .471 
 Ct.Th SAT 
Android FM 
Trunk FM 
.290 
.332 
.305 
.004 
.009 
.027 
<.001 
<.001 
<.001 
.353 
.371 
.366 
.338 
.358 
.353 
 Ct.Pm Gynoid FM 
Android FM 
Trunk FM 
AFM 
-.349 
.454 
-.321 
.435 
<.001 
.001 
.006 
.001 
<.001 
<.001 
<.001 
<.001 
.553 
.553 
.546 
.546 
.544 
.544 
.537 
.537 
 Tb.vBMD SAT 
Trunk FM 
.331 
.344 
.002 
.024 
<.001 
<.001 
.242 
.232 
.225 
.216 
 Tb.N SAT 
Gynoid FM 
AFM 
.604 
.546 
.624 
<.001 
<.001 
<.001 
<.001 
<.001 
<.001 
.267 
.307 
.323 
.250 
.292 
.309 
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Biochemistry 
Bone Turnover 
Obese individuals had lower bone turnover, with lower CTX (p<0.001), PINP (p<0.01) 
and OC (p<0.001) compared to individuals with a normal BMI. Univariate GLM showed 
a significant effect of BMI on CTX (p<0.001), PINP (p<0.01) and OC (p<0.001). 
A    
B    
C    
Figure 47: BTMs in normal BMI and obese individuals 
CTX (left), PINP (centre) and OC (right) by ages combined (A), young (B) and older (C) ).1,2 
 
There was no effect of age on CTX or OC. Younger adults had higher PINP than older 
adults (p<0.01). There was no effect of gender or interactions between age or gender 
and the effect of BMI on CTX, PINP or OC.  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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A    
B     
C     
D    
Figure 48: BTMs in normal BMI and obese individuals by age and gender 
CTX (left), PINP (centre) and OC (right) in young women (A), young men (B), older women (C), 
older men (D) ).1,2 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Coupling of CTX and PINP 
CTX and PINP were highly correlated (r=0.779, p<0.01). Obese individuals had a 
coupling index on average 0.24 SD scores greater than that of normal BMI individuals 
(p<0.01) (Figure 49). There was no effect of gender on coupling index. 
 
The ratio of PINP to CTX was higher in young adults than older adults (p<0.05). Young 
obese adults had a coupling index on average 0.16 SD scores greater than normal BMI 
young adults, which was not significant. Older obese adults had a coupling index on 
average 0.29 SD scores higher than normal BMI older adults (paired t-test: p<0.01, GLM 
p<0.05). 
 
Figure 49: Bone turnover coupling index in normal BMI and obese individuals 
Ages combined (A), young (B), and older (C).1,2 
A B C  
 
Multiple linear regression adjusting for age and gender showed that CTX was the 
significant predictor of aBMD and vBMD at all sites measured, whereas PINP was not a 
significant predictor of aBMD or vBMD (Table 15). 
 
Table 15: CTX as a predictor of BMD 
Dependent 
variable 
Independent 
variables 
Beta p value 
Model 
p value 
R 
square 
Adj R 
square 
WB aBMD 
CTX 
PINP 
-.299 
.031 
<.010 
.749 
<.001 .304 .289 
TH aBMD 
CTX 
PINP 
-.399 
.090 
<.001 
.382 
<.001 .229 .213 
LS aBMD 
CTX 
PINP 
-.342 
.017 
<.010 
.877 
<.001 .136 .188 
Radius vBMD 
CTX 
PINP 
-.287 
.115 
<.050 
.303 
<.010 .087 .068 
Tibia vBMD 
CTX 
PINP 
-.211 
.042 
<.050 
.683 
<.001 .239 .223 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Leptin and Adiponectin 
Obese individuals had higher leptin (p<0.001) and lower adiponectin (p<0.001) than 
individuals with a normal BMI (Figure 50). Univariate GLM showed a significant effect of 
BMI on leptin and adiponectin (p<0.001).  
 
Figure 50: Leptin and adiponectin in normal BMI and obese individuals.1,2 
  
 
Older adults had higher leptin and adiponectin than younger adults (both p<0.001). 
Women had higher leptin and adiponectin than men (both p<0.001), even after 
adjustment for WBFM (both p<0.001) (Figure 51).  
 
There was a significant interaction between age and the effect of BMI on leptin; with a 
greater effect of BMI on leptin in the older adults than the younger adults (p<0.05). There 
was no interaction between age or gender and BMI on adiponectin. 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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A   
B   
C   
D   
Figure 51: Leptin and adiponectin in normal BMI and obese individuals by group 
by age and gender; young women (A), young men (B), older women (C), older men (D).1,2 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Total, Free and Bioavailable E2 
There was no difference in totE2, fE2 or bioE2 between obese individuals and those with 
a normal BMI (Figure 52). 
 
Figure 52: TotE2, fE2, bioE2 in normal BMI and obese individuals.1,2 
 
 
Younger adults had greater totE2, fE2 and bioE2 than older adults (all p<0.001). Women 
had higher totE2 than men (p<0.05), but there was no difference in fE2 or bioE2 by 
gender (Figure 53).  
 
There was an interaction between age and the effect of BMI on totE2 and fE2 (univariate 
GLM, both p<0.05) but not for bioE2 (p=0.052), such that the effect of BMI on totE2 and 
fE2 was greater in older adults than younger adults.  
 
 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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A  
B    
C   
D   
Figure 53: TotE2, fE2 and bioE2 in normal BMI and obese individuals by group 
young women (A), young men (B), older women (C), older men (D).1,2 
 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Glucose, Insulin and Insulin Resistance 
Obese individuals had higher glucose, Insulin and HOMA-IR than individuals with a 
normal BMI (all p<0.001) (Figure 54). GLM showed a significant effect of BMI on glucose, 
insulin and HOMA-IR (all p<0.001). 
 
Figure 54: Glucose, insulin and HOMA-IR of normal BMI and obese individuals. 1,2 
 
 
Older adults had higher glucose than younger adults (p<0.001), but there was no effect 
of age on insulin or HOMA-IR (Figure 55).  
 
There was no effect of gender, or any interaction between age or gender and the effect 
of BMI, on glucose, insulin or HOMA-IR. 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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A  
B  
C  
D  
Figure 55: Glucose, insulin and HOMA-IR of normal BMI and obese individuals by group 
young women (A), young men (B), older women (C), older men (D) 1,2 
 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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SHBG 
Obese individuals had lower SHBG than individuals with a normal BMI (p<0.001) (Figure 
56). Univariate GLM showed BMI had a significant effect on SHBG (p<0.001). There was 
no effect of age on SHBG levels. Women had higher SHBG than men (p<0.001). There 
was an interaction between gender and the effect of BMI on SHBG, with a greater effect 
of BMI on SHBG in women than in men (univariate GLM, p<0.05). 
 
Figure 56: SHBG in normal BMI and obese individuals 
Ages combined (A), young (B) and older (C), all genders (left), women (centre), men (right)  1,2 
A  
B
C  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Albumin 
Obese individuals had lower albumin than individuals with a normal BMI (p<0.01) (Figure 
57). Univariate GLM showed a significant effect of BMI on albumin (p<0.05). Young 
adults had higher albumin than older adults (p<0.01). Men had higher albumin than 
women (p<0.001). There were no interactions between age or gender and the effect of 
BMI on albumin. 
 
Figure 57: Albumin in normal BMI and obese individuals 
Ages combined (A), young (B) and older (C), all genders (left), women (centre), men (right)  1,2 
A  
B  
C  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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IGF-I 
Overall, IGF-I was lower in obese individuals than those with a normal BMI (p<0.05) 
(Figure 58). Univariate GLM showed a significant effect of BMI on IGF-I (p<0.05). 
Younger adults had higher IGF-I than older adults (p<0.001). There was no effect of 
gender, or interactions between age or gender and the effect of BMI, on IGF-I.  
 
Figure 58: IGF-I in normal BMI and obese individuals 
Ages combined (A), young (B) and older (C), all genders (left), women (centre), men (right)  1,2   
A  
B  
C  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Calcium, PTH and 25OHD 
There was no difference in adjusted calcium between obese and normal BMI individuals 
(Figure 59). Obese individuals had higher PTH (p<0.05) and lower 25OHD (p<0.001) 
than nomal BMI individuals (Figure 59).  
 
Figure 59: Adjusted calcium, PTH and 25OHD in normal BMI and obese individuals 
Age groups combined (A), young (B) and older (C) 1,2 
A  
B  
C  
Older adults had higher adjusted calcium, PTH and 25OHD than young adults (calcium 
and PTH p<0.001, 25OHD p<0.01). There was a greater effect of BMI on adjusted 
calcium in young adults, than older adults (p<0.01). There was no effect of gender on 
adjusted calcium, PTH or 25OHD. There was a greater effect of BMI on PTH levels in 
women than men (p<0.05).  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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BAP 
There was no difference in BAP between obese individuals and those with a normal BMI 
(Figure 60). Older adults had higher BAP than young adults (p<0.01). There was no 
effect of gender, or interactions between age or gender and the effect of BMI on BAP. 
 
Figure 60: BAP in normal BMI and obese individuals 
Ages combined (A), young (B) and older (C), all genders (left), women (centre), men (right)  1,2  
A  
B  
C  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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OPG 
There was no difference in OPG between obese and normal BMI indiduals (Figure 61). 
Older adults had higher OPG than young adults (p<0.001). Women had higher OPG than 
men (p<0.01). There were no interactions between age or gender and the effect of BMI 
on OPG. 
 
Figure 61: OPG in normal BMI and obese individuals 
Ages combined (A), young (B) and older (C), all genders (left), women (centre), men (right)  1,2  
A  
B  
C  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Sclerostin 
There was no difference in sclerostin between obese and normal BMI indiduals (Figure 
62). Younger adults had higher sclerostin than older adults (p<0.001). Men had higher 
sclerostin than women (p<0.001). 
 
Sclerostin was not associated with coupling index in young adults. In older adults, 
sclersotin was positively correlated with coupling index (unadjusted r=0.356, adjusted for 
gender r=0.368, both p<0.001). 
 
Figure 62: Sclerostin in normal BMI and obese individuals 
Ages combined (A), young (B) and older (C), all genders (left), women (centre), men (right)  1,2  
A  
B  
C  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Creatinine and eGFR 
There was no difference in creatinine or eGFR between obese individuals and those with 
a normal BMI (Figure 63). There was no effect of age on creatinine. Men had higher 
creatinine than women (p<0.001). Younger adults had higher eGFR than older adults 
(p<0.001). There was no effect of gender on eGFR. There were no interactions between 
age or gender and the effect of BMI on creatinine or eGFR. 
 
Figure 63: Creatinine and eGFR in normal BMI and obese individuals 
Groups combined (A), younger adults (B), older adults (C) 1,2 
A   
B   
C   
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Lipids 
There was no difference in TC between obese individuals and individuals with a normal 
BMI (Figure 64). Obese individuals had lower HDL than individuals with a normal BMI 
(p<0.001) (Figure 64). Obese individuals had higher TC:HDL ratio (p<0.001). Obese 
individuals had higher triglycerides than individuals with a normal BMI (p<0.001) (Figure 
64). Women had a higher TC and HDL than men (both p<0.001) but there was no effect 
of gender on total:HDL ratio or triglycerides. 
 
Figure 64: TC, HDL and triglycerides in normal BMI and obese individuals 
genders combined (left), women (centre), men (right) 1,2 
 
 
Inflammatory Cytokines 
Obese individuals had higher HsCRP than individuals with a normal BMI (p<0.001). 
There was no effect of gender on HsCRP.  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Potential Mediators of Low Bone Turnover in Obesity 
As hypothesised, bone turnover appears to be lower in obesity. As previously stated, 
SAT was identified as the fat depot with the greatest influence on bone microstructure 
and so multiple linear regression models were built to a) determine the effect of SAT on 
bone resorption and formation and b) determine which, if any, of the biochemical factors 
studied, accounted for the effect of SAT on CTX and PINP. The effect of each of the key 
biochemical mediators proposed in Table 9 on CTX and PINP were studied, based on 
the hypothesis outlined for this Chapter. 
 
Mediators of Low Bone Resorption in Obesity 
Adjusting for age and gender, SAT was a negative predictor of CTX (overall model 
p<0.01, adjusted R square 0.078, effect of SAT: beta -0.288, p<0.001).  
 
When leptin was added to this model, SAT was no longer a predictor of CTX (beta -
0.053, p=0.639), but leptin was a negative predictor of CTX (overall model p<0.001, 
adjusted R square 0.101, effect of leptin: beta -0.409, p<0.05). 
 
When TotE2 was added to the CTX model, SAT remained a significant predictor of CTX 
(beta -0.293, p<0.001), and totE2 was also a significant predictor of CTX (overall model 
p<0.001, adjusted R square 0.121, effect of totE2: beta -0.258, p<0.01). Adding fE2 or 
bioE2 instead of totE2 did not alter this relationship (both p<0.01)  
 
When both leptin and TotE2 were added to the CTX model, SAT was no longer a 
significant predictor of CTX (beta -0.074, p=0.505), but both leptin (beta -0.380, p<0.05) 
and TotE2 (beta -0.247, p<0.01) were significant negative predictors of CTX (overall 
model p<0.001, adjusted R square 0.140).  
 
Adiponectin, IGF-I, glucose, insulin and HOMA-IR were not predictors of CTX. 
 
OPG was positively correlated with leptin (r= 0.454, p<0.001). To see whether leptin 
might lower CTX in obesity through positive associations with OPG, multiple linear 
regression adjusting for age and gender was performed with OPG as the dependent 
variable. SAT was a significant predictor of OPG (overall model p<0.001, adjusted R 
square 0.479, effect of SAT: beta -0.128, p<0.05). When leptin was added into this 
model, SAT remained a significant predictor of OPG and leptin was not a predictor 
(overall p<0.001, adjusted R square 0.484, effect of SAT: beta -0.233, p<0.01). 
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Mediators of Low Bone Formation in obesity 
Adjusting for age and gender, SAT was a negative predictor of PINP (overall model 
p<0.001, adjusted R square 0.084, effect of SAT: beta -0.230, p<0.01) and OC (overall 
model p<0.001, adjusted R square 0.106, effect of SAT: beta -0.348, p<0.001). 
 
When leptin was added to the PINP or OC model, SAT was no longer a predictor of PINP 
(beta -0.170, p=0.0140) or OC (beta -0.177, p=0.119), and leptin was not a significant 
predictor of PINP (overall model p<0.01, adjusted R square 0.081, effect of leptin: beta 
-0.108, p=0.502) or OC (overall model p<0.001, adjusted R square 0.112, effect of leptin: 
beta -0.291, p=0.067). 
 
When TotE2 was added to the PINP or OC model, SAT remained a significant predictor 
of PINP (beta -0.235, p<0.001) and OC (beta -0.352, p<0.001), and totE2 was also a 
negative predictor of PINP (overall model p<0.001, adjusted R square 0.116, effect of 
totE2: beta -0.226, p<0.01) and OC (overall model p<0.001, adjusted R square 0.131, 
effect of totE2: beta -0.202, p<0.05). Adding fE2 or bioE2 instead of totE2 did not alter 
this relationship (all p<0.01)  
 
When both leptin and TotE2 were added to the PINP model, SAT was no longer a 
significant predictor of PINP (beta -0.189, p=0.096) and leptin was not a significant 
predictor of PINP (beta -0.082, p=0.605) but TotE2 was a predictor of PINP (overall 
model p<0.001, adjusted R square 0.112, effect of TotE2: beta -0.223, p<0.01). 
 
When both leptin and TotE2 were added to the OC model, SAT was no longer a 
significant predictor of OC (beta -0.193, p=0.085) and leptin was not a significant 
predictor of OC (beta -0.268, p=0.087) but TotE2 was a predictor of OC (overall model 
p<0.001, adjusted R square 0.135, effect of TotE2: beta -0.195, p<0.05). 
 
Adiponectin, IGF-I, glucose, insulin and HOMA-IR were not predictors of PINP. 
 
Adiponectin, IGF-I and glucose were not predictors of OC. When insulin and HOMA-IR 
were added (separately) to the OC model, SAT remained a significant predictor of OC 
(insulin model: beta -0.204, and HOMA-IR model: beta -0.224, both p<0.05) and insulin 
and HOMA-IR were also negative predictors of OC (insulin beta: -0.212, HOMA-IR beta: 
-0.206, both p<0.05). 
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Summary of Results 
A summary of the differences between BMI, age and gender groups for the outcomes 
of this Chapter is provided in Table 16. The variables identified as having a potential 
role in the association between obesity and BMD and microstructure are also labelled. 
 
Table 16: Summary of results of Chapter 4 
Variable 
Effect of 
BMI 
Effect of 
Age 
Effect of 
Gender 
Interactions with 
BMI 
WBFM ↑ - ↑ in women - 
SAT* ↑ - ↑ in women ↑ effect in younger 
VAT ↑ ↑ in older ↑ in men ↑ effect in younger 
VAT:SAT - ↑ in older ↑ in men  
Trunk FM ↑ ↑ in older ↑ in women - 
AFM ↑ - ↑ in women - 
Android FM ↑ ↑ in older - - 
Gynoid FM ↑ ↑ in younger ↑ in women - 
CTX* ↓ - - - 
PINP ↓ ↑ in younger - - 
OC ↓ - - - 
Coupling 
index* 
↑ ↑ in younger - 
↑ effect in older 
Leptin* ↑ ↑ in older ↑ in women ↑ effect in older 
Adiponectin ↓ ↑ in older ↑ in women - 
TotE2* - ↑ in younger ↑ in women ↑ effect in older 
fE2* - ↑ in younger - ↑ effect in older 
BioE2* - ↑ in younger - - 
SHBG ↓ - ↑ in women ↑ effect in women 
OPG - ↑ in older ↑ in women - 
IGF-I ↓ ↑ in younger - - 
Glucose ↑ ↑ in older - - 
Insulin ↑ - - - 
PTH ↑ ↑ in older - ↑ effect in women 
Ca - ↑ in older - ↑ effect in younger 
25OHD ↓ ↑ in older - -  
*Variables implicated in the predictive model as mediating the association between 
obesity and greater BMD and favourable microarchitecture 
 
Discussion 
The results of this Chapter show obese individuals have lower bone turnover, mainly as 
a result of lower bone resorption, accompanied by lower bone formation. Lower bone 
resorption in obesity was the result of greater adiposity and not of greater lean mass. 
Subcutaneous abdominal adiposity was the key negative determinant of bone resorption, 
lowering resorption through greater leptin production. Leptin was higher in older adults 
and the greater effect of adiposity on leptin in older adults than younger adults may go 
some way to explaining the positive coupling index and greater effect of obesity on BMD 
and bone microstructure in older adults, whereas coupling index is not affected by BMI 
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in the young adults, in whom weaker beneficial effects are observed in bone density and 
structure with high BMI. 
 
Obese individuals have lower bone turnover than individuals with a normal BMI, with 
lower CTX and lower PINP and OC. These findings are consistent with the existing 
literature which shows lower makers of resorption and formation with high BMI in 
premenopausal women (410), through the menopausal transition (411) and in  
postmenopausal women (261, 358, 410, 412, 413). Studies in men from which to draw 
comparisons are lacking, although a recent study of young men and women by 
Viljakainen et al. showed PINP, CTX, TRAP, total OC and carboxylated OC were 40%, 
35%, 17%, 31% and 32% lower, respectively, than in non-obese age and gender 
matched controls (414). In further agreement with the results of this Chapter, Viljakainen 
et al. found no difference in coupling index between young obese and non-obese men 
and women (414). There was no effect of age on bone resorption in the present study, 
while younger adults had higher bone formation than older adults, possibly associated 
with the period of consolidation in early adulthood, despite bone turnover typically 
increasing with age (382).   
 
This Chapter shows that leptin appears to be the key mediator of the effect of SAT on 
CTX. Consistent with the findings of the present study, Viljakainen et al. suggested that 
leptin may be the principal determinant of bone turnover in obese young adults (414). 
Goulding and Taylor reported no association between leptin and bone resorption (by 
Deoxypyridinoline) or formation (by OC) in postmenopausal women, although the 
sample size was considerably smaller than that of the present study (415). 
 
Leptin has been shown to reduce ovariectomy-induced trabecular bone loss by 
maintaining Tb.BV/TV and Tb.N in rats (416). Consistent with the effect of obesity on 
bone structure in the present study, there was no effect of leptin on Tb.Th but periosteal 
bone formation was reduced (416). Reduced periosteal bone formation with increased 
leptin levels might account for there being no difference in bone size by Ct.Pm in obese 
individuals compared to normal BMI individuals. In these rats, co-administration of leptin 
and oestrogen decreased bone turnover to a greater extent than oestrogen 
administration alone, which supports the findings of the current study where both E2 and 
leptin contribute to lower bone resorption (416).  
 
Leptin administration reduced bone loss in tail-suspended rats through the uncoupling of 
bone turnover; with a reduction in bone loss and an increase in bone formation at the 
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tibia compared to non-suspended animals (417). The increase in bone formation conflicts 
with the findings of this Chapter which show lower formation and maintenance of 
coupling, although coupling index in obese individuals is higher than in those with a 
normal BMI. 
 
Leptin has been shown to exert anabolic effects on bone when it acts directly on bone 
cells, making it a plausible candidate to explain favourable bone density in obesity (96, 
98). Although leptin is able to act as a growth factor to influence the proliferation of 
hemopoietic stem cells induce MSC differentiation along the chondrocytic lineage (418), 
this effect would most likely drive bone formation, whereas it appears that the 
mechanisms by which older obese adults have greater bone density is through reduced 
bone loss. Therefore the key leptin action in obesity may be the regulation of 
osteoclastogenesis through inhibition of RANKL, supported by increased OPG mRNA 
expression and decreased RANKL mRNA expression with leptin administration in vitro  
(96, 98, 416).  
 
If letpin does lower bone resoprtion through upregulation of OPG, higher OPG may have 
been expected in obesity.  In this study, there was no difference in OPG between obese 
and normal BMI indiduals, consistent with the findings of previous work (419), although 
others have shown lower OPG in obesity (116, 420). Older adults had higher OPG than 
younger adults, as previously shown (421, 422) and in support of a greater protective 
effect of obesity in older adults than younger adults. As leptin did not explain the effect 
of SAT on OPG, other biochemical factors associated with SAT may play a role in the 
mediation of OPG in obesity. 
 
Although leptin exerts negative effects on bone when it acts through the CNS, leptin is 
primarily derived from extraosseous adipocytes, bone marrow adipocytes, chondrocytes 
and osteoblasts in peripheral locations and not from the CNS (96). Thus, whilst the 
overall effect of leptin on bone is determined by contributions of both central and 
peripheral effects, the principal effect is likely to result from the direct, systemic actions 
on osteoclastogenesis (96). Although much of the literature involving mouse models to 
study the effects of leptin on bone suggests leptin has adverse effects on bone, this may 
be attributed to the differences in the method and concentration of leptin administration 
compared to physiological leptin production, as well as the physiological differences 
between mice and humans.  
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The results of the present work are consistent with a suggestion made by Thomas and 
Burguera that “leptin could stimulate bone growth and bone size through angiogenic 
effects and osteogenic activity in immature cortical bone. Later, it may decrease bone 
remodelling in the mature skeleton when trabecular bone turnover is high” (98). In 
Chapter 3 it was shown that obesity has a beneficial effect on the skeleton in young 
adulthood and it is plausible that the lesser effect of leptin on CTX in the young adults 
was due to the difference in mechanism by which leptin exerts protective effects on bone 
with age. 
 
Leptin was higher in older adults than young adults, despite no difference in WBFM 
between groups. This is consistent with the finding of increased expression of leptin with 
age, independent of adiposity, in rats (423). However, Rosenbaum et al. showed leptin 
was higher in pre-menopausal women than postmenopausal women after correction for 
WBFM (424). Similarly, Moller et al. found a positive association between leptin and 
WBFM in young adults but no association between leptin and WBFM in older adults 
(425). There is also some evidence to support no effect of age on leptin concentration 
(426). With age, adiposity increases, accompanied by increased adipocyte size. Larger 
adipocytes are associated with greater expression of leptin , and subcutaneous and 
omental biopsies show greater Ob mRNA expression in individuals with a high BMI 
compared to normal BMI individuals (427-429). 
 
Leptin was higher in women than in men in the present study. This is consistent with 
other studies which report leptin levels in women to be two to three times higher than in 
men (98, 334, 343, 424-427). The difference in leptin by gender is not the result of greater 
FM in women as this association persisted after adjustment for WBFM (343, 424, 426). 
The difference in leptin by gender may be a result of differences in body fat distribution 
in men and women (334, 343, 344). VAT expresses lower leptin than SAT women have 
greater SAT for a given WBFM. Greater leptin expression by SAT may contribute to the 
understanding of why SAT was a stronger predictor of CTX than was VAT (343, 430).  
 
Although leptin expression and circulating levels are controlled by sex hormones, sex 
hormones did not explain differences in leptin by gender (343, 426) but did contribute to 
leptin levels in postmenopausal women (343). However, Baumgartner et al. found that 
sex differences in leptin were associated with testosterone in men (344) and changes in 
leptin with age were associated with changes in testosterone in men, whereas in women, 
changes in BMI not oestrogen were associated with changes in leptin (431).  
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Some studies have shown leptin is positively associated with aBMD (339-342), others 
report a negative association (345-347) and some have reported no association (304, 
335, 348-350). After adjustment for BMI, significant associations between leptin and 
BMD typically become non-significant, as do associations between WBFM and BMD 
when adjusted for leptin, indicating relationships between adiposity and BMD are 
mediated by leptin (334, 342).The relationship between leptin and BMD may differ 
between men and women (334, 341, 342),  
 
In a review of the leptin-bone relationship, Thomas reported that there is evidence of 
associations between leptin and aBMD and bone area by DXA to suggest that “leptin 
might act on the periosteal envelope of cortical bone, thereby increasing bone size” (98). 
This conflicts with the results of the present work, which has studied vBMD and 
microarchitecture to the conclusion that there is no difference in Ct.Pm or cortical area 
in obese individuals who have greater leptin than individuals with a normal BMI. Leptin 
was inversely associated with periosteal circumference in unadjusted analysis in young 
adult men, although this effect did not persist after adjustment for WBFM (432). Recently 
Wong et al. have suggested that neuropeptide YY may drive lower cortical bone 
formation in leptin resistance, with higher cortical apposition, particularly higher 
periosteal apposition, in neuropeptide YY and leptin knockout mice (433). 
 
Recent investigations into the effect of bariatric surgery induced weight loss on bone 
microarchitecture have shown decreases primarily in cortical bone, with decreases in 
cortical density, area and thickness (47). As the peripheral action of leptin has been 
found to impact cortical bone, this supports a role for leptin in the maintenance of cortical 
bone (99). At six and eighteen months following Roux-En-Y bariatric surgery, decreases 
in leptin were significantly correlated with increases in OC, BAP and NTX, with the 
strongest association between leptin and NTX (434). Unlike the decrease in BMI, the 
decrease in leptin was a significant predictor of the increase in NTX (434). These findings 
further illustrate the role of leptin in the regulation of bone turnover, and particularly of 
bone resorption.  
 
While totE2 was no different between normal BMI and obese individuals in the overall 
study population, totE2 appears to reduce bone resorption independent of the 
relationship between SAT and leptin on bone resorption. There was no difference in total, 
free or bioavailable E2 between obese and non-obese groups overall, or in younger 
adults alone. Therefore E2 was perhaps unlikely to explain differences in bone density 
between BMI groups in younger adults, Consistent with the findings of this Chapter, 
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others have reported no difference in fE2 in young obese women (269) and in young 
women by tertile of trunk FM (273). Despite no difference in fE2, lower bone formation 
was associated with greater trunk FM in young women (273) 
 
fE2 and bioE2 were higher in obese older adults than older adults with a normal BMI. 
Thus, the hypothesis that greater circulating E2 in obesity as a result of increased 
aromatisation of androgens might protect obese postmenopausal women from bone 
loss, is supported by the findings of this Chapter, despite not being the predominant 
mechanism by which obesity drives lower bone turnover. The difference in fE2 and bioE2 
between obese and normal BMI groups by age group might contribute to understanding 
why there was a greater effect of obesity on bone density in older adults than younger 
adults; with two mechanisms driving beneficial effects of adiposity on the skeleton in 
older age, compared to the sole effect of leptin in young adults.  
 
There is longstanding evidence of an inverse association between oestrogen and bone 
resorption (332). Heshmati et al. showed oestrogen had a protective effect against bone 
resorption by treating postmenopausal women with Letrozole to virtually eliminate E2 in 
the circulation, which increased bone resorption markers without affecting formation 
markers (435). In postmenopausal women taking HRT, there was no difference in OC 
between obese and normal BMI individuals (412). Unlike normal weight women, there 
was no difference in bone turnover between obese women taking HRT and obese 
women not taking HRT, suggesting oestrogen has a protective effect against lower bone 
formation in obesity (412). 
 
While fE2 and bioE2 are positively associated with Ct.vBMD (436, 437) and Ct.Th in 
older men (437, 438) and inversely with Ct.Po (439), fE2 was a negative predictor of 
bone size by cortical cross sectional area, Ct.Pm and endosteal circumference in male 
adolescents (436). However, Vandewalle et al. recently described greater Ct.Pm and 
endosteal circumference associated with higher oestrogen exposure in obese male 
adolescents compared to matched normal BMI controls (440). As the present work has 
shown no difference in bone size in younger or older adulthood, the effect of oestrogen 
on periosteal apposition in obesity is unclear. Age at obesity onset may affect skeletal 
exposure to oestrogen which might have lasting effects on bone size through adulthood. 
Age at onset of obesity was not collected in the present study. As Bredella et al. found a 
positive association between fE2 and Tb.Th in young obese adults, there being no 
difference in fE2 in young adults may contribute to there being no difference in Tb.Th in 
the present cohort (268).  
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There was no effect of adiponectin, IGF-I or insulin on bone resorption. IGF-I and insulin 
are positive determinants of skeletal acquisition (379). Bredella et al. found that IGF-I 
was inversely associated with total abdominal fat in obese young men and that those 
with high VAT trended toward having lower IGF-I than obese men with low VAT  (268). 
Although obese adults had higher VAT in the present study, VAT:SAT ratio was not 
different between the two groups. This might suggest that any inverse effects of VAT on 
bone turnover through mechanisms such as low IGF-I or higher adiponectin, were 
outweighed by the greater positive effects of SAT on bone turnover.  
 
Despite previous indications that abdominal adiposity may be detrimental to bone, the 
results of this Chapter show that adiposity in all compartments measured was positively 
associated with bone density and favourably associated with bone microarchitectural 
outcomes. As both trunk FM and android FM capture adiposity in both the subcutaneous 
abdominal and visceral compartments, this may explain why SAT was the strongest and 
most consistent predictor of bone microarchitecture, as it was not confounded by any 
effect of visceral adiposity. Furthermore, SAT was determined by CT, whereas trunk FM 
and android FM were determined by DXA, which is less reliable due to confounding 
effects of soft tissue thickness. As VAT:SAT ratio was not different in this population of 
obese individuals compared to the normal BMI individuals, further research into the effect 
of VAT:SAT imbalance on the biochemical milieu in obesity may lead to a better 
understanding of the effect of VAT on bone microarchitecture.  
 
Confounding due to the use of DXA may also explain why WBLM better predicted aBMD 
at central sites, whereas WBFM better predicted vBMD at peripheral sites. While this 
could be a true physiological effect of body composition on measures of BMD at varying 
skeletal sites, there may be an effect of bone size on measures of aBMD by DXA, 
whereas vBMD by HR-pQCT is not affected by bone size. Interestingly, LS.vBMD was 
predicted by both LM and FM, possibly suggesting that central sites are better associated 
with LM but that FM is more closely associated with vBMD.  
 
While others have reported higher sclerostin in individuals with high BMI, this was not 
found in the overall sample in the present study, but was found in the older adults alone 
(359, 369, 374). No difference in sclerostin was reported between bariatric surgery 
patients and controls, although the obese group was significantly shorter in stature than 
the controls, whereas the FAB study population are matched for height (441). Sclerostin 
was higher in men than women, consistent with the current literature (369, 377, 442). In 
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the present study, sclerostin was higher in younger adults than older adults. This is 
conflicting with the current literature which shows sclerostin increases with age (369, 
442). Differences between studies may be attributed to variation in sclerostin 
immunoassays and heterogeneity of populations studied (375). 
 
The main limitation to the work in this Chapter is the cross-sectional study design. The 
results therefore only indicate associations between adiposity, leptin and resorption, and 
it cannot be taken from this work alone that leptin is the cause of low bone resorption in 
obesity.  
 
RANKL was not measured in this study due to low circulating levels being difficult to 
measure using available techniques. As there was no difference in OPG between obese 
and normal BMI individuals, it would be interesting to investigate the OPG:RANKL ratio 
to better understand how (and if) leptin regulates bone turnover by reducing  
osteoclastogenesis in obesity. 
 
Much of the literature indicates a role for testosterone in the relationship between 
adiposity and bone density, however testosterone was not measured at part of the FAB 
study. Testosterone may play a role in regulating leptin and previous work has shown 
testosterone to be more strongly associated with leptin than E2, especially in in men 
(343, 431). However, E2 has been shown to be more important for bone than 
testosterone in men (438, 439).  
 
There are several other adipokines which may play a role in the relationship between 
adiposity and bone which were not investigated in this study. Resistin and visfatin are 
adipokines produced by white adipose tissue and positively associated with FM (443, 
444). Resistin might be associated with osteoblast proliferation, and is expressed by 
circulating peripheral mononuclear cells and bone marrow which are associated with 
osteoclastogenesis (96, 335, 445). Visfatin is highly expressed in VAT (444), regulated 
by GH, inflammatory cytokines and glucocorticoids and increases production of IL-1β, 
IL-6 and TNF-α (97). Visfatin may also play a role in insulin metabolism (444). 
Relationships between BMD and resistin and visfatin are unclear but appear to be weakly 
inverse or not significant (342, 446-448). 
 
Only total leptin was measured in this study; whether free leptin is associated with lower 
bone resorption to an equal extent in obesity was not determined but may provide a more 
accurate marker of bone resorption in obesity than total leptin. Total serum adiponectin 
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was measured in the FAB study, and it is acknowledged that there may be differences 
in the effect of total serum adiponectin versus high molecular weight adiponectin on BMD 
(103, 105).  
 
Contributions of bone marrow fat, brown fat and muscle fat were not assessed in this 
study. Based on current understanding of the function of each of these fat compartments 
it seems unlikely that any one of the compartments would exert a greater effect on bone 
density or microarchitecture than SAT, but it is recognised that each of these 
compartments is likely to exert some effect on the relationship between total adiposity, 
bone turnover and bone density. Future work should address such contributions. 
 
Investigating whether age at onset of obesity has an effect on bone acquisition and bone 
size which persists through adulthood might increase current understanding of the 
mechanism by which obese individuals have greater bone density without a difference 
in bone size, compared to normal BMI individuals. 
 
In conclusion, this Chapter has tested several hypotheses to better understand the 
mechanisms by which obesity might exert positive effects on bone density and bone 
microarchitecture. This Chapter has shown that obese individuals have lower bone 
turnover, mainly as a result of lower bone resorption, which is associated with lower bone 
formation. Lower resorption in obesity was associated with greater adiposity, best 
predicted by subcutaneous abdominal adiposity. Lower resorption might be driven by 
greater leptin production associated with the subcutaneous abdominal compartment. 
Oestrogen is associated with lower resorption independent of the effect of leptin. The 
greater effect of obesity on bone density and microstructural properties of bone in older 
adults might be explained by higher leptin, free E2 and bioavailable E2 levels and a 
greater effect of adiposity on leptin in older adults than young adults. Older adults also 
have a positive coupling index, whereas coupling index is not affected by BMI young 
adults. 
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CHAPTER 5: 
 
MUSCLE MASS AND PHYSICAL 
PERFORMANCE IN OBESITY   
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CHAPTER 5: Muscle Mass and Physical Performance in Obesity 
 
Background 
Chapters 3 and 4 have shown that obese adults have greater BMD, favourable bone 
microarchitecture and greater bone strength than adults with a normal BMI, associated 
with lower bone turnover which might be driven by the effects of greater leptin and E2 in 
obesity. These traits are likely to contribute to the lower risk of hip and vertebral fracture 
in obesity. However, the greater risk of proximal humerus and ankle fracture in obesity, 
despite greater bone density and strength, remains unexplained. Greater risk of proximal 
humerus and ankle fracture in obesity could be due to greater propensity for falls, as 
older obese women have been shown to fall more frequently than non-obese individuals 
(23, 49, 261, 278). Furthermore, fall characteristics, such as fall direction, ability to break 
a fall and soft tissue influences on impact forces, may differ between obese and normal 
BMI individuals. The cause of greater fall frequency and differences in fall patterns 
between obese and normal BMI adults is unclear.  
 
It could be that greater fall frequency or differences in fall patterns between obese and 
normal BMI individuals are related to low LM and/or impaired muscle function. Several 
age-related changes in muscle tissue are also common to obesity. With age, changes in 
muscle tissue include decreases in fibre number and fibre atrophy, conversion to type 1 
fibres, denervation and excitation–contraction uncoupling (449). These changes 
contribute to a loss of strength and impaired physical function, potentially associated with 
a greater number of falls.  
 
It is possible that age related changes in muscle composition and function are 
exaggerated in obese individuals due to greater fat infiltration of skeletal muscle, or 
myosteatosis, in obesity (450, 451). Studies have shown fat infiltration of the muscles of 
the lower limb to be associated with lower muscle power and strength, poor neurological 
and physical function and greater fracture risk (450, 452-457). Muscle fat may also be 
associated with the release of inflammatory factors which may impair muscle function 
and physical performance (457). The extent of intramuscular fat infiltration can be 
identified from assessments of muscle density on pQCT or MRI imaging, where lower 
muscle density on the image indicates greater intramuscular fat infiltration. 
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Muscle Mass, Muscle Strength and Physical Performance 
With ageing, LM and muscle strength deteriorate along different time courses, with the 
loss of muscle strength occurring more rapidly than the loss of LM (458). Age-related 
decreases in LM occur at a rate of approximately 1 to 2% per year from the fifth decade, 
while the loss of muscle strength occurs at a rate of approximately 1.5% per year, 
increasing to 3% in the sixth decade (459). Therefore, if obesity is associated with greater 
decreases in LM with age compared to non-obese individuals, there may be considerable 
loss of muscle strength. Dissociation of the loss of LM and muscle function could affect 
physical performance in obesity even if LM is greater or indifferent in obese individuals 
compared to non-obese individuals. 
 
Frailty, Sarcopenia, and Dynapenia 
Individuals at risk of functional decline due to muscular deterioration can be defined in 
several ways. Previously, individuals may have been described as frail, characterised by 
the presence of three or more of the following indicators: weight loss, weakness by grip 
strength in the lowest 20th percentile, self-reported exhaustion, slowness by fifteen foot 
walk speed in the lowest 20th percentile and low physical activity (460). Several additional 
overlapping, conditions have been described, which differ in whether they are 
characterised by a loss of LM, muscle function, or both. The term sarcopenia was coined 
initially by Rosenberg from the Greek words sarx (flesh) and penia (loss) (461). Thus 
traditionally sarcopenia was considered a condition purely concerning the loss of LM. At 
present, no standard definition of sarcopenia exists, although this is a topic of much 
debate. Recently, sarcopenia has been used to describe the loss of both LM and muscle 
function. Dynapenia has been used to describe the loss of muscle strength, power and 
force not caused by neurologic or muscular disease (462). There is currently no standard 
definition or standard diagnostic criteria for dynapenia, but dynapenia is typically inferred 
from performance of a range of physical function tests, such as isometric strength and/or 
tests of static and dynamic performance.  
 
It has been suggested that dynapenia may be a better predictor of physical function than 
the pure loss of LM, as declines in LM explain a relatively low percentage of the variability 
in muscle strength decline and maintaining LM does not necessarily prevent the loss of 
muscle strength with age (458). Loss of muscle strength and loss of appendicular LM 
(ALM) have been shown not to correlate (463) and to be dissociated in obesity (464); 
hence their distinction may be of importance. BMI has been shown to inversely predict 
the loss of ALM; predicting 83% of the variation in loss of ALM, whereas BMI only 
predicted 3% of the variance in loss of muscle strength (463). Whether obese individuals 
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are more appropriately categorised as sarcopenic or dynapenic is not clear, but it may 
be important to distinguish the two conditions, to best identify obese individuals at the 
greatest risk of falls. 
 
Sarcopenia, Bone Density, Falls and Fractures 
Sarcopenia is positively associated with the prevalence of osteoporosis (465-468). This 
may be due to reduced muscle-bone interactions and lower forces exerted on bone by 
the muscle, as well as indirect associations, such as lower levels of physical activity.  
 
In young obese individuals, muscle area was positively associated with L4 Tb.vBMD 
(269), Tb.N (268) and estimated failure load (268). LM was positively associated with 
aBMD, Ct.Th and bending strength but was not associated with vBMD at the FN or distal 
radius (469). Thigh muscle density trended positively with bone strength in young obese 
men, indicating lower muscle fat might have a positive effect on bone strength (268). 
Muscle area and density may be associated with bone formation (269). Although in 
Chapter 4 it was shown that WBLM was not a predictor of bone microarchitecture or 
vBMD, LM was a predictor of aBMD at central sites. It is possible that individual 
compartments of LM, such as ALM, or the size and density of individual muscle groups 
might affect bone density and microstructure irrespective of the effect of total body LM. 
 
In addition to effects on BMD and bone microstructure, low LM is associated with 
impaired balance and an increased risk of falls (469, 470). Di Monaco et al. showed a 
high prevalence of sarcopenia in women with hip fracture (468). Physical performance 
is inversely associated with the risk of falls (471-473). Gait speed, chair stand ability and 
overall physical performance scores have been associated with prevalent and incident 
hip and vertebral fracture (471, 474). Greater intramuscular fat is also associated with 
fracture risk (452, 475, 476). 
 
Not only might obese individuals with sarcopenia or dynapenia fall more frequently than 
non-affected individuals, but fall direction, fall forces such as torsion or compression, and 
fall impact could also be affected by poor physical function. Such differences in fall 
kinetics may contribute to the site specific fracture risk in obesity.  
 
Differences in body fat distribution may affect balance; with abdominal adiposity able to 
displace the centre of mass, for example (477). Alterations in foot structure may also 
develop in response to high body weight and this could affect postural stability and gait 
(478). Obesity is associated with pes planus, a pronated foot type, greater rear-foot 
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eversion and foot abduction, all of which may contribute to altered postural stability and 
increased risk of ankle fracture, particularly Webber C ankle fracture, typically observed 
with greater BMI (59, 478). 
 
It is not known whether differences in fall characteristics in obesity can be explained by 
poorer physical performance, sarcopenia, dynapenia or anatomical factors. 
 
Mechanisms Linking Obesity, Sarcopenia and Falls 
Several biochemical factors which have been identified as markers for sarcopenia are 
also common to obesity. Vitamin D (479), albumin (480, 481) and IGF-I (482, 483) are 
positively associated with physical performance, but are all lower in obese individuals 
than normal BMI individuals (Chapter 4).While albumin may exert protective effects on 
LM through associations with inflammatory markers (480), IGF-I prevents myocyte 
apoptosis (482). There may be links between 25OHD and the accumulation of muscle 
fat (484). 
 
Muscle tissue is the main site for glucose uptake and muscle strength is associated with 
higher insulin sensitivity and muscular glucose uptake (485). As circulating glucose is 
higher and insulin sensitivity lower in obese individuals than normal BMI individuals 
(Chapter 4), there may be impaired regulation of glucose metabolism by skeletal muscle 
in obesity, associated with lower muscle strength. The formation of advanced glycation 
end-products is increased in obesity (486) and linked to muscle stiffness and poorer 
physical function (487, 488). 
 
There may be associations between sex hormones, sarcopenia and poor physical 
function (489). Such associations may be age dependent, as no significant associations 
were observed between free testosterone or fE2 and thigh muscle area or density in 
young women (269). As testosterone and E2 are abundant in young women, there may 
be a threshold effect before associations can be detected. 
 
Inflammatory cytokines are up-regulated in obesity, and have been associated with 
sarcopenia and poor physical performance (490-492).  
 
Obese individuals have lower HDL, which is positively associated with physical 
performance (493, 494). Distribution of adiposity may affect the relationship between 
obesity, HDL and physical performance, with lower HDL in dynapenic adults with 
abdominal obesity than non-abdominally obese dynapenic adults and controls (495).   
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Creatine kinase (CK) is an enzyme which converts creatine to phosphocreatine and 
circulating levels increase with muscle degeneration (496). CK has been shown be 
greater in obesity, although without adjustment for LM it is unclear whether this reflects 
greater LM or more muscle degeneration in obesity (496).  
 
Finally, anaemia may be more prevalent in obesity and has been associated with poor 
physical performance, low muscle strength and an increased risk of falls (497-501). 
 
Summary 
The site-specificity of fracture risk in obesity, despite greater BMD, favourable cortical 
and trabecular microarchitecture and bone strength, may be attributed to falls 
mechanisms. Fall characteristics and greater fall risk in obesity may be attributed to 
impaired LM, poor physical function or both. Obese individuals exhibit multiple 
biochemical traits associated with impaired LM and/or poor muscle function. Fall 
characteristics and greater risk of falls might necessitate alternative fracture prevention 
strategies in obese individuals for the prevention of ankle and proximal humerus fracture, 
and highlight a need for active fracture prevention despite ‘normal’ BMD by densitometry.  
 
In light of a recent recommendation that “a combination of serum markers, diagnostic 
imaging, and functional tests of muscle function would constitute an ideal biomarker 
panel” for sarcopenia (502), this Chapter aims to evaluate LM, physical function, and 
sarcopenia prevalence in an obese and normal BMI population, using biochemical 
markers, imaging and functional tests, to determine whether non-skeletal factors such 
as, but not limited to greater fall frequency, might explain fracture risk in obesity. 
 
Research Questions and Aims 
Research Questions: 
1. Are there differences in WBLM or ALM between normal BMI and obese 
individuals? 
2. Do any differences in LM between normal BMI and obese individuals result in 
differences in muscle function and physical performance by BMI? 
3. Is the prevalence of sarcopenia different in normal BMI and obese groups? 
4. Do obese people fall more frequently than those with a normal BMI? 
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Aims: 
1. To compare LM in normal BMI and obese individuals to determine determine 
associations between obesity and LM. 
2. To compare muscle function in normal BMI and obese individuals to determine 
determine associations between obesity and physical performance. 
3. To compare the prevalence of sarcopenia in normal BMI and obese adults and 
asscertain any associations between sarcopenia and BMD, bone structure and 
strength, and fall frequency.  
4. To compare reported fall history in obese and normal BMI groups and determine 
whether fracture patterns in obesity might be explained by greater falls risk 
despite greater BMD. 
 
 
Methods 
Number of falls in the six months prior to consent and perceived difficulty completing 
habitual tasks such as climbing and descending stairs, dressing and grooming oneself, 
walking various distances etc. were self-reported in the lifestyle questionnaire described 
in Chapter 2.  
 
Full details on all assays can be found in Chapter 2. CK and lipid profile were measured 
by automated ECLIA (Cobas c701, Roche Diagnostics, Mannheim, Germany). 
Haemoglobin was measured by automated analyser from the full blood count analysis 
(Sysmex XN Series, Sysmex, Norderstedt, Germany). Glucose was measured by 
automated immunoassay (Cobas c702 auto-analyser, Roche Diagnostics, Mannheim, 
Germany). HsCRP was measured by automated nephelometry (BNII System, Siemens, 
Siemens Healthcare Diagnostics, Surrey, UK). IL-6 was measured by automated 
immunoassay (Cobas e601 auto-analyser, Roche Diagnostics, Mannheim, Germany). 
Albumin and 25OHD were measured by automated ECLIA (Cobas e411, Roche 
Diagnostics, Mannheim, Germany). IGF-I was measured by automated CLIA (IDS-iSYS, 
Immunodiagnostic Systems, Boldon, UK). 
 
SHBG was measured by automated ECLIA (Cobas e602 auto-analyser, Roche 
Diagnostics, Mannheim, Germany).  
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Total E2 was determined by automated ECLIA (Cobas e411, Roche Diagnostics, 
Mannheim, Germany).  
 
Free E2 (fE2) was determined as: 
fE2 (mol/L) = (-b + √(b2 – 4ac)) / 2a 
Where:  N= 1+ affinity constant of albumin for E2 x albumin 
  a = N * affinity constant of SHBG for E2 
  b = N + affinity constant of SHBG for E2 * (SHBG - Total E2) 
  c = -Total E2  
Affinity constant of albumin for E2 = 4.21 × 104 L/mol  
Affinity constant of SHBG for E2  = 3.14 × 108 L/mol 
 
Bioavailable E2 (bioE2) was calculated as:  
bioE2 (mol/L) = (1+ affinity constant of albumin for E2 x albumin)* fE2 
 
Whole body LM was determined by DXA (Discovery A, Hologic Inc., Bedford, MA, USA) 
and ALM was calculated as the sum of the LM of the arms and legs (Chapter 2).  
 
SPPB score was calculated from performance in a repeated chair stand test, six metre 
walk to determine gait speed, and a six metre narrow walk to determine balance. Muscle 
strength was determined from maximal hand grip strength (Chapter 2).  
 
Sarcopenia was defined using the European Working Group on Sarcopenia in Older 
Persons (EWGSOP) definition (249). Individuals were categorised as: 
5) Not sarcopenic (Normal ALM) 
6) Pre-sarcopenic (Low ALM) 
7) Sarcopenic (Low ALM and either weakness or poor SPPB score) 
8) Severely sarcopenic (Low ALM, weakness and poor SPPB score) 
 
Low ALM was defined as an ALM corrected for height (ALM (kg) /(height (m)2) (Skeletal 
muscle index (SMI)) <7.23 kg/m2 (men) or <5.67 kg/m2 (women) (249). Weakness was 
defined as a maximal hand grip strength <30 kg (men) or <20 kg (women). A poor SPPB 
score was defined as a SPPB score ≤8. 
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Statistical Analysis 
One older female participant was excluded from the analysis of chair stand performance 
and SPPB score as she was deemed unable to complete the repeated chair stand safely 
due to her hip width exceeding the chair arm parameters. This was not recorded as 
‘unable to complete the test’ as I made the decision not to proceed from the single chair 
stand performance, rather than the participant’s failure to attempt or complete the 
repeated chair stand test. 
 
All variables were assessed for normality and log transformed where necessary. As 
paired t-tests were to be used to determine significant differences between normal BMI 
and obese groups, the absolute differences between the matched pairs were assessed 
for normality. Where the difference between the pairs was skewed, the raw data was log 
transformed and the differences re-evaluated for normality. 
 
Paired samples t-tests were used to determine significant differences in LM and physical 
function between normal BMI and obese groups, for the entire sample, by age group and 
by age and gender. Where transformed values remained non-normal (gait speed, 
WBLM, SMI), the Wilcoxon Signed Rank test was used. Chi-squared test was used to 
determine the association between BMI group and sarcopenia classification. 
 
Univariate general linear models were used to identify whether age group, gender and 
BMI had an effect on LM and physical performance outcomes and to identify interactions 
between age or gender and the effect of BMI on LM and physical function.  
 
Pearson correlation coefficient was used to determine associations between logged LM 
and logged function parameters and between logged biochemical mediators and logged 
function parameters. Spearman’s rank correlation coefficient was used where the 
sample distribution remained non-normal. Multiple linear regression was used to 
determine the association between adiposity and physical performance, adjusting for 
possible confounders.  
 
Analysis was performed using IBM SPSS Statistics for Windows (Version 21.0. Armonk, 
NY: IBM Corp.). Significance was accepted when p<0.05.  
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Results 
Muscle Mass in Obesity 
Obese individuals had greater WBLM, ALM and SMI than normal BMI individuals (all 
p<0.001) (Figure 65).  
 
Figure 65: WBLM, ALM and SMI in normal BMI and obese individuals1,2 
 
 
Young adults had greater WBLM, ALM and SMI than older adults (all p<0.001). Men had 
greater WBLM, ALM and SMI than women (all p<0.001). There were no interactions 
between age or gender and the effect of BMI on WBLM or ALM, but there was a greater 
effect of BMI on SMI in women (p<0.01). Multiple linear regression showed the effect of 
BMI on WBLM, ALM and SMI remained significant after adjusting for age and gender (all 
p<0.001).  
 
 
Physical Performance in Obesity 
Grip Strength 
There was no difference in grip strength between obese and normal BMI individuals. 
Younger adults had greater grip strength than older adults (p<0.01). Men had a greater 
grip strength than women (p<0.001). There were no interactions between age or gender 
and the effect of BMI on grip strength. After adjusting for age and gender, there remained 
no effect of BMI on grip strength.  
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Gait Speed 
Obese individuals had slower gait speed than normal BMI individuals (p<0.001 ages 
combined and older adults, younger NSD) (Figure 66). Older adults had slower gait than 
young adults (p<0.001). There was an interaction between age and BMI on gait speed 
such that the effect of BMI on gait speed was greater in older adults (p<0.05). There was 
no effect of gender on gait speed. Multiple linear regression showed adjusting for age, 
the effect of BMI on gait speed remained significant (p<0.001).  
 
Figure 66: Gait speed in normal BMI and obese individuals 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C   
D E F  
 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Chair Stand Time 
Obese individuals took longer to complete the repeated chair stand test than normal BMI 
individuals (p<0.001 combined, p<0.001 younger, p<0.05 older) (Figure 67). Older adults 
took longer to complete the test than young adults (p<0.001). There was no effect of 
gender on chair stand time. There was an interaction between age and BMI on chair 
stand time such that the effect of BMI on chair stand time was greater in the younger 
adults (p<0.05). Multiple linear regression showed, the effect of BMI on chair stand time 
remained significant after adjusting for age (p<0.001).  
 
Figure 67: Repeated chair stand time for normal BMI and obese individuals 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C     
D E F  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Balance 
Obese individuals had poorer balance assessed by the narrow walk test than normal 
BMI individuals (p<0.01 all and older, younger did not differ) (Figure 68). Older adults 
had poorer balance than young adults (p<0.001). Men had poorer balance than women 
(p<0.001). There were no interactions between age or gender and the effect of BMI on 
balance. Multiple linear regression showed the effect of BMI on balance remained 
significant after adjusting for age and gender (p<0.001).  
 
Figure 68: Balance in normal BMI and obese individuals  
determined by number of deviations on a narrow walk. Groups combined (A), young women (B), 
young men (C), older women (D), older men (E)1,2 
 
 
 
SPPB Score 
Obese individuals had lower SPPB scores than normal BMI individuals (all p<0.001) 
(Figure 69). Older adults had lower SPPB scores than young adults (p<0.001). There 
was no effect of gender on SPPB score or interactions between age or gender and BMI 
on SPPB score. The relationship between BMI and SPPB score remained significant 
after adjusting for age and gender (p<0.001). A model consisting of age, BMI and PTH 
best predicted SPPB score (adjusted R square 0.473, overall model p<0.001, BMI beta 
-0.478, p<0.001, age: beta -0.511, p<0.001, PTH: beta 0.125, p<0.05).   
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
 168 
 
Figure 69: SPPB score of normal BMI and obese individuals 
Groups combined (All), young (A), older (B), young women (C), young men (D), older women (E), 
older men (F)1,2 
All  
A B C   
D E F  
 
Associations Between LM and Physical Performance in Obesity 
Grip strength was associated with SPPB score (r=0.157, p<0.05), gait speed (r=0.351, 
p<0.001), balance (r=0.160, p<0.05) and chair stand time (r=-0.198, p<0.01).  
 
WBLM, ALM and SMI were positively associated with grip strength (WBLM r=0.963, ALM 
r=0.704, SMI r=0.498, all p<0.001). After adjustment for age and BMI, associations 
between LM and grip strength remained positive (all p<0.001) (Figure 70). 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01, ***p<0.001, NSD no significant difference 
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Figure 70: Association between LM and grip strength 
WBLM (Left), ALM (Centre), SMI (Right), normal BMI=blue, obese =green 
Partial r given after adjustment for age and BMI 
 
Chair stand time was associated with gait speed (r=-0.596, p<0.001) and poor balance 
(r=1.71, p<0.05). Slower gait was associated with poorer balance (r=-0.184, p<0.05). 
 
In unadjusted analyses, WBLM, ALM and SMI were positively associated with number 
of walk deviations (WBLM r=0.348, ALM r= 0.317, SMI r= 0.342, all p<0.001), but not 
with chair stand time or gait speed. After adjustment for age and BMI, WBLM, ALM and 
SMI were positively associated with number of walk deviations (partial correlations: 
WBLM r=0.266, ALM r=0.258, both p<0.001, SMI r=0.230, p<0.01) and gait speed 
(partial correlations: WBLM r=0.166, ALM r=0.182, both p<0.05, SMI r=0.190, p<0.01), 
but there remained no association with chair stand time. 
 
WBLM and SMI were negatively correlated with SPPB score (WBLM r= -0.179, p<0.05, 
SMI r= -0.222, p<0.01), but there was no association between ALM and SPPB score 
(Figure 71). After adjustment for age and BMI, WBLM, ALM and SMI were no longer 
associated with SPPB score. 
 
Figure 71: Association between LM and SPPB score 
WBLM (Left), ALM (Centre), SMI (Right), normal BMI=blue, obese =green 
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Sarcopenia in Obesity 
Based on the EWGOSP definition, 2% of the total study population were pre-sarcopenic, 
4% sarcopenic and 7.1% severely sarcopenic. There was a significant association 
between BMI group and sarcopenia status (Chi square, p<0.01). 5.1% of young normal 
BMI individuals were sarcopenic. 3.3% of older normal BMI individuals were pre-
sarcopenic, 3.3% sarcopenic and 11.7% severely sarcopenic. None of the obese 
individuals were sarcopenic, due to their greater LM. 
 
Based on SMI alone (SMI criteria: women <5.67 kg/m2, men <7.23 kg/m2), 13% of all, 
5% of young and 18.3% of older adults with a normal BMI were sarcopenic. No obese 
individuals were classed as sarcopenic, due to their greater LM. There was a significant 
association between BMI group and sarcopenia status (Chi square p<0.001). 
 
In contrast, based on SPPB score alone, as a proxy for dynapenia, 49.5% of all, 20.5% 
of young and 68.3% of older normal BMI adults were dynapenic. 82.8% of all, 64.1% of 
young and 95% of older obese individuals were dynapenic. There was a significant 
association between BMI group and dynapenia status (Chi square, p<0.01). 
 
Falls in Obesity 
Older obese adults reported more falls than older adults with a normal BMI (ages 
combined p=0.066, younger NSD, older p<0.05) (Figure 72). 15% of all obese adults, 
5% of young obese adults and 10% of older obese adults had fallen in the 6 months prior 
to recruitment, compared to 5%, 1.3% and 3.3% in the respective normal BMI groups. 
There was no effect of gender on reported number of falls. 
 
Figure 72: Mean number of falls in normal BMI and obese individuals 
Age groups combined (Left) and by age group (Right) 
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Risk Factors for Falls in Obesity 
Number of falls was not associated with grip strength, balance or LM (WBLM, ALM and 
SMI). Number of falls was associated with chair stand time (r=0.204, p<0.001), gait 
speed (r= -0.214, p<0.01) and SPPB score (r= -0.233, p<0.01). 
 
There was no difference in alcohol intake between obese and normal BMI groups, with 
a mean (SD) 6.46 (6.1) unit intake per week in obese and 7.18 (6.4) units per week in 
normal BMI individuals. There was no association between alcohol intake and falls.  
 
There was a similar prevalence of neurological conditions (n=6 obese, n=7 normal BMI), 
respiratory conditions including asthma and COPD (n=14 obese, n=13 normal BMI), 
psychological conditions including depression (n=2 obese, n=3 normal BMI) between 
groups. Musculoskeletal conditions including osteoarthritis away from study sites were 
more common in obesity (n=23 obese, n=13 normal BMI).  
 
There was no difference in the number of hours of physical activity completed by obese 
and normal BMI groups (obese mean (SD) 8.5 (15.2) hours, normal BMI mean (SD) 10.5 
(14.7) hours). There was no association between number of hours of activity and falls. 
There was no difference in estimated METs (1 MET being the amount of oxygen 
consumed while sitting at rest) expended per week between obese (mean (SD) 35.05 
(69.8) METs) and normal BMI individuals (mean (SD) 47.01 (62.7) METs). There was no 
association between METs expended per week and falls. 
 
Obese individuals had lower habitual mobility scores (mean (SD) 22.57 (2.9)) than 
normal BMI individuals (mean (SD) 23.55 (2.1)) indicating greater difficulty completing 
habitual activities such as walking, climbing stairs and personal care (all p<0.01). Older 
adults had lower mobility scores than younger adults (Univariate GLM, p<0.01). There 
was no effect of gender on habitual mobility score. After adjusting for age, the effect of 
BMI on habitual mobility score remained significant (p<0.001). Habitual mobility score 
was negatively correlated with number of falls (r= -0.393, p<0.001). 
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Sarcopenia and Falls in Obesity 
Figure 73 shows the number of falls reported by obese and normal BMI individuals, by 
the EWGSOP and alternative definitions. Figure A illustrates that obese individuals 
reported more falls than those with a normal BMI, but were not classified as sarcopenic 
by the EWGSOP criteria (due to their higher LM). Figure B further demonstrates that 
obese individuals fell more, despite greater LM. Figure C shows that obese individuals 
with poor physical performance, irrespective of LM, reported more falls. 
 
Figure 73: Number of falls by sarcopenia or dynapenia classification 
A  
 
B  
 
C  
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Potential Biochemical Mediators of Poor Physical Function in Obesity 
Inflammation, LM and Physical Performance 
HsCRP was not correlated with WBLM or ALM but was positively associated with SMI 
(r=0.249, p<0.01). After adjustment for age and BMI, HsCRP was negatively correlated 
with WBLM (r=-0.210), ALM (r=-0.223) and SMI (r=-0.224) (all p<0.05). 
 
HsCRP was negatively associated with gait speed (r=-0.361, p<0.001) and grip strength 
(r=-0.252, p<0.01), and positively associated with chair stand time (r=0.227, p<0.05). 
HsCRP was inversely associated with SPPB score (r=-0.354, p<0.001). After adjustment 
for age and BMI, HsCRP remained negatively associated with gait speed and grip 
strength, but was no longer associated with chair stand time or SPPB score (Figure 74). 
 
Figure 74: Associations between HsCRP and physical function 
Normal BMI=blue, obese =green 
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Albumin, LM and Physical Performance 
Albumin was inversely correlated with HsCRP (r=-0.448, p<0.001) but not associated 
with WBLM, ALM or SMI. After adjustment for age and BMI, albumin was positively 
associated with WBLM (r=0.263), ALM (r=0.264) and SMI (r=0.276) (all p<0.001). 
 
Albumin was positively correlated with gait speed (r=0.171), grip strength (r=0.151) and 
SPPB score (r=0.159) (all p<0.05) but not associated with chair stand time After 
adjustment for age and BMI, albumin was positively associated with grip strength 
(r=0.127, p<0.05) but not associated with gait speed, chair stand time or SPPB score 
(Figure 75). 
 
 
Figure 75: Associations between albumin and physical function 
Normal BMI=blue, obese =green 
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IGF-I, LM and Physical Performance 
IGF-I was not associated with WBLM, ALM or SMI. After adjustment for age and BMI, 
IGF-I was positively correlated with WBLM (r=0.195 p<0.01), ALM (r=0.215, p<0.001) 
and SMI (r=0.233, p<0.001). 
 
IGF-I was associated with gait speed (r=0.329, p<0.001), grip strength (r=0.145, p<0.05), 
chair stand time (r=-0.267, p<0.001) and SPPB score (r=0.327, p<0.001) (Figure 76). 
After adjustment for age and BMI, IGF-I was positively associated with grip strength 
(r=0.128, p<0.05) but not associated with gait speed, chair stand time or SPPB score. 
 
 
Figure 76: Associations between IGF-I and physical function 
Normal BMI=blue, obese =green 
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Glucose, LM and Physical Performance 
Glucose was positively associated with WBLM (r=0.199, p<0.01), ALM (r=0.154, p<0.05) 
and SMI (r=0.217, p<0.01). After adjustment for age and BMI, glucose remained 
positively associated with WBLM (r=0.167, p<0.01), ALM (r=0.154, p<0.05) and SMI 
(r=0.138, p<0.05). 
 
Glucose was associated with gait speed (r=-0.255, p<0.01), chair stand time (r=0.246, 
p<0.01) and SPPB score (r=-0.288, p<0.001) (Figure 77). Glucose was not associated 
with grip strength. After adjustment for age and BMI, glucose was not associated with 
gait speed, grip strength, chair stand time or SPPB score. 
 
 
Figure 77: Associations between glucose and physical function 
Normal BMI=blue, obese =green 
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Haemoglobin, LM and Physical Performance  
Obese individuals had higher haemoglobin than normal BMI individuals (p<0.01 all, NSD 
younger, p<0.01 older). Haemoglobin was positively associated with WBLM (r=0.289), 
ALM (r=0.283) and SMI (r=0.260) (all p<0.001). After adjustment for age and BMI, 
haemoglobin remained positively associated with WBLM (r=0.373), ALM (r=0.374) and 
SMI (r=0.379) (all p<.001). 
 
Haemoglobin was not correlated with gait speed or chair stand time. Haemoglobin was 
positively correlated with grip strength (r=0.437, p<0.001) and inversely with SPPB score 
(r=-0.183, p<0.05) (Figure 78). After adjustment for age and BMI, haemoglobin remained 
positively associated with grip strength only (r=0.262, p<0.001). 
 
 
Figure 78: Associations between haemoglobin and physical function 
Normal BMI=blue, obese =green 
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HDL, LM and Physical Performance 
HDL was inversely associated with WBLM (r=-0.581), ALM (r=-0.557) and SMI (r=-0.597) 
(all p<0.001). After adjustment for age and BMI, HDL remained inversely associated with 
WBLM (r=-0.392), ALM (r=-0.364) and SMI (r=-0.351) (all p<0.001).  
 
HDL was inversely associated with grip strength (r=-0.227) and chair stand time (r=-
0.186) (both p<0.05) and positively associated with gait speed (r=0.257, p<0.01) and 
SPPB score (r=0.343, p<0.001) (Figure 79). After adjustment for age and BMI, HDL was 
inversely associated with grip strength only (r=-0.277, p<0.01). 
 
Figure 79: Associations between HDL and physical function 
Normal BMI=blue, obese =green 
 
 
CK, LM and Physical Performance  
CK did not differ between obese and normal BMI individuals. CK was positively 
associated with WBLM (r=0.328), ALM (r=0.349) and SMI (0.284) (all p<0.001). After 
adjustment for age and BMI, CK remained positively associated with WBLM (r=0.407), 
ALM (r=0.415) and SMI (r=0.430) (all p<0.001). 
 
CK was positively correlated with gait speed (r=0.204, p<0.01) and grip strength 
(r=0.374, p<0.001) but was not associated with chair stand time or SPPB score (Figure 
80). After adjustment for age and BMI, CK remained positively associated with gait speed 
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(r=0.176, p<0.01) and grip strength (r=0.326, p<0.001) but not associated with chair 
stand time or SPPB score.  
 
Figure 80: Associations between CK and physical function 
Normal BMI=blue, obese =green 
 
 
E2, LM and Physical Performance 
WBLM was positively associated with totE2 (r=0.177, p<0.01), fE2 (r=0.229, p<0.001), 
and bioE2 (r=0.241, p<0.001). ALM was positively associated with totE2 (r=0.199, 
p<0.01), fE2 (r=0.248, p<0.001), and bioE2 (r=0.263, p<0.001). SMI was positively 
associated with totE2 (r=0.144, p<0.05), fE2 (r=0.222, p<0.001), and bioE2 (r=0.228, 
p<0.001). After adjustment for age and BMI, (or age, BMI and gender), totE2, fE2 and 
bioE2 were no longer associated with WBLM, ALM or SMI. 
 
E2 was associated with chair stand time (totE2: r=-0.194, fE2: r=-0.163, bioE2: r=-0.177, 
all p<0.01), grip strength (totE2: r=0.136, fE2: r=0.140, bioE2: r=0.150, all p<0.05), gait 
speed (bioE2: r=0.125 p<0.05) and SPPB score (totE2: r=0.161, fE2: r=0.131, bioE2: 
r=0.153, all p<0.05). After adjustment for age and BMI, (or age, BMI and gender), E2 
was no longer associated with grip strength, gait speed, chair stand time or SPPB score.   
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25OHD, LM and Physical Performance 
25OHD was inversely associated with WBLM (r=-0.305), ALM (r=-0.300) and SMI (r=-
0.332) (all p<0.001). After adjustment for age and BMI, 25OHD was no longer associated 
with WBLM, ALM or SMI.  
 
25OHD was not correlated with gait speed, grip strength, chair stand time or SPPB score 
before or after adjustment for age and BMI. 
 
 
Adiposity, Physical Performance and Falls 
To determine associations between adiposity and physical performance, WBFM, 
HsCRP, albumin, IGF-I, totE2, haemoglobin, HDL and glucose were entered into a 
stepwise multiple linear regression model with SPPB score as the dependent variable. 
WBFM was a significant determinant of SPPB (overall model p<0.001, adjusted R square 
0.199, effect of WBFM: beta -0.454, p<0.001). Adding totE2 to the model improved the 
prediction of SPPB score (overall model p<0.001, adjusted R square 0.245, effect of 
WBFM: beta -0.439, p<0.001, effect of totE2: beta -0.230, p<0.01). 
 
To determine the association between adiposity and falls, WBFM, totE2 and PTH were 
entered into a stepwise multiple linear regression model with number of falls as the 
dependent variable. The model showed WBFM was a significant determinant of reported 
number of falls (overall model p<0.05, adjusted R square 0.024, effect of WBFM: beta 
0.170, p<0.05). 
 
After adjusting for age, mobility score and SPPB score, BMI was no longer a predictor of 
number of falls. The only significant predictor of number of falls was mobility score 
(overall model p<0.001, adjusted R square 0.164, effect of mobility score: beta -0.410, 
p<0.001), suggesting that the effect of BMI on falls is mediated through poor physical 
performance. 
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Summary of Results 
A summary of the results of Chapter 5 is provided in Table 17 
 
Table 17: Summary of results Chapter 5 
The effects of BMI, age and gender and interactions between age or gender and BMI on muscle mass, 
physical performance and number of falls. 
Variable 
Effect of BMI 
(%difference) 
Effect of 
 Age 
Effect of 
Gender 
Interactions 
WBLM ↑ (27.3%) ↑ in younger ↑ in men - 
ALM ↑ (27.6%) ↑ in younger ↑ in men - 
SMI ↑ (28.2%) ↑ in younger ↑ in men Gender-BMI1 
Prevalence of 
sarcopenia 
↓    
Gait Speed ↓ (-8.3%) ↑ in younger - Age-BMI2 
Chair Stand Time ↑ (17.4%) ↑ in older - Age-BMI3 
Grip Strength - (3.3%) ↑ in younger ↑ in men - 
Narrow walk 
deviations  
↑ (91.8%) ↑ in older ↑ in men - 
SPPB Score ↓ (-21.6%) ↑ in younger - - 
Habitual Mobility ↓ (-4.2%) ↑ in younger - - 
Number of falls ↑(older) ↑ in older   
HsCRP ↑(older) - - - 
Albumin ↓ ↑ in younger ↑ in men - 
IGF-I ↓ ↑ in younger - - 
Total E2 - ↑ in younger ↑ in women Age-BMI2 
Haemoglobin ↑    
HDL ↓(older) - ↑ in women - 
CK -    
25OHD ↓ ↑ in older - - 
Glucose ↑ ↑ in older - - 
Data shown as a percentage of the mean of the normal BMI group 
1 Greater effect of BMI in women than men 
2 Greater effect of BMI in older adults 
3 Greater effect of BMI on chair stand time in younger adults  
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Discussion 
The results of this Chapter show that physical performance and habitual mobility are 
worse in obese adults than adults with a normal BMI. Poor physical performance and 
mobility might be associated with a greater fall frequency in older adulthood and could 
affect fall kinetics. Poor physical performance in obese adults is not due to low LM; with 
obese adults having greater LM of the total body and appendicular regions. Poor physical 
performance may contribute to the greater risk of ankle and proximal humerus fracture 
in obese adults compared to those with a normal BMI, through associations with the 
number of falls and possibly by affecting fall direction and fall kinetics. 
 
Several risk factors for falls were assessed including alcohol intake, medical conditions 
and medication use associated with greater risk of falls and physical activity participation. 
Greater number of falls in obesity was not due to greater alcohol intake. Having an 
alcohol intake of no more than 21 units per week was one of the inclusion criteria for the 
study; hence alcohol intakes were low to moderate. Although positive associations 
between adiposity and alcohol consumption are reported in high intake or binge drinkers, 
moderate consumption is typically negatively or not associated with adiposity (503). 
Greater number of falls in obesity was not due to greater prevalence of medical 
conditions known to increase the risk of falls, which was similar between normal BMI and 
obese groups. Individuals with medical conditions known to affect bone metabolism were 
excluded from the study and this may have included those with conditions influencing 
falls risk. Other conditions which are more common in obesity and associated with 
greater risk of falls, such as depression, may have led to individuals invited to participate 
in this study having declined to do so as a result of their condition (504, 505). Therefore 
the obese individuals in this sample may be of better general health than the general 
obese population. As obese individuals had poorer physical function and fell more often, 
the difference between obese and normal BMI groups was perhaps even 
underestimated. Greater physical activity has been shown to have a strong influence on 
balance and is generally associated with fall prevention (506). However, physical activity 
may be associated with greater fall risk, through exposure to environments predisposing 
to a fall. In the general population, it would have been expected that physical activity 
levels would be lower in obesity than those with a normal BMI. When recruiting to the 
study, individuals participating in competitive sport or moderate intensity physical activity 
for greater than seven hours per week were excluded. Therefore, no between-groups 
differences in physical activity were expected and differences in physical performance 
resulting from physical activity, rather than adiposity were minimised. As there was no 
difference in weekly physical activity duration or METs expended per week between 
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groups, greater number of falls in obesity cannot be attributed to physical activity. It is 
therefore most likely that the greater number of falls in obesity was due to poor physical 
performance.  
 
The finding that obese older adults fall often than older adults with a normal BMI is 
consistent with previous findings (23, 49, 261, 278). Poor physical performance in obesity 
has also been shown by others. In the EIPDOS and NHANES III studies, obese women 
were more likely to report difficulties in performing habitual activities than women with a 
normal BMI (507, 508) and this was also reported in men with moderate obesity in the 
NHANES III cohort (508). Obese men and women have previously been shown to have 
lower SPPB scores than non-obese individuals (509). 
 
Poor physical performance may be partly attributed to higher HsCRP in obese adults 
which was inversely associated with gait speed. Poor physical performance was not 
attributed to low 25OHD in obesity. There are several other potential causes of poor 
physical performance in obesity, with different causes associated with poor performance 
in different components of the performance battery: 
 
Effective completion of the chair stand test requires the individual to retain control of their 
centre of mass whilst generating forward and upward motion. This might require greater 
effort in obesity, where there may be an anteriorly displaced centre of mass, especially 
in those with abdominal obesity. As there appears not to be greater muscle strength in 
obesity, this may further increase the effort required to complete the chair stand test 
effectively. Using kinematic and kinetic data, Sibella et al. showed that although normal 
weight individuals completed a repeated stand test with forward trunk flexion and a hip 
joint torque approximately twice that of the knee, in obesity, participants positioned their 
feet posteriorly (closer to the level of the back of the chair), resulting in greater knee 
torque with reduced trunk flexion (510). Participants in the FAB study were instructed to 
begin the test with their feet flat and knees bent at a 90° angle. Participants were 
instructed not to lift their feet when returning to the seated position, so as not to ‘rock’ 
and gather momentum for the forthcoming stand. Therefore any differences in foot 
positioning in the present study are perhaps unlikely or extremely discrete. 
 
Slower gait speed in obesity is consistent with the findings of others and is associated 
with an altered step frequency and a shorter stride length (506, 511, 512). As the energy 
expenditure to facilitate movement of greater body mass is higher in obesity compared 
to normal BMI individuals, obese individuals exhibit “a longer stance phase, shorter 
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swing phase and a greater period of double support” when walking (506, 511, 513). 
Obesity has also been associated with greater step width, reflecting the greater leg girth 
and possibly in an attempt to improving dynamic balance (506, 513). Differences in gait 
speed and gait kinematics in obesity are plausible adaptations to compensate for 
impaired dynamic balance as a result of body size, composition and distribution or joint 
pain (514).  
 
Poor balance in obesity may be attributed to differences in body fat distribution affecting 
the body’s centre of mass. Corbeil et al. used mathematical modelling to show that when 
the body’s centre of mass is displaced in an anterior direction, greater ankle torque was 
required to stabilise the body, increasing the risk of falls (477). As greater BMI does not 
necessarily result in anterior displacement of the centre of mass, illustrated by Gravante 
et al., the distribution of adiposity is likely to be a key factor in determining falls risk 
attributed to altered centre of mass (515).  
 
Additionally, common alterations in foot structure in obesity, such as pes planus, greater 
rear-foot eversion and foot abduction, can affect postural stability and gait (478, 506, 
512, 516, 517). Pes planus results from weakened ligaments in the foot being placed 
under greater loading conditions in obesity. Greater peak plantar pressure with greater 
body mass has been reported during both stance and dynamic states (515, 517-519) 
with greater plantar pressures reported under the mid-foot in particular. Greater rear-foot 
eversion may cause additional strain in musculo-tendinous structures of the lower limb. 
High BMI exerts greater loading forces which have been linked to greater muscle-tendon 
unit stiffness (520), although others report no association between BMI and muscle-
tendon unit stiffness (516). Greater muscle-tendon unit stiffness can affect plantar 
landing kinematics and plantar pressure, foot posture, motion accuracy and overall joint 
stability (518, 520). Greater tendon and/or ligament stiffness may contribute to greater 
risk of falls through a lack of joint stability due to decreased visco-elasticity. The role of 
ligament and tendon stiffness in obesity, particularly surrounding ankle fracture, remains 
to be fully characterised.  
 
There was no difference in grip strength between obese and normal BMI individuals in 
the present study, indicating that in obesity, grip strength might be poor indicator of 
overall physical function. This finding is consistent with that of another study (521), 
although others have shown associations between grip strength and BMI (483, 522). The 
relationship between obesity and muscle strength may be site-specific as there is 
evidence to support greater trunk and lower extremity muscle strength in obesity (464, 
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506). Relatively low muscle strength for LM in obesity may be attributed to reduced 
oxidative capacity and decreased capillary density of muscle fibres (506). There may 
also be a reduced neuromuscular activation of motor units, although it has been shown 
that there is no difference in the contraction of muscles fibres in obese and normal BMI 
individuals following percutaneous stimulation, suggesting that the muscle fibres are 
capable of contraction but lack stimulation in obesity (523).  
 
Overall, there is a strong suggestion that physical function may be impaired in obesity. 
With the potential for poor physical performance to increase the risk of falls and ultimately 
fractures, identification of individuals at greatest risk is important. Although sarcopenia 
has been associated with greater risk of falls in the general population (524), the results 
of this Chapter show that greater fall frequency in obesity was not due to sarcopenia. 
Obese individuals had higher LM than individuals with a normal BMI and, as low LM must 
be observed for functional decline to be recognised by the EWGSOP consensus 
definition, consequently no obese individuals were sarcopenic (249). This finding was 
consistent with that of Newman et al. who found none of the obese participants in a 70-
79 years age group subsample of the Health ABC study to be sarcopenic due to their 
greater LM (525). Zoico et al. found that half of elderly women with high FM but normal 
LM had impaired functional performance compared to healthy premenopausal women 
(526). Clearly, having ‘normal’ or above ‘normal’ LM does not necessarily confer 
protection against functional limitation and poor physical performance in obese adults.  
 
In obesity, high FM appears more influential than low LM with respect to mobility and 
physical performance. Similarly, in the Cardiovascular Health Study, high FM predicted 
disability in older men and women, whereas low fat-free mass did not (527). Muscle 
strength was shown to be a stronger predictor of functional limitation and poor health 
than LM (528). In the Health ABC Study, although grip strength and physical 
performance were associated with the risk of hospitalisation, LM and thigh muscle cross 
sectional area were not risk factors for hospitalisation (529). Cawthon et al. reported that 
clustered factors of adiposity and body size were strongly associated with disability risk, 
whilst greater strength and larger lean body size were not associated with disability risk 
(530). Support for studying muscle function over LM to determine physical performance 
and falls risk has also been provided by exercise intervention studies which have shown 
that it is possible to maintain muscle strength and density despite a concurrent loss of 
LM with age (530).  
Whether definitions of sarcopenia should be amended to account for FM is a topic of 
considerable debate. Both LM and FM are altered with weight change, typically with a 
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1:4 increase of LM to FM (531) and greater LM is required to enable movement of greater 
body mass. Adipose status has been shown to heavily influence LM whilst negatively 
affecting physical performance (506). Therefore, it may be argued that to determine 
whether an individual has insufficient LM to function adequately, as is the aim of current 
sarcopenia guidelines, adiposity should be a taken into account. Although the EWGSOP 
consensus acknowledges that LM alone is inadequate to identify functional decline, the 
current definition of sarcopenia does not consider adipose status (249). 
 
By not adjusting for FM, others have reported a failure to identify a large proportion of 
the population at risk of falls and fracture (276). Newman et. al found that adjusting ALM 
for height and FM resulted in the classification of a greater proportion of obese individuals 
as sarcopenic than the use of SMI where ALM is adjusted for height squared irrespective 
of adiposity (525). Recognising an individual’s adiposity and applying adiposity adjusted 
cut-offs for LM and/or a combination of risk factors for falling rather than a dependence 
on low LM, may improve identification of obese individuals at risk of falls and fractures 
(276).  
 
However, at present there is no agreed method of correcting LM for adiposity, when 
assessing sarcopenia. Other authors have suggested identifying sarcopenic individuals 
as those with a LM which is at least two standard deviations from the mean of a gender 
specific, young population. This could have been developed from the 25 to 40 year old 
obese group applied to the older obese adults in the present study, such that muscle 
mass thresholds are relative to BMI. Further research is needed to identify the most 
appropriate LM and FM compartments to be considered in any adjustment, as the 
distribution of adiposity will likely affect the outcome and the resultant relationship with 
physical function.  
 
Sarcopenic obesity describes an increase in FM combined with a net loss in body LM,  
with approximately 8.4% of women and 13.5% of men affected by sarcopenic obesity 
beyond 80 years of age (276, 509). Due to the small sample size, it was not possible to 
study the effect of sarcopenic obesity on physical function or fall frequency from the 
present data. Sarcopenic obesity is associated with impaired physical performance and 
increased disability risk (276, 532, 533). From the results of this Chapter, where the 
obese population have a high LM with impaired physical function, it is plausible that 
physical function may be considerably worse in sarcopenic obesity with a high ratio of 
FM to LM resulting in increased demand “on an inadequate locomotor system” (276). 
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However, as the results of this Chapter suggest that function is driven by factors other 
than LM, the relationship between LM and function in sarcopenia may not be linear.  
 
In a state of low LM with high FM, it might be hypothesised that functional outcomes in 
sarcopenic obesity are worse than in non-sarcopenic obesity (534). Sarcopenic obesity 
has been associated with poorer physical function (521). Sarcopenic obese women were 
more likely to report difficulty in performing habitual activities than obese non-sarcopenic 
women in the EIPDOS cohort, though generally not significantly so, and there was a 
small number of sarcopenic obese-women in this sample (507). In the same cohort, 
sarcopenic obese women were more likely to report difficulty performing habitual 
activities than sarcopenic non-obese women (507). Poor physical performance may be 
partly attributed to sarcopenic obese individuals having a longer forefoot contact phase 
and a shorter initial contact phase, greater oscillation in the metatarsals compared to 
non-obese and obese non-sarcopenic individuals (532). However, sarcopenic obesity 
was not associated with functional performance in older women (526) or with self-
reported difficulty in completing habitual activities (508). There was no difference in 
physical function or SPPB score between sarcopenic obese women and men and non-
sarcopenic obese individuals but obese sarcopenic individuals had a poorer SPPB score 
than non-sarcopenic, non-obese individuals and obese sarcopenic women had a poorer 
SPPB score than  non-obese sarcopenic women (509). 
 
The only biochemical factor to predict physical performance in obesity was totE2. While 
others have suggested that adipokines and inflammatory cytokines may mediate a link 
between adiposity and muscle strength (528), assuming that potential mediators of a 
relationship between adiposity, LM and function in non-obese individuals extrapolate to 
obese individuals may not be a suitable approach when the relationship between 
adiposity, LM and function is dissociated in obesity compared to normal BMI individuals.  
 
The strengths of this work include the use of DXA based estimates of LM and the use of 
validated methods to determine muscle strength and function to provide an accurate 
assessment of LM and muscle function. While other studies have investigated LM, 
sarcopenia and physical performance in obesity, and some with a non-obese control 
group, the individually-matched study design and control for physical activity in this study 
provides a more clear understanding of the differences between obese and normal BMI 
groups attributed to adiposity rather than confounding factors.  
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There are some limitations to the work in this Chapter. While there were statistically 
significant correlations between biochemical factors and physical function variables, the 
correlations only accounted for a very small proportion of the variance in the relationship. 
Alternative factors may better explain associations between muscle mass and physical 
performance in obesity.   
 
Study participants had to be mobile and willing to travel to attend the research facility to 
participate. It must be acknowledged that this may result in a degree of sample bias and 
that the results may not be generalisable to the whole population.  
 
Data on fall history was only collected for the six months prior to recruitment. Collecting 
falls data over a longer period of time might enable a more accurate assessment of fall 
prevalence in the study population. Due to the small number of reported falls, it was not 
possible to calculate meaningful hazard ratios for falls in the obese and non-obese 
groups. No data was collected on fall direction. Whilst relying on participants to recall 
such information may prove problematic, simply determining whether participants fell 
forwards, backwards or sideways would enable us to better understand the way obese 
individuals fall, which could then be related to fracture prevalence. 
 
One of the study inclusion criteria was that participants must not have fractured in the 
twelve months preceding recruitment (Chapter 2). Although any fall could cause fracture, 
only five to ten percent do result in a fracture (535). As any individuals who reported 
fracture in the twelve months prior when screened, were excluded, the true number of 
falls experienced by both BMI groups in the population is likely to have been 
underestimated by at least five to ten percent. As none of the falls recorded in the study 
resulted in fracture, it was necessary to assume no difference between a fall resulting in 
fracture and a fall with no fracture implication. However, this is unlikely to be the case as 
whether or not a fall results in fracture is not due to chance, but due to differences in fall 
arrest, fall kinematics and skeletal adequacy. 
 
The degree of difficulty experienced when completing habitual activities was self-
reported and self-perceived, which may affect the validity of these results. 
 
Physical activity was assessed as both hours per week and METs per week to give an 
overall indication of the energy expended by physical activity taking into account intensity 
and duration. A pre-determined MET value was identified from the literature, based on 
an individual weighing 70kg, for each of the activities reported in the lifestyle 
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questionnaire and the duration of reported activity. METs should be calculated as the 
amount of oxygen consumed per kg weight times the duration (minutes) and so the lack 
of adjustment for the individual’s body weight may have affected the accuracy of the MET 
results, such that METs of the obese group were underestimated. 
 
The risk of proximal humerus fracture may be related to slower reaction time in obesity. 
Slower reaction time may predispose an individual to proximal humerus fracture if there 
is inability to outstretch the forearm arm in time to break their fall (535). Berrigan et al. 
showed that rapid arm movement time was slower in obese versus normal BMI 
individuals and that rapid arm movement in obesity was accompanied anterior 
movements of the trunk (536). These findings support the hypothesis that obese 
individuals fracture their proximal humerus more frequently due to poor balance and 
slower arm movement, resulting in fall impact on the shoulder, rather than the wrist. 
Although obese individuals may have greater soft tissue thickness at the upper body 
which may infer some protection against proximal humerus fracture, this protection may 
be outweighed by greater body weight and increased fall forces. The effect of soft tissue 
thickness on proximal humerus fracture has not been studied to date. Incorporating a 
reaction time task into the study would have enhanced our understanding of the present 
findings in relation to fracture risk. 
 
While the assessment of gait speed by six metre walk is a validated method, when 
participants begin the walk at the zero metre mark, reaction time and time to initiate 
motion may influence the overall six metre walk time. Whilst this may be considered a 
reflection of physical performance, completing the six metre walk with a preceding two 
metre lead up may give more accurate reflection of true gait speed, as has been 
suggested by others (537). Using deviations from a narrow walk course to assess 
balance allows a relatively simple assessment of mediolateral balance. Although 
mediolateral balance is important for dynamic activities such as gait (506), and would be 
the balance axis involved in a sideways fall resulting in proximal humerus fracture, the 
differences in centre of mass discussed earlier in this discussion suggest that balance in 
alternative axes may also be affected and of interest in obesity. No motion analysis was 
performed in this cohort to assess gait or rear-foot eversion in more detail. Motion 
capture can be troublesome in obese populations due to the incurrence of error from 
movement of the cutaneous markers with increasing subcutaneous adiposity. 
 
Fat infiltration of the muscle was not determined in the present study. Intramuscular 
adiposity increases with increasing BMI and has been associated with poorer muscle 
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strength, power and physical function (453-456, 538). Muscle adiposity could be 
determined from the abdominal CT scan described in Chapter 4 using the psoas, erector 
spinae, rectus abdominus, internal and external oblique and transversus abdominus 
muscle groups. Determining peripheral muscle fat could also be done using the HR-
pQCT imaging of the tibia described in Chapter 2.  
 
In conclusion, by standard definitions of sarcopenia, obesity appears protective of 
sarcopenia due to greater LM, but physical function scores and habitual mobility are 
impaired, such that obese adults may be at greater risk of dynapenia. Adjusting SMI for 
FM and/ or determining muscle quality rather than mass, may better identify obese adults 
at greatest risk of poor physical performance. Older obese adults fall more frequently 
than non-obese adults. There are physiological differences between obese and normal 
BMI adults, which may contribute to poor physical function. Poor physical performance 
might be associated with greater fall frequency and differences in fall kinetics, and 
explain the greater risk of proximal humerus and ankle fracture in obese adults.  
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CHAPTER 6: Vitamin D Metabolism in Obesity 
Background 
Vitamin D status is a determinant of calcium absorption and may also have a role in 
immunity and inflammation. In the UK, a small proportion of our vitamin D comes from 
dietary sources such as oily fish, eggs and fortified foods (vitamin D3) and from dietary 
supplements. However, the majority of our vitamin D comes from exposing the skin to 
UVB rays (wavelength 290 to 310 nm). UVB exposure stimulates the conversion of 7-
dehydrocholesterol to pre-D3 when the B-ring of 7-dehydrocholesterol is broken. Pre-D3 
isomerises to become vitamin D3 and is released into the circulation. In the liver, vitamin 
D3 is converted to 25OHD by one of four cytochrome P450 (CYP) enzymes; CYP2R1, 
CYP3A4, CYP27A1, or CYP2J2 before being released to circulate bound to vitamin D 
binding protein (DBP) or albumin (539) (Figure 81). 
 
25OHD Insufficiency  
Low 25OHD results in a decrease in intestinal calcium absorption, which lowers serum 
calcium. This leads to increased PTH, which results in increased bone turnover and a 
loss of bone mineral, as calcium is released into the circulation to increase and 
subsequently maintain serum calcium while intestinal calcium absorption is low. This 
process of demineralisation is associated with bone weakness as seen in rickets and 
osteomalacia and is a risk factor for osteoporosis. Low 25OHD is associated with several 
chronic diseases, some cancers, and higher all-cause and cardiovascular mortality, 
however there is a lack of in-vivo evidence to imply a causal role of low 25OHD in such 
conditions (540, 541).  
 
Deficient, Insufficient or Replete 
Several definitions of vitamin D adequacy have been published, most of which are based 
on PTH and skeletal responses to 25OHD. Debate concerning such thresholds is 
ongoing and it is unknown what 25OHD concentration should considered sufficient for 
the alternative functions of vitamin D where there is less evidence for such effects in-
vivo. 25OHD levels greater than 50 nmol/l have been proposed as adequate by the US 
Institute of Medicine, with levels of 30 to 50 nmol/l considered insufficient and below 30 
nmol/l as deficient (542, 543), although the US Endocrine Society recommends a level 
greater than 75 nmol/l be deemed sufficient, 50 to 75 nmol/l insufficient and below 50 
nmol/l deficient (544). For the purposes of this Chapter, the Institute of Medicine 
classifications will be used. 
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Variations in measurements of 25OHD by different immunoassays have been reported 
(545) and consequently there has been a move to standardise the method for measuring 
serum 25OHD and a move toward using international standards to improve precision.  
 
Groups at High Risk of Low 25OHD 
Vitamin D insufficiency is common in the UK, particularly during the winter months due 
to low UVB exposure (546). Specific groups have been identified as being at particularly 
high risk of vitamin D insufficiency, including children under 3 years of age, adults over 
65 years of age, pregnant and lactating women, individuals who avoid sun exposure, or 
live at high latitudes, have darkly-pigmented skin or with chronic kidney disease (547). 
Recently, those with genetic polymorphisms in the vitamin D receptor (VDR), vitamin D 
binding protein (DBP) or calcium-sensing receptor and obese individuals have been 
identified as being at greater risk of low 25OHD (548). 
 
25OHD in Obesity 
Obese individuals have low circulating total 25OHD and this has been found across 
different ethnicities and worldwide (407, 549-558). However, low total 25OHD in obesity 
does not appear to be associated with the typical effects of vitamin D deficiency on the 
skeleton. In this thesis it has been shown that obese individuals have higher PTH, but 
despite this, bone turnover is lower; with greater BMD at all sites measured (Chapters 3 
and 4). This raises questions over whether the traditional vitamin-D endocrine axis is 
altered in obese individuals and whether low total 25OHD is the most appropriate marker 
of true vitamin D status in obesity. Others have reported similar findings. In obese 
premenopausal women, while there were inverse associations between total 25OHD and 
BMI, total abdominal adiposity and SAT, there was no association between total 25OHD 
and L4 Tb.vBMD or PINP (269). There was no apparent effect of lower 25OHD on bone 
microarchitecture or bone mechanical properties in obese men (268). If the vitamin D 
axis is indeed altered in obesity, such that bone turnover, and consequently BMD, are 
unaffected by lower 25OHD, there may no requirement to supplement obese individuals 
with vitamin D for skeletal benefit.  
 
Although much of the literature has focused on associations between total circulating 
25OHD and health outcomes, most 25OHD circulates bound to binding proteins; DBP 
and albumin. Only 0·02 to 0·05% of total 25OHD is free, or unbound, with approximately 
10% bioavailable (bound to albumin) (559). Free and bioavailable fractions may be 
important as these are the fractions which can be considered biologically available as 
only free lipophilic ligands are able to cross cell membranes and exert physiological 
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effects through intercellular interactions (560). It is currently unknown how, or if, the free 
and bioavailable fractions of 25OHD in obesity differ compared to those of non-obese 
groups and whether differences in DBP concentration or DBP genotype contribute to 
such differences.  
 
Potential Causes of Low 25OHD in Obesity 
Low UVB Exposure 
Although it has been established that following UVB exposure, synthesis of vitamin D in 
obesity is normal and so low total 25OHD is not a consequence of impaired cutaneous 
synthesis of D3 (407), obese people may receive less exposure to UVB radiation than 
individuals with a normal BMI (561). Immobility and sedentary lifestyles may limit the 
exposure of obese individuals to the outdoors. Obese individuals who do go outdoors 
may be less likely to expose large areas of skin due to the social stigma of obesity.  
 
Low Dietary and/or Supplementary Intake 
Low total 25OHD could result from a low intake of dietary vitamin D in obesity (562). 
Obese individuals may be more likely to consume high calorie foods of low nutritional 
content. Obese individuals may also be less likely to take vitamin D containing 
supplements which might also contribute to lower 25OHD. 
 
Low Vitamin D Binding Protein Concentration 
Circulating DBP levels and binding of 25OHD to DBP may be inhibited by inflammatory 
cytokines and triglycerides, which are higher in obesity (563-565). Although it is not yet 
clear whether obesity affects DBP levels or free 25OHD (566, 567), lower concentrations 
of binding proteins for 25OHD in obese individuals may positively affect free 25OHD, 
resulting in normal free 25OHD despite low total 25OHD.  
 
Greater Volumetric Dilution 
As vitamin D is fat soluble and stored in adipose tissue (568), greater adiposity could be 
providing a greater pool for the volumetric dilution of 25OHD (569). Passive distribution 
into a larger pool may result in lower circulating 25OHD in obesity, as illustrated by the 
blunted response of obese individuals to vitamin D supplementation (557, 570-573) and 
particularly by the blunted difference in summer and winter 25OHD levels in obesity 
(396). Diminished summer rises in circulating 25OHD may be suggestive of volumetric 
dilution as despite a larger body surface area and no difference in cutaneous synthesis 
of D3 from UVB exposure compared to non-obese individuals, circulating 25OHD is 
lower in obesity (407).  
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Potential Consequences of Low 25OHD in Obesity 
While the results of Chapters 3 to 5 suggest that lower 25OHD does not have a 
detrimental effect on skeletal parameters or muscle function in obesity, this will be 
investigated in more detail in this Chapter. 
 
Total 1,25-dihydroxyvitamin D in Obesity 
25OHD is hydroxylated to the active hormone 1,25-dihydroxyvitamin D (1,25(OH)2D) by 
1α-hydroxylase, the enzymatic product of the CYP27B1 gene. This 1α-hydroxylation 
takes place mainly in the kidney, but also at extra-renal sites. Although 25OHD is able 
to bind to the VDR, the binding affinity of 1,25(OH)2D for the VDR is approximately one 
thousand times greater than that of 25OHD. When 1,25(OH)2D binds to the VDR, the 
biologic effects of vitamin D are initiated with  the ultimate normalisation of serum calcium 
concentrations (Figure 81). 
 
Figure 81: Simplified illustration of vitamin D metabolism 
Adapted from (574) 
  
 
24-hydroxylase, a product of the CYP24A1 gene, catabolises 25OHD to 24,25(OH)2D 
and degrades 1,25(OH)2D to calcitroic acid. The production of 1α-hydroxylase as a result 
of increased CYP27B1 expression is increased by PTH to raise circulating 1,25(OH)2D 
levels and PTH supresses production of 24-hydroxylase through decreased expression 
of CYP24A1 to decrease catabolism of 1,25(OH)2D to calcitroic acid. The effects of PTH 
are mediated by those of FGF-23, which supresses production of 1α-hydroxylase and 
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induces production of 24-hydroxylase through increased expression of CYP24A1 to 
catabolise 1,25(OH)2D to calcitroic acid (574).  
 
The majority of studies have shown inverse associations between adiposity and total 
1,25(OH)2D (441, 549, 556, 558, 575-577), although only two studies show lower total 
1,25(OH)2D in an obese group compared to a non-obese group (441, 578). Whether 
1,25(OH)2D levels are more strongly associated with certain fat compartments remains 
unclear (110, 268, 269). 
 
Only 0·2 to 0·6% of total 1,25(OH)2D is free, or unbound (560). It is currently unknown 
how, or if, the free and bioavailable fractions of 1,25(OH)2D in obesity differ compared to 
those of non-obese groups and whether differences in DBP concentration or DBP 
genotype contribute to such differences.  
 
Low 25OHD, Muscle Mass and Physical Performance 
Low vitamin D status in obesity may be associated with the poor muscle function and 
physical performance observed in Chapter 5. Although total 25OHD was not associated 
with WBLM, ALM or SMI, or with physical function (Chapter 5), only total 25OHD, 
unadjusted for seasonality was investigated. There might be effects of free 25OHD and 
total and free 1,25(OH)2D on both LM and muscle function in obesity which could 
contribute to the greater number of falls reported in older obese adults.  
 
Vitamin D appears to be indirectly associated with muscle function through associations 
with calcium and phosphate (579). Vitamin D may also have direct effects on muscle 
function through activation of VDRs which are found in muscle tissue. Activation of 
skeletal muscle VDRs by 1,25(OH)2D has been shown to stimulate the activation of 
pathways involved in calcium metabolism and myogenesis (579). Furthermore, skeletal 
muscle has been shown to express CYP27B1, indicating that skeletal muscle may be an 
important site for the conversion of 25OHD to 1,25(OH)2D (579). Vitamin D may also 
increase myocyte mitochondrial oxidative function (580). 
 
Vitamin D may play a role in the maintenance of LM and/or muscle function over time. 
Scott et al. reported that higher baseline 25OHD was associated with better maintenance 
of lower-limb strength but was not associated with maintenance of appendicular lean 
mass (ALM) (581, 582). This finding may be relevant in obesity where there is low 
25OHD and poor muscle performance, despite greater appendicular LM (ALM) (Chapter 
5). Whether 25OHD is associated with LM in obesity is unclear, with a recent study of 
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obese premenopausal women suggesting there is no association between 25OHD and 
thigh muscle cross sectional area (269).  
 
Vitamin D insufficiency is also associated with greater muscle fat infiltration (484, 581). 
However, the relationship between obesity, low 25OHD and physical function may not 
be explained by muscle fat infiltration as in obese premenopausal women there was no 
association between 25OHD and thigh muscle density as an indicator of muscle 
adiposity (269). 
 
25OHD levels have generally been positively associated with muscle strength (583-585), 
although some report null (586) or inverse associations (587). Total 1,25(OH)2D may 
also be positively associated with measures of physical function (587). Vitamin D 
supplementation in those who are vitamin D deficient is positively associated with muscle 
strength (588) and balance (588, 589). Supplementation of those who are vitamin D 
replete does not appear to yield the same benefits; with the supplementation of vitamin 
D only improving muscle strength in those with a low 25OHD at baseline (<25 nmol/L) 
(589, 590). 
 
Low 25OHD and Falls  
Low 25OHD is associated with greater falls risk in older adults and the elderly (394, 401, 
581, 591, 592), as is lower 1,25(OH)2D (587). The current evidence indicates that vitamin 
D supplementation in people who are vitamin D deficient protects against falls in older 
people (589, 591, 593) and supplementation with both vitamin D and calcium may further 
reduce fall risk (593). Bischoff-Ferrari et al. concluded that whether supplemental vitamin 
D was cholecalciferol or ergocalciferol or an active form of vitamin D (1α-
hydroxycalciferol or 1,25-dihydroxycholecalciferol) may affect reductions in falls risk, 
although overall, a significant risk reduction of 19 to 22% was reported (594). Evidence 
for benefit in terms of falls risk in young adults is less clear (591, 595). Whether low 
25OHD is associated with greater risk of falls in younger adults and in obesity is 
unknown. It is unclear whether supplementing obese adults with vitamin D to prevent 
falls due to impaired physical function would be beneficial. 
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Research Question, Aims and Hypotheses 
Research Question: 
Is obesity associated with both low total and free vitamin D and if so, what are the 
potential causes and musculoskeletal consequences of low vitmain D in obesity? 
 
Aims 
1. To establish whether obese people have low total 25OHD and 1,25(OH)2D. 
2. To investigate whether obese people have low free 25OHD and 1,25(OH)2D. 
3. To determine the potential cause(s) of low 25OHD and/or 1,25(OH)2D in obesity. 
4. To investigate associations between 25OHD and BMD, bone structure and bone 
strength to establish whether there are any skeletal consequences of low 25OHD 
in obesity. 
5. To investigate associations between total and free 25OHD and 1,25(OH)2D and 
physical performance. 
6. To determine whether body fat distribution is associated with 25OHD. 
 
Hypotheses: 
1. Total 25OHD and 1,25(OH)2D are lower in obesity. 
2. Lower dietary vitamin D intake and greater pool size are associated with low 25OHD 
levels in obesity. 
3. As result of lower dietary vitamin D intake, greater pool size and lower DBP and 
albumin, free 25OHD and 1,25(OH)2D are lower in obesity. 
4. There are no skeletal implications of low circulating total 25OHD in obesity. 
5. Low total and free 25OHD and 1,25(OH)2D are associated with lower SPPB score. 
 
 
Methods 
All participants from the original FAB Study described in Chapter 2 were invited to 
participate in the vitamin D sub-study. Participants who no longer met the original study 
inclusion criteria were excluded. Participants taking prescribed vitamin D were ineligible. 
Eligible participants attended for a single visit to the Clinical Research Facility, Northern 
General Hospital, Sheffield, in the autumn (September to October 2012) or spring (April 
to May 2013). Weekly average sunlight hours for the study periods can be found in 
Appendix 3. 
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Height (cm) and weight (kg) were measured and BMI calculated, as described in Chapter 
2. Triceps skinfold thickness (mm) was measured and used as an indicator of peripheral 
subcutaneous adiposity. Waist and hip circumference were measured and WHR used 
as a marker of visceral adiposity, as described in Chapter 2. BMD, bone structure, bone 
strength, body composition and physical function were assessed in the original FAB 
study, as described in Chapter 2.  
 
UVB exposure, SPF habits, supplementary vitamin D and dietary vitamin D intake were 
determined from questionnaires (Appendix 1, described fully in Chapter 2). Dietary 
vitamin D data was analysed using the DIETQ software program (Tinuviel Software, 
Warrington, UK). 
 
Total 25OHD and 1,25(OH)2D 
The serum concentration of total 25OHD is most commonly measured to determine 
vitamin D status. High circulating total 25OHD is associated with high cellular 
1,25(OH)2D, which reflects the physiologically relevant vitamin D status. Although 
25OHD has an effect on calcium absorption, this effect appears to be mediated by 
indirect actions, whereas 1,25(OH)2D has a direct effect on calcium absorption (596). 
Whereas 25OHD acts a static marker of vitamin D status, reflecting supply and 
expenditure, 1,25(OH)2D is affected by vitamin D intake, circulating 25OHD, 25-
hydroxylase and 1α-hydroxylase activity. Therefore, although 1,25(OH)2D may therefore 
provide a better indicator of the biological status of vitamin D, the lesser physiologic 
variability of total 25OHD relative to 1,25(OH)2D explains why total 25OHD is the most 
commonly measured metabolite (574). Total 25OHD was measured by automated 
ECLIA (Cobas e411, Roche Diagnostics, Mannheim, Germany). Total 1,25(OH)2D was 
measured by manual immunoassay (Immunodiagnostic Systems, Boldon, UK). 
 
25OHD2 and 25OHD3 
Although the measurement of total 25OHD reflects overall 25OHD status, both 25OHD3 
and 25OHD2 contribute to this measurement and immunoassays may not distinguish the 
two forms. 25OHD3 and 25OHD2 were therefore measured by liquid chromatography 
tandem mass spectrometry (LC-MS/MS) in the laboratory of the Institute of Human 
Development, University of Manchester, UK.  
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DBP and DBP Genotyping 
DBP was measured by manual immunoassay (Human Vitamin DBP Quantikine ELISA, 
R&D Systems, UK). Genetic variation in the DBP gene has given rise to several DBP 
genotypes. The ancestral form of DBP, or group specific component (Gc), Gc1f has 
undergone two amino acid changes; a D432E (previously D416E) and a T436K 
(previously T420K)  change to form Gc1s and Gc2, respectively (559). Circulating DBP 
concentrations vary by haplotype, with Gc2 associated with the least abundant DBP and 
Gc1f the most DBP (109, 559, 567). Genetic variations in the DBP gene are also 
associated with circulating total 25OHD levels (109, 567). Differences in circulating levels 
of 25OHD by DBP genotype are most likely the result of different affinities of DBP for 
25OHD by DBP haplotype (559, 597). Gc1f has the highest affinity for 25OHD with a 
dissociation constant (Kd) of 0.9 nM, compared to Gc1s (Kd 1.7 nM) and Gc2 with the 
lowest affinity for 25OHD (Kd 2.8 nM) (559). Gc1f also has the highest affinity for 
1,25(OH)2D (Kd 56 nM) compared to Gc1s (Kd 160 nM) and again, Gc2 the lowest affinity 
(Kd 240 nM) (559, 597-599). If the conversion of 25OHD to 1,25(OH)2D is substrate 
dependent, dependence of physiological availability of 25OHD on DBP genotype may 
make DBP an important determinant of 1,25(OH)2D (255). DBP genotyping was 
performed in the laboratories of the Sheffield Diagnostic Genetics Service, Sheffield 
Children’s Hospital, as described in Chapter 2. 
 
Free 25OHD 
Free 25OHD was measured by immunoassay (Future Diagnostics BV, Wijchen, 
Netherlands) in the laboratory of Future Diagnostics (Wijchen, Netherlands) (254). 
(Chapter 2)  
 
Free 25OHD and 1,25(OH)2D 
Free 25OHD and 1,25(OH)2D were measured by immunoassay as described in Chapter 
2. Free and bioavailable fractions may be important as these are the fractions which can 
be considered biologically available and able to exert physiological effects through 
intercellular interactions (560). Free 25OHD and free 1,25(OH)2D were also calculated 
using the following equations (255, 256): 
Free 25OHD  = Total 25OHD/ (1+(6*105 x albumin) + (7*108 x DBP))  
Free 1,25(OH)2D = Total 1,25(OH)2D/ (1+(5.4*104M-1 x albumin) + (3.7*107M-1 x DBP)) 
 
CTX, PINP, OC (Cobas e411, Roche Diagnostics, Mannheim, Germany) and BAP (IDS-
iSYS, Immunodiagnostic Systems, Boldon, UK) were measured to assess bone 
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turnover. Albumin, creatinine, calcium, phosphate, PTH, CK, triglycerides, lipid profile, 
IGF-I, HsCRP were measured as described in Chapter 2. 
 
Statistical Analysis 
Mean (SD) age, height and BMI of the study sample were calculated by age, gender and 
BMI group. All variables were assessed for normality and log transformed where 
necessary.  
 
Measured and calculated free 25OHD were compared using correlation, Passing-Bablok 
regression and Bland-Altman plots. Independent samples t-tests, or Mann-Whitney U-
tests, were used to determine differences between normal BMI and obese individuals. 
Paired t-tests were not used in this Chapter as not all participants from the FAB study 
took part in the sub-study and restricting analysis to complete pairs of normal BMI and 
obese individuals reduced the sample size.  
 
Analysis of variance or Kruskal Wallis tests were used to determine differences by DBP 
diplotype or genotype. Univariate general linear models were used to identify significant 
effects of age and gender on vitamin D outcomes and interactions between age, gender 
and BMI on vitamin D outcomes. Vitamin D was adjusted for time of visit (i.e. September 
to October or April to May). 
 
Multiple linear regression was used to see if the relationship between BMI and the 
outcome variable changed after adjusting for age (as a continuous variable) and gender. 
In multiple regression analysis, covariates which had a variance inflation factor ≥10 or 
tolerance statistic ≤0.1 were removed from the model.  
 
Percentage difference between the mean of the normal BMI group and that of the obese 
group for principal outcomes was calculated to facilitate comparisons of the magnitude 
of the difference between variables.  
 
Analysis was performed using IBM SPSS Statistics for Windows (Version 21.0. Armonk, 
NY: IBM Corp.). Passing-Bablok regression was performed in MedCalc (Version 13.0.2, 
MedCalc, Belgium). Significance was accepted when p<0.05.  
 
The sub-study had 90% power at 5% two-sided significance to detect a minimum 
statistically significant correlation coefficient of 0.22.   
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Results 
The overall sample consisted of 167 individuals of which 82 had a normal BMI and 85 
were obese. Characteristics of the study population are shown in Table 18. Obese and 
normal BMI individuals were of a similar age and height (Table 18). Compared to the full 
population described in Chapter 3, mean ages were similar although the sub-study 
sample was slightly younger (approximately 1 to 2 years difference between the group 
means). In the vitamin D sample there was a larger difference in height between normal 
BMI and obese young women (approximately 2 cm difference between means) and older 
men were slightly taller (approximately 1 cm difference between the means). The FAB 
and sub-study samples were similar in terms of BMI.  
 
Table 18: Characteristics of the vitamin D sub-study sample 
by age, gender and BMI group. Data shown as mean (SD) 
 
 
Total 25OHD in Obesity 
Table 19 shows the distribution of 25OHD status within the overall sample and by age 
and BMI group. 
 
Table 19: Vitamin D status of the sub-study sample 
by age and BMI group. Data shown as percentage 
  Deficient 
(<30 nmol/l) 
Insufficient 
(30-50 nmol/l) 
Replete 
(>50 nmol/l) 
Overall  22.7 30.1 47.2 
25 to 40 Years 
Normal BMI 33.3  33.3 33.3 
Obese 57.7 30.8 11.5 
55 to 75 Years 
Normal BMI 3.7 25.9 70.4 
Obese 19.6 32.1 48.2 
 
  
 Women Men 
 25 to 40 Years 55 to 75 Years 25 to 40 Years 55 to 75 Years 
 Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
n 16 16 27 28 12 13 27 28 
Age, 
years 
36.16 
(3.8) 
36.96 
(5.1) 
67.12 
(5.7) 
66.83 
(5.7) 
34.70 
(4.8) 
33.95 
(4.4) 
66.63 
(5.1) 
66.53 
(5.8) 
Height, 
cm 
166.18 
(6.5) 
165.48 
(6.8) 
161.10 
(4.5) 
159.81 
(4.1) 
177.66 
(7.8) 
180.26 
(7.4) 
174.43 
(6.5) 
174.58 
(7.7) 
BMI, 
kg/m² 
22.47 
(1.5) 
34.94 
(5.1) 
22.49 
(1.6) 
36.02 
(5.0) 
23.16 
(1.4) 
33.39 
(3.4) 
23.51 
(1.3) 
35.16 
(3.8) 
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Obese individuals had lower total 25OHD than individuals with a normal BMI (p<0.01 
overall, p<0.05 younger, p<0.01 older) (Figure 82). Older adults had a higher total 
25OHD than younger adults (p<0.001). Women had a higher total 25OHD than men 
(p<0.01). There was no interaction between age or gender and the effect of BMI on total 
25OHD. Multiple linear regression showed the relationship between BMI and total 
25OHD was significant after adjusting for age (as a continuous variable) and gender 
(overall model: p<0.001, adjusted R square 0.298, effect of BMI: beta -0.307, p<0.001). 
 
Figure 82: Total 25OHD in normal BMI and obese individuals 
Ages combined (A), young (B), and older (C).1,2 
A B C  
 
 
Total 25OHD2 and 25OHD3 in Obesity 
Total 25OHD2 was undetectable in the majority of samples (detectable in n=2 (1.2%)) 
and so was not included in the statistical analysis. Total 25OHD3 by LC-MS/MS was 
strongly correlated and showed good agreement with total 25OHD by immunoassay 
(p<0.001, R square 0.771) (Figure 83).  
 
Obese individuals had a lower 25OHD3 than those with a normal BMI (p<0.01 overall, 
p<0.05 younger and older) (Figure 84). Older adults had a higher 25OHD3 than younger 
adults (p<0.001). There was no effect of gender on 25OHD3 or interactions between age, 
gender and BMI on 25OHD3. Multiple linear regression showed the relationship between 
BMI and 25OHD3 was significant after adjusting for age (as a continuous variable) 
(overall model: p<0.001, adjusted R square 0.310, effect of BMI: beta -0.266, p<0.001). 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Figure 83: Association between total 25OHD and 25OHD3 
by correlation (A), Passing-Bablok regression (B) and Bland-Altman plot (C) 
A  B  
C  
 
 
Figure 84: Total 25OHD3 by LC-MS/MS in normal BMI and obese individuals 
Ages combined (A), young (B), and older (C).1,2 
A B C  
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Free 25OHD in Obesity 
Measured free 25OHD results were compared to those for calculated free 25OHD. 
Although correlation between the methods was strong (R square 0.447, p<0.001), there 
was a significant difference between free 25OHD by measured and calculated methods 
(p<0.001), with the measured method giving lower free 25OHD results, particularly at 
higher average free 25OHD levels (Figure 85). 
 
Figure 85: Association between measured and calculated free 25OHD 
by correlation (A), Passing-Bablok regression (B) and Bland-Altman plot (C) 
A  B  
C  
 
Obese individuals had lower free 25OHD than individuals with a normal BMI (p<0.01 
overall (measured and calculated), p<0.05 younger (measured and calculated), older 
p<0.01 measured, p<0.05 calculated) (Figure 86). Older adults had a higher free 25OHD 
than younger adults (p<0.001 measured, p<0.01 calculated). There was no effect of 
gender on measured free 25OHD, but women had a higher calculated free 25OHD than 
men (p<0.01). There were no interactions between age or gender and the effect of BMI 
on measured free 25OHD.  
 
Multiple linear regression showed the relationship between BMI and measured free 
25OHD was significant after adjusting for age (overall model p<0.001, adjusted R square 
0.269, effect of BMI beta -0.286, p<0.001). Multiple linear regression showed the 
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relationship between BMI and calculated free 25OHD was significant after adjusting for 
age and gender (overall model p<0.001, adjusted R square 0.234, effect of BMI beta -
0.294, p<0.001). 
 
Figure 86: Free 25OHD in normal BMI and obese individuals 
by measured (A-C) and calculated (D-F) methods, ages combined and by age group.1,2 
A B C
D E F  
 
 
Possible Causes of Low Vitamin D in Obesity 
Dietary Vitamin D Intake in Obesity 
There was no difference in dietary vitamin D intake between normal BMI and obese 
individuals (Figure 87). Dietary calcium intake was not different in obese individuals 
compared to normal BMI individuals. There was no effect of age or gender on dietary 
calcium intake. 
 
There was no difference in self-reported energy intake and therefore no difference in the 
amount of dietary vitamin D consumed per kcal of total energy intake, between normal 
BMI and obese individuals. Older adults had a greater dietary vitamin D intake (p<0.05) 
and a greater intake of vitamin D per kcal of total intake (p<0.05) than younger adults. 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
 207 
Women had a greater intake of vitamin D (p<0.05) and a greater intake of vitamin D per 
kcal of total intake (p<0.01) than men. There were no interactions between age, gender 
and BMI on vitamin D intake.  
 
Figure 87: Dietary vitamin D intake in normal BMI and obese individuals 
Ages combined (A), younger (B) and older (C) groups.1,2 
A B C  
 
After adjusting for age and gender, BMI was not a significant predictor of vitamin D intake 
or intake of vitamin D per kcal of total intake, with age the only significant predictor of 
vitamin D intake (overall model: p<0.05, adjusted R square 0.025, effect of age: beta 
0.177, p<0.05) and age and gender predicting vitamin D intake per kcal of total intake 
(overall model: p<0.01, adjusted R square 0.074, effect of age: beta 0.217, p<0.01, effect 
of gender: beta -0.2, p<0.01).  
 
Supplementation in Obesity 
Obese individuals were less likely to take supplements containing vitamin D than normal 
BMI individuals (p<0.05) (Figure 88). Older adults took more supplements containing 
vitamin D than young adults (p<0.05). There was no effect of gender on supplement 
habits. Multiple linear regression adjusting for age and gender showed an effect of BMI 
on whether people were taking vitamin D containing supplements (overall model p<0.05, 
adjusted R square 0.031, effect of BMI beta -0.189, p<0.05). 
 
Figure 88: Percentage of normal BMI and obese individuals taking supplements 
containing vitamin D 
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UVB Exposure in Obesity 
There was no difference in sun exposure between normal BMI and obese individuals 
(Figure 89). There was no effect of age or gender on annual sun exposure score.  
 
Figure 89: Annual sun exposure of normal BMI and obese individuals 
ages combined (A), young (B) and older.1,2 
A B C  
 
98.8% of the sample never used sunbeds. The remaining 1.2% used sunbeds less than 
once per month. There was no difference in the frequency of sun protection factor (SPF) 
use between normal BMI and obese groups (Figure 90A). Women wore SPF more often 
than men (p<0.01). There was no difference in the SPF factor applied between normal 
BMI and obese, by gender, or by age (Figure 90B). 
 
 
Figure 90: Sun protection factor habits of normal BMI and obese individuals 
Error bars represent 95% confidence intervals 
A B  
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference 
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Vitamin D Binding Proteins in Obesity 
Obese individuals had lower albumin than normal BMI individuals (p<0.05 overall, NSD 
younger, NSD older) (Figure 91). There was no effect of age on albumin. Men had higher 
albumin than women (p<0.001). There were no interactions between age, gender and 
BMI with albumin. Multiple linear regression showed the relationship between BMI and 
albumin was significant after adjusting for age and gender (overall model: p<0.001, 
adjusted R square 0.073, effect of BMI: beta -0.169, p<0.05). 
 
Figure 91: Albumin in normal BMI and obese individuals 
Ages combined (A), younger (B) and older (C) groups.1,2 
A B C  
 
There was no difference in DBP concentration between normal BMI and obese 
individuals (Figure 92). There was no effect of age or gender on DBP. Adjusting for age 
and gender did not affect the relationship between BMI and DBP.  
 
Figure 92: DBP in normal BMI and obese individuals 
Ages combined (A), younger (B) and older (C) group.1,2 
A B C  
 
 
Albumin was not correlated with total or free 25OHD, but was positively correlated with 
total 1,25(OH)2D (r=0.169, p<0.05). DBP was positively correlated with total 25OHD 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference. 
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(r=0.223, p<0.01), 25OHD3 (r=0.231, p<0.01) and total 1,25(OH)2D (r=0.163, p<0.05) 
and negatively correlated with free 25OHD (calculated, r=-0.237, p<0.01) and free 
1,25(OH)2D (r=-0.438, p<0.001). 
 
DBP Genotype 
Distribution of DBP diplotypes and genotypes are presented in Table 20. The most 
common diplotype was GC2-1s and the least common was GC1f-1f. The most common 
genotype was GC1-1 and the least common was GC2-2 (Table 21). 
 
Table 20: Percentage distribution of the DBP diplotypes 
for the rs4588 and rs7041 SNPs by age, gender and BMI group. Most common diplotype for each 
group shown in bold. 
 
There was no difference in age, height, BMI, WHR, triceps skinfold, sun exposure, 
dietary intake of vitamin D, calcium or D per kcal of total energy intake, supplement 
usage, albumin, eGFR, CK, creatinine, PTH, calcium, phosphate, IGF-I, HsCRP, lipid 
profile or BTMs between the DBP diplotypes or genotypes (all p>0.05).  
 
Table 21: Percentage distribution of the DBP genotypes 
for the rs4588 and rs7041 SNPs, by age, gender and BMI group. Most common genotype for each 
group shown in bold.  
 
DBP concentration by Genotype 
DBP concentration differed between the diplotypes (p<0.001) and genotypes (p<0.001). 
Post-hoc testing of pairwise comparisons showed a significant difference in DBP 
  Women Men 
  25 to 40 Years 55 to 75 Years 25 to 40 Years 55 to 75 Years 
 
Total 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
1s-1s 30.5 18.8 37.5 37.0 32.1 33.3 15.4 29.6 32.1 
1f-1f 1.2 0.0 6.3 0.0 0.0 0.0 7.7 0.0 0.0 
1s-1f 16.2 18.8 12.5 11.1 25.0 16.7 15.4 22.2 7.1 
2-2 9.6 18.8 6.3 7.4 7.1 16.7 0.0 11.1 10.7 
2-1s 35.9 25.0 31.3 37.0 32.1 25.0 53.8 37.0 42.9 
2-1f 6.6 18.8 6.3 7.4 3.6 8.3 7.7 0.0 7.1 
  Women Men 
  25 - 40 Years 55 - 75 Years 25 - 40 Years 55 - 75 Years 
 
Genotype 
Total 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
Norm. 
BMI 
Obese 
1-1 47.9 37.5 56.3 48.1 57.1 50.0 38.5 51.9 39.3 
1-2 42.5 43.8 37.5 44.4 35.7 33.3 61.5 37.0 50.0 
2-2 9.6 18.8 6.3 7.4 7.1 16.7 0.0 11.1 10.7 
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between the six diplotypes (all p<0.001 except between Gc1s-1f and Gc2-1s where 
p<0.05) and between the three genotypes (Gc1-1 and Gc2-2 p<0.001, Gc1-1 and Gc1-
2 p<0.001, Gc1-2 and Gc2-2 p<0.01) (Figure 93). 
 
Figure 93: DBP concentration by DBP Diplotype and genotype 
   
Age and diplotype, but not gender or BMI, were determinants of DBP (overall model 
p<0.001, adjusted R square 0.309, effect of age: beta 0.130, p<0.05, effect of diplotype: 
beta -0.538, p<0.001). Age and genotype, but not gender or BMI, were determinants of 
DBP (overall model p<0.001, adjusted R square 0.247, effect of age: beta 0.145, p<0.05, 
effect of genotype: beta -0.477, p<0.001). 
 
Total 25OHD by DBP Genotype 
Total 25OHD differed between the diplotypes (p<0.05) and genotypes (p<0.01). Post-
hoc testing of pairwise comparisons showed a difference between all six diplotype 
groups (p<0.05) and between the Gc1-1 and Gc1-2 (p<0.05), and Gc1-1 and Gc2-2 
(p<0.05) but not between Gc1-2 and Gc2-2 (Figure 94).  
 
Figure 94: Total 25OHD by DBP Diplotype and genotype 
   
Multiple linear regression showed age, gender, BMI and DBP diplotype had significant 
effects on total 25OHD (overall model p<0.001, adjusted R square 0.328, effect of age: 
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beta 0.437, p<0.001, effect of gender: beta -0.128, p<0.05, effect of BMI: beta -0.309, 
p<0.001, effect of diplotype: beta -0.184, p<0.01). Age, BMI and DBP genotype, but not 
gender, had significant independent effects on total 25OHD (overall model p<0.001, 
adjusted R square 0.331, effect of age: beta 0.439, p<0.001, effect of BMI: beta -0.320, 
p<0.001, effect of genotype: beta -0.225, p<0.001).  
 
Free 25OHD by DBP Genotype 
Free 25OHD (measured and calculated) did not differ by diplotype or genotype, before 
and after adjusting for age, gender and BMI.  BMI and age, but not gender, diplotype or 
genotype, were significant predictors of measured free 25OHD (overall model p<0.001, 
adjusted R square 0.269, effect of BMI: beta -0.286, p<0.001, effect of age: beta 0.452, 
p<0.001) and calculated free 25OHD (overall model p<0.001, adjusted R square 0.234, 
effect of BMI: beta -0.294, p<0.001, effect of age: beta 0.381, p<0.001, effect of gender: 
beta -0.149, p<0.05). 
 
Total 1,25(OH)2D by DBP Genotype 
Total 1,25(OH)2D did not differ by diplotype or genotype (both p>0.05).  
 
BMI and age were significant predictors of total 1,25(OH)2D after adjustment for age and 
gender (overall model p<0.01, adjusted R square 0.063, effect of BMI: beta -0.210, 
p<0.01, effect of age: 0.179 p<0.05). BMI, age, and genotype were significant predictors 
of total 1,25(OH)2D after adjustment for gender (overall model p<0.001, adjusted R 
square 0.082, effect of BMI: beta -0.220, p<0.01, effect of age: 0.170 p<0.05, effect of 
genotype -0.156, p<0.05). 
 
Free 1,25(OH)2D by DBP Genotype 
Free 1,25(OH)2D differed by diplotype (p<0.001) but not by genotype (Figure 95).  
 
Figure 95: Free 1,25(OH)2D by DBP Diplotype and genotype 
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Post-hoc testing of pairwise comparisons showed a difference between all six diplotypes 
(all p<0.05 except between Gc1s-1s and Gc2-1f where p<0.001). BMI and diplotype or 
genotype were predictors of free 1,25(OH)2D after adjustment for age and gender 
(diplotype model p<0.01, adjusted R square 0.069, effect of BMI: beta -0.156, p<0.05, 
effect of diplotype: 0.231, p<0.01) (genotype model p<0.01, adjusted R square 0.069, 
effect of BMI: beta -0.153, p<0.05, effect of diplotype: 0.160, p<0.01). 
 
 
Associations Between Total and Free 25OHD and 1,25(OH)2D by DBP Diplotype 
and Genotype 
Figure 96 and Figure 97 illustrate the variation in free 25OHD for a given total 25OHD 
by DBP diplotype and genotype, and the variation in free 1,25(OH)2D for a given total 
1,25(OH)2D by diplotype and genotype.  
 
Gc1s-1s and Gc1-1 were consistently found to have lower free 25OHD or 1,25(OH)2D 
for a given total 25OHD or 1,25(OH)2D, while Gc2-1f and Gc2-2 showed the highest free 
concentration for a given total concentration. 
 
Figure 96: Total and free 25OHD and 1,25(OH)2D by DBP genotype 
Gc1-1 = blue, Gc1-2 =green, Gc2-2 = red. Dotted lines indicate serum 25OHD status thresholds. 
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Figure 97: Total and free 25OHD and 1,25(OH)2D by DBP Diplotype 
Dotted lines indicate serum 25OHD status thresholds. 
  
  
 
 
Consequences of Low 25OHD in Obesity 
Total 1,25(OH)2D in Obesity 
Total 1,25(OH)2D was positively correlated with total 25OHD (p<0.001, r= 0.384) and 
25OHD3 (p<0.001, r= 0.869) (Figure 98).  
 
Figure 98: Association between total 1,25(OH)2D and 25OHD and 25OHD3 
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Obese individuals had lower total 1,25(OH)2D than normal BMI individuals (p<0.01 
overall, NSD younger, p<0.01 older) (Figure 99). Older adults had higher total 
1,25(OH)2D than younger adults (p<0.01). There was no effect of gender or interactions 
between age, gender and BMI on total 1,25(OH)2D.  
 
Figure 99: Total and free 1,25(OH)2D in normal BMI and obese individuals 
Ages combined (left), younger (centre) and older (right) group.1,2 
   
     
 
Multiple linear regression models showed the relationship between BMI and total 
1,25(OH)2D was significant after adjusting for age and gender (overall model p<0.01, 
adjusted R square 0.058, effect of BMI: beta -0.210, p<0.01, effect of age: beta 0.179, 
p<0.05, effect of gender: beta -0.014, p=0.850). 
 
BMI remained significant when albumin, PTH, eGFR and phosphate, the principal 
determinants of total 1,25(OH)2D, were added to the model (overall model p<0.01, 
adjusted R square 0.082, effect of BMI: beta -0.213, p<0.01, effect of age: beta 0.257, 
p<0.01, effect of albumin: beta 0.181, p<0.05, no significant effect of gender, PTH, eGFR 
or phosphate). 
  
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference. 
 216 
Free 1,25(OH)2D in Obesity  
Obese individuals had lower calculated free 1,25(OH)2D than individuals with normal BMI 
(p<0.05 overall, NSD younger, NSD older). There was no effect of gender or age on free 
1,25(OH)2D.  
 
Multiple linear regression showed BMI was the only significant predictor of free 
1,25(OH)2D after adjusting for age and gender (overall model p<0.05, adjusted R square 
0.021, effect of BMI: beta -0.165, p<0.05).  
 
With further adjustment for age, gender, PTH, albumin, eGFR and phosphate the model 
was no longer significant and a stepwise linear regression model showed that BMI was 
the only significant predictor of free 1,25(OH)2D (overall model p<0.05, adjusted R 
square 0.027, beta -181). 
 
Vitamin D and PTH in Obesity 
There was no difference in PTH between normal BMI and obese individuals (Figure 100). 
There was no effect of age or gender on PTH. There was an interaction between gender 
and BMI on PTH, such that PTH was higher in obese women than normal BMI women 
but lower in obese men than normal BMI men (p<0.05).  
 
Figure 100: PTH in normal BMI and obese individuals 
Ages combined (left), younger (centre) and older (right) group.1,2 
       
 
After adjusting for age and gender there remained no significant association between 
BMI and PTH (adjusted R square -0.11). PTH was not correlated with total or free 25OHD 
or 1,25(OH)2D. Multiple linear regression models showed that PTH was not determined 
by age, gender, BMI, total or free 25OHD or 1,25(OH)2D.   
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference. 
 217 
Vitamin D and Bone Turnover in Obesity 
Obese individuals had lower CTX than normal BMI individuals (p<0.01 overall, p=0.053 
younger, p<0.05 older). Young adults had higher CTX than older adults (p<0.05), but 
there was no effect of gender on CTX (Figure 101).  
 
Obese individuals had lower OC than normal BMI individuals (p<0.001 overall, p<0.01 
younger, p<0.05 older). There was no effect of age or gender on OC. (Figure 101) 
 
There was no difference in PINP or BAP between obese and normal BMI individuals, or 
by age or gender (Figure 101).  
 
In the overall sample, total or free 25OHD and 1,25(OH)2D were not correlated with CTX, 
PINP, OC or BAP in unadjusted analyses. In obese individuals alone, free 25OHD was 
negatively correlated with BAP in unadjusted analyses (r=-0.235, p<0.05 measured, r=-
0.225, p<0.05 calculated). Adjusting for age, gender and BMI, total 25OHD was inversely 
related to PINP (r=-0.180, p<0.05). There remained no association between total 25OHD 
and CTX, OC or BAP, or between free 25OHD, total and free 1,25(OH)2D and any of the 
BTMs after adjustment.  
 
A multiple linear regression model accounting for the effects of age, gender, BMI, total 
25OHD and PTH significantly predicted CTX (overall model p<0.01, adjusted R square 
0.067) and BMI was a significant predictor within the model (beta -0.196, p<0.05). 
 
A multiple linear regression model accounting for the effects of age, gender, BMI, total 
25OHD and PTH significantly predicted OC (overall model p<0.05, adjusted R square 
0.057) and BMI was a significant predictor within the model (beta -0.279, p<0.001). 
 
Adjustment for age and gender did not affect the relationship between PINP and BMI or 
BAP and BMI. PINP or BAP were not predicted by models of age, gender, BMI, total 
25OHD and PTH.  
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Figure 101: BTMs in normal BMI and obese sub-study individuals 
CTX (A), PINP (B) and OC (C) by ages combined (left), young (centre) and older (right).1,2 
A        
B        
C       
 
 
Bone Density, Microstructure and Strength by DBP Genotype 
There was no difference in aBMD, vBMD, bone microarchitecture or bone strength by 
DBP diplotype or genotype (ANOVA p>0.05). After adjusting for age, gender and BMI, 
there was a significant association between DBP diplotype and WB aBMD (overall model 
p<0.001, adjusted R square=0.397, effect of diplotype: beta -0.126, p<0.05), and 
between DBP diplotype and tibial estimated failure load (overall model p<0.001, adjusted 
R square=0.608, effect of diplotype: beta -0.135, p<0.01), but all other associations 
                                               
1 Box and whisker plots showing the median, interquartile range and outliers (defined as being 
more than one and a half interquartile ranges above or below the interquartile range) 
2 *p<0.05, **p<0.01. ***p<0.001, NSD no significant difference. 
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between DBP diplotype or genotype and aBMD, vBMD, bone microarchitecture or bone 
strength remained non-significant. 
 
aBMD (Figure 102), and vBMD (Figure 103) were negatively correlated with measures 
of total and free 25OHD and 1,25(OH)2D (supported by Table 22). The negative 
association between 25OHD and BMD was unexpected, but possibly explained by 
obesity causing both low 25OHD and high BMD. Multiple linear regression showed that 
after adjustment for age, gender and BMI, total 25OHD was not a significant predictor of 
WB (beta 0.075), TH (beta -0.001) or LS aBMD (beta 0.038) (tolerance statistic= 0.751, 
0.751, 0.766 respectively) or of tibia vBMD (beta -0.066), radius vBMD (-0.155) or LS 
vBMD (beta -0.056). 
 
Multiple linear regression showed that after adjustment for age, gender and BMI, total 
25OHD was not a significant predictor of estimated failure load at the radius (beta 0.038) 
or tibia TH (beta 0.055). 
 
Table 22: Correlation coefficients between BMD and vitamin D metabolites 
 
Total 
25OHD 
Free 
25OHD 
Measured 
Free 
25OHD 
Calculated 
25OHD3 
Total 
1,25(OH)2D 
Free 
1,25(OH)2D 
WB 
aBMD 
-0.168* NS -0.170* -0.141* -0.200** -0.181** 
TH 
aBMD 
-0.292*** -0.214* -0.270*** -0.285*** -0.236*** -0.179** 
LS 
aBMD 
-0.181** -0.161* -0.166* -0.202** -0.238*** -0.185** 
Radius 
vBMD 
-0.266*** -0.237** -0.234** -0.227** 0.189** -0.140* 
Tibia 
vBMD 
-0.288*** 0.273** -0.273*** -0.309*** -0.194** -0.181** 
LS 
vBMD 
NS NS NS NS NS NS 
*p<0.05, **p<0.01, ***p<0.001, NS not significant 
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Figure 102: Associations between vitamin D and aBMD 
At the whole body (Left), total hip (centre) and lumbar spine (right), by total 25OHD (A), free 25OHD 
(B), total 1,25(OH)2D (C) and free 1,25(OH)2D (D). Green=obese, blue = normal BMI 
A  
B  
C  
D  
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Figure 103: Associations between vitamin D and vBMD 
At the distal radius (Left), distal tibia (centre) and lumbar spine (right), by total 25OHD (A), free 
25OHD (B), total 1,25(OH)2D (C) and free 1,25(OH)2D (D). Green=obese, blue = normal BMI 
A  
B  
C  
D  
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Vitamin D and Biochemical Factors in Obesity 
Total 25OHD (r=0.254, p<0.01), free 25OHD (measured r=0.245, p<0.01, calculated 
r=0.188, p<0.05) and 25OHD3 (r=0.221, p<0.05) were positively correlated with adjusted 
calcium. Adjusted calcium was not associated with total or free 1,25(OH)2D. Total and 
free 25OHD and 1,25(OH)2D were not correlated with IGF-I, phosphate, creatinine or 
CK. 
 
Is Vitamin D Affected by Serum Lipids or Inflammatory Markers? 
TC was not correlated with total or free 25OHD or 1,25(OH)2D. HDL was positively 
correlated with total (r=0.260, p<0.01) and free 25OHD (r=0.206, p<0.01), and total 
(r=0.273, p<0.01) and free 1,25(OH)2D (r=0.180, p<0.05). TC:HDL ratio and triglycerides 
were negatively correlated with total (r=-0.241 p<0.01) and free 25OHD (-0.243, p<0.01) 
and total (r=-0.265, p<0.05) and free 1,25(OH)2D (r=-0.215, p<0.05). Triglycerides 
remained associated with total 25OHD after adjustment for age, gender, BMI, TC, HDL 
and LDL (overall model p<0.001, adjusted R square 0.303, effect of triglycerides: beta -
0.164, p<0.05). TC, HDL and LDL were not significant predictors of total 25OHD after 
adjustment for age, gender, BMI and triglycerides. 
 
HsCRP was positively correlated with VAT and SAT (both p<0.001) and inversely 
associated with albumin (r=-0.193, p<0.05). HsCRP was not correlated with total or free 
25OHD but was negatively correlated with total 1,25(OH)2D (r=-0.227, p<0.01) and free 
1,25(OH)2D (r=-0.226, p<0.05). After adjusting for age, gender, BMI and albumin, 
HsCRP remained a predictor of 1,25(OH)2D (p<0.01, adjusted R square 0.046) and the 
only significant predictor of free 1,25(OH)2D (p<0.01, adjusted R square 0.045).  
 
Vitamin D and Body Fat Distribution in Obesity 
Significant correlations between adipose compartments and vitamin D metabolites are 
shown in (Table 23). No significant correlations were observed for WHR, VAT or VAT:SAT 
ratio. 
 
Table 23: Correlations between fat compartments and vitamin D metabolites 
Data shown as r values 
 Total 
25OHD 
Free 
25OHD 
25OHD3 
Total 
1,25(OH)2D 
Free 
1,25(OH)2D 
WB FM -0.253** -0.270** -0.272** -0.210** NS 
Trunk FM -0.231** -0.243** -0.222** -0.181* NS 
SAT -0.270** -0.271** -0.221** -0.207** -0.178* 
Triceps skinfold -0.222** -0.210** -0.249** NS NS 
*p<0.05, **p<0.01, ***p<0.001, NS not significant  
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Vitamin D and Physical Performance in Obesity 
SPPB score was not correlated with total or free 25OHD (measured or calculated), 
25OHD3 or total 1,25(OH)2D, but was positively correlated with free 1,25(OH)2D 
(r=0.173, p<0.05).  
 
After adjustment for age, gender and BMI, SPPB score was positively correlated with 
total 1,25(OH)2D (r=0.234, p<0.01) and free 1,25(OH)2D (r=0.217, p<0.01). However, the 
addition of total or free 1,25(OH)2D did not improve the model described in Chapter 5 for 
the prediction of SPPB score.  
 
Gait speed was negatively correlated with 25OHD3 by LC-MS/MS (r=-0.176, p<0.05) and 
grip strength was negatively correlated with free 25OHD (r=-0.156, p<0.05), but after 
adjustment for age, gender and BMI no measures of physical function were correlated 
with total or free 25OHD, 25OHD3, or 1,25(OH)2D.  
 
Adding 25OHD3 did not improve the model for predicting gait speed (multiple linear 
regression with gait as the dependent variable, age and BMI as independent variables; 
overall model p<0.001, adjusted R square 0.272, with age, BMI and 1,25(OH)2D as 
independent variables; overall model p<0.001, adjusted R square 0.277; beta 
1,25(OH)2D  -0.028, p=0.729).  
 
Adding free 25OHD slightly improved the model for predicting grip strength (multiple 
linear regression with grip strength as the dependent variable, age, gender and BMI as 
independent variables; overall model p<0.001, adjusted R square 0.571, with age, 
gender, BMI and 1,25(OH)2D as independent variables; overall model p<0.001, adjusted 
R square 0.580; beta free 25OHD  -0.031, p=0.614). 
 
Summary of Results 
A summary of the general findings of this Chapter is given in Table 24 
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Table 24: Summary of results of Chapter 6 
The effects of BMI, age and gender and interactions between age or gender and BMI on 25OHD 
levels and potential causal factors and consequences of low 25OHD in obesity. 
Variable 
Effect of BMI 
(%difference) 
Effect of 
 Age 
Effect of 
Gender 
Interactions 
Total 25OHD ↓(-25.5) ↑in older ↑women - 
25OHD3  ↓(-20.8) ↑in older - - 
Free 25OHD (M) ↓(-23.1) ↑in older - - 
Free 25OHD (C) ↓(-24.9) ↑in older ↑women - 
Dietary intake - ↑in older ↑women - 
Supplement use ↓ ↑in older - - 
Sun exposure - - - - 
Albumin ↓(-2.9) - ↑men - 
DBP concentration -  (-4.1) - - - 
DBP genotype - - - - 
Total 1,25(OH)2D ↓(-17.4) ↑in older - - 
Free 1,25(OH)2D ↓(-16.3) - - - 
PTH -  (+6.4) - - Gender-BMI1 
CTX ↓(-14.3) ↑in younger - - 
PINP - (-8.6) - - - 
OC ↓(-17.5) - - - 
BAP - (-1.1) - - - 
Data shown as a percentage of the mean of the normal BMI group 
M=measured free 25OHD, C= calculated free 25OHD 
1 PTH higher in obese than normal BMI women, lower in obese than normal BMI men 
 
 
Discussion 
Total 25OHD levels are lower in obesity. Associations between 25OHD and adiposity 
have been widely reported (395, 402, 405, 407, 549-551, 558, 575, 600-602) and were 
recently supported by the results of a meta-analysis of the association between 25OHD 
and BMI in healthy adults (603). Several smaller studies of pre-bariatric surgery patients 
have shown low 25OHD in obese individuals compared to non-obese controls (405, 565). 
 
Free 25OHD levels are also lower in obesity. This is the first study to investigate the 
difference in free 25OHD between obese individuals and a non-obese control group and 
the first study to report associations between adiposity and measured free 25OHD. 
 
Younger people have lower total and free 25OHD than older people. Whilst some studies 
have reported greater total 25OHD with increasing age (601, 604), there is a greater 
body of evidence to support inverse associations between 25OHD and age (395, 605, 
606). Need et al. reported an increase in 25OHD between the ages ~45 to ~65 years but 
this was followed by a significant decline in 25OHD to ~75 years (601). In older adults, 
vitamin D status was inversely associated with BMI, WC, FM, FM corrected for height 
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and percentage FM to fat free mass, but none of these associations were observed in 
younger adults age 20 to 40 years (557). Lower total 25OHD in younger people may due 
to lower dietary intakes in this age group. Lower dietary vitamin D intakes were reported 
in Danish teenage girls compared to elderly women (607). Vitamin D intake increased 
with age in adults aged 25 to 69 years (575, 608). The finding of lower 25OHD in younger 
adults is consistent with that of a large study of British adults which found those aged 50 
to 64 years consumed more oily fish than any other age group and that although low 
25OHD was widespread in all age groups, "it was most noticeable in older children, 
young adults (including women of childbearing age) and older people living in 
institutions”, with the young adults in the SACN report being of a similar age to those in 
the present study (609). There may be more rapid clearance of 25OHD in young people, 
which could lower circulating 25OHD. 
 
Women had higher 25OHD than men, as previously shown (610, 611), although others 
have reported higher total 25OHD in men (109). There were no differences in 25OHD3 
or measured free 25OHD by gender, although calculated free 25OHD was lower in men. 
Previous suggestions that differences in 25OHD status by gender are a result of greater 
adiposity for a given BMI in women appear counterintuitive, as this would result in men 
having a greater serum 25OHD, opposing the results of this study (603). As women had 
a greater dietary intake of vitamin D than men, this may explain such findings although 
additional evidence to support gender differences in vitamin D intake is conflicting (608, 
612, 613). 
 
The most likely cause of low 25OHD in obesity is greater volume of distribution resulting 
from greater SAT (WBFM, SAT and triceps skinfold) (but not visceral fat), acting as a 
sump. 25OHD is inversely associated with waist circumference (404), WHR (402) total 
abdominal FM (269), SAT (269, 404, 549) and VAT (404, 549, 614). During a 2.6 year 
longitudinal study of 25OHD, adiposity, adipokines and lipids in older adults, those with 
incident vitamin D deficiency had a greater BMI and trunk FM than individuals who 
remained vitamin D replete, while subjects with recovery of vitamin D deficiency had 
lower BMI and WBFM and trunk FM  (600). Measuring 25OHD3 in the fat tissue of pre-
bariatric surgery patients by LC-MS/MS, Blum et al. found that serum and fat tissue 
concentrations of 25OHD3 were positively correlated (615). This demonstrates that fat 
tissue does indeed function as a depot for vitamin D storage. Thus although obese 
individuals have lower circulating 25OHD, the positive association between serum and 
fat tissue concentrations of 25OHD3 is likely explained by the greater number of 
adipocytes each with a relatively lower concentration of 25OHD in obesity. The concept 
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of volumetric dilution, rather than sequestration of 25OHD into adipose tissue has also 
been proposed (569). The circulating 25OHD response to vitamin D supplementation 
has been shown to be blunted in obesity (557, 570, 572, 573, 575) and there is less 
seasonal variation in circulating 25OHD into the winter months (601) Greater adiposity 
is also associated with lower 25OHD after irradiation (407). The larger pool size in 
obesity may require a greater loading dose to achieve adequate circulating levels. 
 
Lower 25OHD in obesity was not due to lower dietary intake of vitamin D. High BMI has 
been linked to lower vitamin D intakes in younger and older adults (395, 608, 616). In 
older American adults, the major modifiable predictors of low vitamin D status were being 
obese, having a low dietary and supplementary vitamin D intake, and physical inactivity 
(617). However, there was no difference in dietary or supplementary vitamin D intake 
between a group of young women with 25OHD <90nmol/L and an average BMI of 28.6 
kg/m2 and a group with 25OHD >90nmol/L and an average BMI 26.0 kg/m2 (618). No 
difference in vitamin D intake was observed between obese and non-obese pre and 
postmenopausal women (596). The lack of difference in vitamin D intake was not due to 
obese adults consuming more vitamin D through consumption of more kcal, as obese 
people reported consuming the same amount of vitamin D per kcal of their total dietary 
intake as the normal weight group. As reported total kcal intake was not different between 
the groups, this may raise doubt over the validity of the reported kcal intakes and obese 
individuals may be more likely to under-report kcal intake. Overall vitamin D intakes were 
low; with the mean dietary vitamin D considerably below recommended intakes by the 
US Institute of Medicine (15µg per day) and Endocrine Society (37.5-50.0µg per day).  
 
The lower prevalence of supplementation in obesity may contribute to the lower 
circulating total and free 25OHD. 25OHD2 was detectable by LC-MS/MS in very few 
participants. Low rates of detection were also reported by Schwartz et al., who found a 
6% detection rate (560). Obese people were shown to take fewer dietary supplements 
in the NHANES study (2003-2006 data), with 48% of obese compared to 56% of those 
with a normal BMI taking supplements (619). Although this analysis excluded 
supplementary calcium and vitamin D, general supplementary habits may be 
generalizable to vitamin D supplementation. Others have also reported lower 
supplementation in those with high BMI, particularly in women (402, 608), although the 
present results indicate no gender difference in supplement intake. Older people take 
more supplements containing vitamin D than younger people, which was also found in 
the NHANES study (613, 619).  
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There was no difference in UVB exposure between obese and normal BMI groups. Skin 
synthesis of vitamin D in response to UVB exposure was found not to differ between 
normal BMI and obese adults (407) and therefore a lack of difference in exposure would 
be expected to result in a lack of difference in circulating vitamin D, which was not the 
case. Kull et al. reported that individuals with the greatest percentage body fat and those 
with a BMI greater than 30 kg/m2 were more likely to avoid sunbathing altogether, and 
there was a significant difference in the body fat percentage and BMI between those who 
exposed their arms and face and those who exposed their whole body when sunbathing 
(561). Hours of sunlight exposure were negatively correlated with BMI in 
postmenopausal women, but not significantly so (601). However, in a UK study, sunlight 
exposure was also found not to vary with BMI (620) and others report no difference in 
sun exposure between normal BMI and obese groups (602). Harris et al. found that while 
men were exposed to UVB for more hours per week than women, percentage FM and 
age were not significant predictors of hours of sun exposure and the percentage of skin 
exposed did not differ across quartiles of percentage FM (616). SPF use was no different 
between normal BMI and obese groups, similar to the findings of Harris and Dawson-
Hughes (616). UVB exposure may play more of a role in the relationship between obesity 
and vitamin D status in settings where UVB is more intense such as in Saudi Arabia 
(395).  
 
Obese people had lower albumin, and albumin was inversely associated with HsCRP. 
Therefore it is likely that the lower albumin was due to the greater inflammation observed 
in obesity as a result of greater SAT and VAT. Previous studies have identified links 
between low 25OHD and inflammation, with DBP being inversely associated with CRP 
and inflammation (564). Typically, lower albumin would be expected to result in a greater 
proportion of free 25OHD, and in a state where 25OHD is low, such as obesity, may be 
expected to normalise or increase free 25OHD. However, this was not the case and 
lower free fractions were observed in obesity. Lower free fractions may be better 
explained by DBP levels, than albumin. DBP bound fractions are stronger determinants 
of the biological effects of vitamin D metabolites than those which are albumin bound, 
due to the higher affinity of DBP to 25OHD and 1,25(OH)2D placing greater restriction 
on the ability of vitamin D metabolites to cross cell membranes, compared to the affinities 
for albumin.  
 
There was no difference in DBP between normal BMI and obese groups. Similarly there 
was no association between DBP and BMI (109, 550), FM (109) or percentage FM (109) 
in previous studies. However, positive associations between DBP, BMI and FM (567) 
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and negative associations between DBP and BMI (255) have also been reported. DBP 
was positively associated with total 25OHD in the present study. Positive association 
between DBP and total 25OHD was also reported by Bolland et al. in women, but not in 
men (109), while others have found no association between total 25OHD and DBP (550, 
567) and have argued that the lack of association between DBP and total 25OHD is 
somewhat similar to the lack of association between DBP and 25OHD observed in other 
conditions where vitamin D is low and yet DBP is not abnormal (621). DBP was positively 
associated with total 1,25(OH)2D in both the present study and previous work (567). As 
the major transporter of vitamin D metabolites in the circulation, DBP being inversely 
correlated with free 25OHD and 1,25(OH)2D was expected. Although DBP levels do not 
explain low total 25OHD in obesity, DBP may be a significant contributor to the low free 
25OHD and free 1,25(OH)2D in obesity as despite the positive correlations between total 
25OHD and DBP, DBP levels are not lower despite lower total 25OHD, resulting in a 
greater proportion of DBP to 25OHD and so a lower proportion of free 25OHD in obesity. 
Powe et al. proposed that 25OHD may regulate the production of DBP to regulate the 
free or bioavailable fraction of 25OHD when levels are low (255). The results of the 
present study do not appear to support this, as despite low 25OHD, DBP are ‘unchanged’ 
relative to those of normal BMI. 
 
The results suggest that the interaction between 25OHD and DBP in obesity is not 
affected by CK; with no difference in CK between normal BMI and obese groups and 
there was no association between total or free 25OHD or 1,25(OH)2D and CK. However, 
the interaction between 25OHD and DBP may be affected by lipids. While there was no 
difference in TC in obesity, HDL was lower and inversely associated with total and free 
25OHD and 1,25(OH)2D. Triglycerides were elevated in obesity and negatively 
associated with total and free 25OHD and 1,25(OH)2D, although after adjustment only 
the association between total 25OHD and triglycerides remained. A longitudinal study 
found incident vitamin D deficiency was predicted positively by triglycerides, although 
after adjustment for seasonality, gender, age, BMI, smoking and physical activity, this 
association was no longer significant (600). There was no association between TC, HDL, 
LDL or TC:HDL ratio and incident vitamin D deficiency (600). Recovery of vitamin D 
deficiency was negatively predicted by triglycerides and TC:HDL ratio (600). Annual 
change in 25OHD was associated with TC:HDL ratio in univariate analyses and positively 
associated with HDL and negatively with IL-6  and TC:HDL ratio after adjustment for 
baseline 25OHD, seasonality, gender, age, BMI, smoking, sun exposure and activity 
(600). Overall, it appears that a more inflammatory environment could reduce the 
availability of active vitamin D in obesity. 
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There was no effect of age on vitamin D binding proteins, as found by Bolland et al. 
(109). However whilst Bolland et al. reported higher DBP in women than men, this was 
not seen in the present study (109). 
 
The DBP genotype distribution in this study sample was similar to that previously 
described (622). Gc1s and Gc2 have been shown to be the most common alleles (622), 
and in this study the most common diplotype was Gc2-1s followed by Gc1s-1s, the same 
as reported by Lauridsen et al. (598). The most common genotype was Gc1-1 and the 
least common, Gc2-2 as previously reported (598, 622). There was no difference in 
genotype or diplotype between normal and obese groups. Lauridsen et al. found no 
difference in BMI by DBP genotype and no difference in skinfold thickness at various 
sites by genotype (598). These results suggest that DBP genotype is unlikely to explain 
low free 25OHD levels in obesity.  
 
DBP levels differed by DBP diplotype and genotype, with the highest concentration of 
DBP in the Gc1s-1s diplotype and the Gc1-1 genotype, as previously shown (598). 
Although Gc1f-1f was previously associated with the highest DBP concentration, there 
were very few participants with this diplotype in the study. The lowest DBP was seen in 
those with Gc2-1f diplotype and Gc2-2 genotype, as expected (598). 
 
While total 25OHD differed by diplotype and genotype, with higher 25OHD in those with 
the Gc1-1 genotype, free 25OHD did not differ by diplotype or genotype. This can be 
explained by Gc1-1 being associated with the highest total 25OHD but also with the 
highest DBP concentration and so there was no difference in free 25OHD by genotype. 
Despite this logical explanation, Lauridsen et al. found Gc1-1 to be associated with the 
highest total 25OHD but also with the highest free 25OHD, possibly attributed to 
differences in the proportion of 25OHD to DBP compared to the present work (598). In 
Belgian men no differences were reported in 25OHD by DBP genotype (567). 
  
It was hypothesised that higher affinity forms of DBP would result in lower circulating 
1,25(OH)2D. However, there was no difference in 1,25(OH)2D by DBP diplotype or 
genotype, although the low prevalence of Gc1f-1f, meant that the group with the highest 
affinity was underrepresented. Others have reported higher levels of total 1,25(OH)2D in 
those with the Gc1-1 genotype (567, 598) and Chun et al. have shown that “Gc1f-1f is 
better able to maintain serum levels of vitamin D metabolites as a consequence of more 
efficient retention of 25OHD3 and 1,25(OH)2D after megalin-mediated uptake of DBP by 
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kidney cells” (623). Although others found no difference in free 1,25(OH)2D by genotype 
(598), after adjustment, free 1,25(OH)2D differs by diplotype and genotype, explained by 
Gc1-1 having the highest total 1,25(OH)2D but concurrently the highest DBP and highest 
affinity constant, and so the lowest free 1,25(OH)2D, while the opposite was true for Gc2-
2. 
 
Differences in the association between free and total 25OHD and free and total 
1,25(OH)2D by diplotype and genotype illustrate the potential for more accurate 
assessment of true vitamin D sufficiency by acknowledging of the effect of DBP genotype 
on the free  fraction. Although reference ranges for free 25OHD sufficiency have not 
been proposed, more detailed assessment of 25OHD status would improve on current 
practice of determining sufficiency solely by measuring total 25OHD (622). Chun et al. 
have shown by mathematical modeling, that “an individual with 100 nM total 25D and 
Gc1f-1f DBP genotype would have less free 25D than an individual with 50 nM total 25D 
carrying either Gc1s-2 or Gc2-2 genotype” (624). Chun et al. showed that at a 25OHD 
of 50 nM, free 25OHD as a percentage of total 25OHD varied by DBP genotype from 
0.026 to 0.074%, which is somewhat considerable given the that free 25OHD typically 
accounts for 0.02 to 0.05% of total 25OHD (624). The same trend was observed for 
1,25(OH)2D, where at 100 pM, free 1,25(OH)2D constituted 0.4 to 1.3% of total 
1,25(OH)2D (624). As the association between total and free values differed increasingly 
by diplotype and genotype with increasing concentration of total 25OHD in the present 
study, characterising DBP traits may be particularly important for individuals with 
sufficient to replete total 25OHD but a Gc1s-1s or 1-1 genotype. 
 
DBP diplotype was associated with WB aBMD and estimated failure load at the tibia but 
not with other skeletal parameters. This is consistent with the findings of Taes et al. who 
showed no difference in BMD or BTMs by DBP diplotype or genotype in Belgian men 
(567), and with the findings of Lauridsen et al. who reported no difference in aBMD by 
DBP genotype at all sites measured (598). 
 
Overall, the results of this Chapter suggest that low 25OHD associated with high BMI is 
not due to associations with vitamin D binding proteins. As there was no difference in 
genotype or diplotype between normal and obese groups, DBP genotype is unlikely to 
explain low 25OHD in obesity.  
 
There was no difference in PTH between normal BMI and obese groups and there was 
no association between PTH and total or free 25OHD or 1,25(OH)2D. PTH is generally 
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positively associated with adiposity and inversely associated with 25OHD (395, 402, 441, 
555, 612, 625-627). Pitroda et al. and Cohen et al. reported no difference in PTH across 
tertiles of percentage body fat and trunk FM respectively, although despite trends 
towards low 25OHD with adiposity, these were not significant and so perhaps no 
difference in PTH would be expected as a consequence (273, 625). Other studies 
involving obese participants have reported lower 25OHD accompanied by higher PTH 
levels in those with the highest BMI (396, 402). Bell et al. and Bolland et al. have shown 
that PTH levels are associated with adiposity independently of 25OHD levels (626, 627) 
and the lack of association between PTH and total and free 1,25(OH)2D was also 
reported by Lauridsen et al. (598). Phosphate, a down-regulator of PTH independent of 
calcium, was lower in the obese group, and might contribute to there being no difference 
in PTH between the groups (625). 
 
Pitroda et al. suggested that the duration of adiposity may affect the relationship between 
25OHD and PTH, with chronic 25OHD deficiency contributing to enlargement of the 
parathyroid gland and greater PTH (625). Duration of adiposity has not been studied in 
the FAB cohort, but whether participants had remained at a constant weight, lost weight, 
gained weight or lost and gained weight in the year before recruitment was not 
associated with PTH. More detailed studies of weight history may provide an insight into 
possible causes of ‘normal’ PTH despite low 25OHD in obesity. 
 
The most notable consequence of low total and free 25OHD was low total 1,25(OH)2D, 
suggesting that the conversion of 25OHD to 1,25(OH)2D in obesity is substrate 
dependent, as suggested by Lagunova et al. who found total 25OHD was the strongest 
predictor of total 1,25(OH)2D levels in overweight and obese individuals (578). Inverse 
associations between 1,25(OH)2D and BMI (556, 558, 575-577, 602), WBFM (556) and 
SAT (549) have previously been reported, with lower 1,25(OH)2D reported in obese men 
and women than in non-obese participants (441, 611). In mice, leptin has been shown 
to reduce 1α-hydroxylase expression in the kidneys; lowering serum 1,25(OH)2D (600). 
Whether leptin plays a role in renal 1α-hydroxylase expression in obese humans is 
unclear, and warrants further research.  
 
In young adults, Bell et al. showed that while 25OHD was lower, urinary calcium was 
also lower and serum PTH and 1,25(OH)2D higher in obese than non-obese participants 
(626). Interestingly, Shapses et al. found that compared to women with a normal BMI, 
obese women had lower 25OHD and higher PTH, but there was no difference in 
1,25(OH)2D between the groups (596). By a radioisotope method they showed that the 
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obese women had a higher true fractional calcium absorption than non-obese women, 
positively associated with PTH but not with 25OHD or 1,25(OH)2D (596). Further 
conflicting results have been shown by Grethen at al. who found that compared to 
controls, obese people awaiting bariatric surgery had a 25OHD and serum calcium which 
was not different to that of the controls, but despite this, their PTH was higher and their 
1,25(OH)2D lower (441). However, the controls in this study consisted of six obese, four 
overweight and ten normal BMI individuals, not matched for height, and therefore it is 
perhaps unexpected that there was a difference in findings compared to the results of 
the present study.  
 
Although younger adults had lower total 25OHD than older adults, there was no 
difference in PTH by age group and 1,25(OH)2D was lower in younger people. This may 
reflect a lower rate of 1α-hydroxylation of 25OHD in younger people or simply the 
substrate dependent nature of the conversion of 25OHD to 1,25(OH)2D. 
 
It is clear that as previously indicated (626, 628), the vitamin D endocrine system and 
the vitamin D-PTH association in particular, is altered in obesity, however a lack of 
consistency in findings makes it difficult to confirm the way in which it is altered. Studies 
sampling serum across seasons, involving multiple ethnicities and not controlling for 
stature with regard to volumetric dilution, may contribute to this lack of consistency in 
reported findings.  
 
Participants with hyperparathyroidism were excluded from the FAB study due to the 
skeletal effects of high PTH potentially confounding the effect of adiposity on bone. 
Whether excluding these individuals explains why others report differences between 
normal BMI and obese groups which were not observed in this work is unclear, but this 
would not explain why lower 25OHD fails to drive higher PTH in the obese group in this 
study. Although 1,25(OH)2D acts in a negative feedback mechanism to limit production 
of 25OHD from vitamin D, low 1,25(OH)2D in obesity suggests that low 25OHD is not 
due to lower hepatic 25-hydroxylation of vitamin D inhibited by elevated levels of 
1,25(OH)2D and PTH as previously described (626, 629).  
 
Lower free 1,25(OH)2D in obesity may be a consequence of lower 1,25(OH)2D combined 
with no difference in DBP in obese people. 
 
The results of this Chapter showed no difference in CTX (after adjustment) or PINP in 
obesity, although osteocalcin was lower in the obese group compared to the normal 
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weight group. Typically, high PTH as a result of vitamin D deficiency leads to greater 
bone turnover and bone loss and this pathway has been observed in obesity previously 
(395, 396). The results of this Chapter conflict with the findings presented in Chapter 4, 
and those of another study (358), both of which showed lower bone turnover in obesity. 
It is most likely that no differences in BTMs were observed in the obese group compared 
to the normal BMI group because in this smaller, unpaired sample, PTH was not different 
between the groups and therefore failed to drive higher bone turnover. The finding that 
younger adults had higher CTX than older adults might be explained by bone turnover 
being higher in early adulthood due to the period of consolidation, despite bone turnover 
typically increasing with age. As there was no difference in CTX by age group in the main 
study (Chapter 4), this difference may be an effect of the smaller sample size and lack 
of pairing in the vitamin D sub-study analysis. 
 
When the results of this Chapter and those of Chapter 3 are considered together, there 
appear to be no adverse skeletal consequences of low 25OHD in obesity, with greater 
BMD, favourable bone microstructure and greater bone strength in obese individuals 
compared to those with a normal BMI.  
 
Although 1,25(OH)2D has a direct positive effect on calcium absorption, low 1,25(OH)2D 
in obesity does not seem to be restricting calcium absorption to a detrimental effect on 
the skeleton (596). Others have reported no association between 1,25(OH)2D and BMD 
(255). 
 
After adjustment for potential confounders, total 25OHD was not a significant predictor 
of BMD. These results are supported by other studies which have shown associations 
between adiposity, particularly SAT, and 25OHD but no effect of 25OHD on BMD at peak 
bone mass (110), in obese premenopausal women (269) or in postmenopausal women 
(630). Similarly, Lenders et al. showed that obese adolescents maintained a normal BMD 
despite having low 25OHD, although in this study, PTH decreased with increasing VAT 
(631). Irrespective of adiposity, Arabi et al. found that after adjustment for age, height, 
LM, and PTH, there was no effect of total 25OHD on BMD, with the exception of the 
trochanter in men and suggested that the negative effects of low vitamin D on BMD in 
the general elderly population are mediated through PTH levels and LM and not through 
independent effects of 25OHD (632). In a longitudinal study, Arabi et al. reported no 
correlation between mean total 25OHD and change in BMD except at the trochanter 
(r = 0.19, p < 0.01) from baseline to follow up at four years, while mean PTH was 
negatively correlated with change in BMD after adjustment, indicating that PTH, and not 
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25OHD, predicted bone loss (633). The lack of association between low 25OHD and 
skeletal parameters in obesity suggests that supplementation of vitamin D for skeletal 
benefit may not be necessary in those with a high BMI. 
 
SPPB score was not associated with measures of 25OHD and although SPPB score 
was positively associated with free 1,25(OH)2D, inclusion of 1,25(OH)2D did not improve 
the model for predicting SPPB. Therefore low 25OHD does not appear to explain poor 
physical function in obesity. While some have reported associations between 25OHD 
and physical performance (583, 584, 589, 634-636), others have reported similar findings 
to the current work, with no association between low 25OHD and physical function (586, 
587, 637). Kwon et al. reported that concomitant lower albumin and 25OHD were 
associated with lower muscle strength and poorer balance (638), supporting the findings 
of the present study. Low vitamin D status in obesity may not be associated with falls. 
Greater risk of some fractures in obesity, possibly associated with poor physical function, 
greater prevalence of falls and/or differences in fall kinetics may be better explained by 
factors other than low 25OHD, such as altered foot structure and centre of mass, as 
proposed in Chapter 5. 
 
Despite evidence to support vitamin D supplementation in fall prevention; this may not 
be beneficial in obesity. Bischoff-Ferrari et al. found that if supplementation did not raise 
25OHD to at least 60nmol/L, there may be no reduction in falls risk (594), and given the 
evidence that supplementation response is blunted in obesity, this may further 
demonstrate that there is little benefit of supplementation with vitamin D in obesity for 
the prevention of falls.  
 
The strengths of this work include the two short (one month) recruitment windows which 
enabled measurement of vitamin D to be controlled for seasonal variation. All blood 
sampling was performed between 08:00 and 10:00, reducing the confounding effects of 
diurnal variation, particularly on 1,25(OH)2D and DBP which has been ignored by others 
(550). Although matched pairing was not applied to the analysis for this Chapter to 
increase sample size, all participants were sampled from those originally recruited to the 
FAB study which prospectively recruited individually-matched pairs. Therefore, even 
though it cannot be said that participants were matched in this analysis, age and height 
were similar between groups. Having also controlled for socioeconomic status through 
postcode matching within the original sample, differences in diet, supplement use and 
sun exposure habits were less likely to be attributed to differences in socioeconomic 
status and more likely reflections of adiposity related traits. Individuals who used of 
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hormonal contraceptives in the year prior to recruitment to the FAB study or prior to the 
vitamin D visit were excluded. As DBP is higher in those using hormonal contraceptives, 
this strengthens the analysis of the role of DBP in the relationship between adiposity and 
vitamin D in young women (639). 
 
Having two methods to determine free 25OHD increased confidence in the free 25OHD 
observations. Although the measured free 25OHD was consistently lower than that of 
the calculated method, this is most likely due to calculated free 25OHD being subject to 
assay variation in total 25OHD, DBP and albumin due to the calculation by which it is 
determined. The relationship between measured and calculated free 25OHD was very 
recently described by Schwartz et al. in a group of healthy individuals and others with 
conditions known to affect albumin and DBP concentrations (560). The authors reported 
that calculated free 25OHD was overestimated compared to measured free 25OHD, as 
found in the present study, and that this could be due to error from assuming a single 
affinity constant for DBP, based on knowledge that different DBP diplotypes have 
different affinities for 25OHD (560). Schwartz et al. concluded that the use of measured 
free 25OHD was favourable over calculated methods but as the majority of the current 
literature presents calculated free 25OHD, performing both analyses provided data for 
meaningful comparison with previous findings (560). Using LC-MS/MS to determine 
25OHD2 and 25OHD3 provides a more comprehensive assessment of total 25OHD than 
traditional assay methods where the fractional components of total 25OHD may not be 
distinguished.  
 
A strength, but also a limitation, of this work is that only Caucasian individuals were 
studied. There are differences in body fat distribution and there may be differences in 
the strength of the relationship between 25OHD and obesity in different ethnicities (549, 
550, 556, 577, 640). As a result, the findings of this Chapter may not be generalisable to 
the entire population or to alternate ethnic groups.  
 
Polysulfone badges may have provided a more accurate quantification of UVB exposure 
than the questionnaire method used in this study, however the study timeframe did not 
allow for this.  
 
There are several alternative hypotheses which have been proposed to explain low 
25OHD in obesity which have not been addressed by the work in this Chapter and which 
warrant further investigation. Firstly, hepatic synthesis of 25OHD may occur at a lower 
rate in obesity, possibly contributed to by a higher prevalence of non-alcoholic fatty liver 
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disease in obesity, which is associated with lower 25OHD (628). No indicator of liver 
function was measured and so this could not be investigated as a potential mechanism.  
 
HOMA-IR was greater in the obese group, and insulin resistance may down-regulate the 
expression of 25-hydroxylase in the liver, reducing 25OHD formation (600). However, 
without measures of 25-hydroxylase (or 1α-hydroxylase) expression it was not possibly 
to investigate this further. 
 
 In obese women, fat tissue itself has been shown to have altered expression of enzymes 
for both the formation and catabolism of 25OHD and 1,25(OH)2D compared to non-obese 
women (539). Lower expression of the 25-hydroxylase CYP2J2 in the SAT of obese 
women may indicate less 25-hydroxylation, while decreased expression of the 1α-
hydroxylase CYP27B1 in SAT these women might suggest lower conversion of 25OHD 
to 1,25(OH)2D, potentially contributing to lower circulating 25OHD and 1,25(OH)2D levels 
in obesity (539). Although there were no differences in CYP24A1 in adipose tissue 
between the normal BMI and obese women, if greater FM was taken into account, it may 
be that obese people do degrade more vitamin D within fat tissue, further supporting a 
role for altered enzymatic expression in adipose tissue in contributing to lower 25OHD 
and 1,25(OH)2D levels in obesity (539). 
 
The type of fat consumed in the diet may affect the serum 25OHD response to 25OHD3 
supplementation; with monounsaturated fatty acids raising and polyunsaturated fats 
lowering the effect of supplementation on serum levels (641). Fatty acid consumption 
was not investigated in this study but may be an important factor in understanding the 
blunted 25OHD response to supplementation in obesity. 
 
Production of 1,25(OH)2D is inhibited by calcium, phosphate, and FGF-23 (441). FGF-
23 was not measured in the present study. As FGF-23 is positively associated with FM 
(642) it may contribute to lower 1,25(OH)2D in obesity. 
 
Although DBP diplotypes vary in their affinities for 25OHD and 1,25(OH)2D, such 
variations in affinity were not taken into account when calculating an individual’s free 
25OHD or free 1,25(OH)2D. Assuming a constant affinity of DBP for 25OHD or 
1,25(OH)2D may result in a degree of inaccuracy in the analysis of the relationship 
between free metabolites and DBP diplotype. 
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Analysing the effect of variation in the DBP gene by grouping DBP diplotypes into 
genotypes was advantageous for simplifying the analysis. However, merging Gc1f-1f, 
Gc1f-1s and Gc1s-1s to Gc1-1 effectively results in the analysis of the effect of the 
rs4588 SNP alone, as Gc1-1 always has threonine at the 436 position and Gc2-2 always 
has lysine at the 436 position (643). For example, comparing Gc1-1, with Gc1-2 and 
Gc2-2 is actually comparing ttcc, gtcc and ggcc (GC1-1) with ttca and gtca (Gc1-2) with 
ttaa (Gc2-2); the T436K change is that governing any effect. There may be greater value 
in studying DBP diplotype, over genotype.  
 
Aside from the skeletal effects of vitamin D, vitamin D has also been shown to have 
effects on glucose metabolism, immune function, the risk of some cancers, cognitive 
function, CVD and mortality (644). Whether low 25OHD in obesity has consequences for 
any of these non-skeletal effects is unknown and warrants further research. 
 
In conclusion, this Chapter provides novel evidence that both total and free 25OHD are 
lower in obese adults compared to adults with a normal BMI. This is most likely due to 
volumetric dilution or greater pool size and is not due to differences in dietary vitamin D 
intake or UVB exposure, although supplementary D intakes are lower in obesity. 
Concentrations of the vitamin D binding proteins DBP and albumin, may contribute to 
the lower free 25OHD and 1,25(OH)2D seen in obesity. PTH does not appear to mediate 
the effect of 25OHD on BMD. DBP genotype may play an important role in the 
association between total and free vitamin D fractions, but is not a determinant of low 
25OHD in obesity. There do not appear to be any skeletal consequences of low 25OHD 
in obesity and low 25OHD does not seem to be a mediator of the negative effect of 
obesity on physical performance. Obese people will need higher loading doses of vitamin 
D to achieve the same circulating levels as individuals with a normal BMI, but it is not 
clear that there would be musculoskeletal benefits to achieving the same circulating 
25OHD level as individuals with a normal BMI. 
  
 238 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7: 
 
DISCUSSION   
 239 
CHAPTER 7: Discussion 
Main Findings 
I sought to better understand in this thesis why obese people are protected against some 
fractures but at greater risk of fracture at other sites and identify potential drivers of the 
site-specific differences in fracture risk observed in obesity. Obese adults have greater 
bone density than normal BMI individuals at all sites measured. Greater bone density is 
due to greater trabecular density; due to greater trabecular number and lower trabecular 
spacing, with no difference in trabecular thickness. Older obese adults also have greater 
cortical density, due to greater tissue mineral density, and lower cortical porosity at the 
tibia. Younger and older obese adults have greater Ct.Th at the tibia, and Ct.Th is also 
greater at the radius in older obese adults. There is no difference in bone size between 
obese and normal BMI individuals. 
 
There was a greater effect of obesity on bone density and bone microstructural 
parameters in older adults than younger adults. Whilst patterns of bone microarchitecture 
were consistent between the distal radius and distal tibia in the older adults, younger 
adults appeared to exhibit less significant effects of obesity at the radius compared to 
the tibia. Despite this, bone strength is greater at both the radius and tibia in both younger 
and older obese adults. In older adults, the magnitude of the difference between normal 
BMI and obese individuals was similar at the distal radius and distal tibia suggesting the 
effect of obesity is not mediated by greater mechanical loading. Despite greater BMD 
and favourable bone microarchitecture, the effect of obesity on BMD and bone 
microarchitectural parameters and bone strength is not commensurate to greater body 
weight in obesity. However, assuming a linear relationship between body weight and 
bone microstructural response may be inappropriate. The greater effect of obesity on 
bone density and structural parameters in older adults suggests that the predominant 
effect of obesity is to reduce bone loss.  
 
Reduced bone loss may be a consequence of lower bone turnover, shown by lower bone 
resorption and lower bone formation. Coupling index is not affected by obesity in young 
adults, but the positive coupling index in older obese adults may contribute to the greater 
effect of obesity on BMD and microstructure in this age group. Lower bone resorption in 
obesity was associated with greater adiposity and not with greater lean mass. While all 
adipose depots were positively associated with bone density and favourably with bone 
microstructural outcomes, subcutaneous abdominal adiposity appeared to exert the 
greatest protective effect against bone resorption. 
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The association between subcutaneous abdominal adipose tissue and bone resorption 
was accounted for by circulating leptin levels. It might be that leptin lowers bone 
resorption by increasing OPG, preventing the binding of RANKL with RANK and thus 
inhibiting osteoclastogenesis, although there was no difference in OPG between obese 
and normal BMI adults. There may also be positive effects of leptin on 
osteoblastogenesis. Higher circulating leptin and the greater effect of adiposity on leptin 
in older adults than young adults may contribute to the greater effect of obesity on bone 
density and microarchitectural parameters in older adults. E2 also appears to exert a 
protective effect against bone resorption, independent of the effect of leptin. There was 
no effect of insulin, IGF-I, glucose or adiponectin on bone resorption. 
 
Older obese adults fell more frequently in the six months prior to recruitment than the 
older adults with a normal BMI. It has been shown that despite having greater lean mass, 
there is no differenece in muscle strength between normal BMI and obese adults and 
physical performance is impaired in obese individuals. Thus, obese individuals may be 
better classfied as dynapenic than sarcopenic. Poor physical perfomance in obesity may 
be partly mediated by higher HsCRP which is associated with slower gait.  
 
Obese adults have low total 25OHD. There is no difference in DBP between obese and 
normal BMI adults, but obese adults have lower albumin, a likely result of greater 
inflammation. Despite this, free 25OHD is lower in obesity. There is no difference in 
dietary vitamin D intake or sun exposure habits between obese and normal BMI groups, 
suggesting that the primary cause of low 25OHD in obesity is greater volumetric dilution. 
Obese adults take fewer vitamin D containing supplements than those with a normal BMI 
which may also contribute to low 25OHD levels. The consequences of low circulating 
25OHD in obesity were primarily low total and free 1,25(OH)2D, associated with higher 
PTH than normal BMI individuals.  
 
Despite low 25OHD associated with high PTH, there do not appear to be adverse 
skeletal consequences of low 25OHD in obesity; with low 25OHD associated with lower 
bone turnover, greater BMD, favourable microarchitecture and greater bone strength. 
Low total and free 25OHD are not associated with physical performance. Although low 
total and free 1,25(OH)2D were associated with poorer SPPB score, inclusion of total 
and free 1,25(OH)2D did not improve the prediction of SPPB score. 
 
Poor physical performance despite greater muscle mass (dynapenia) in obesity may 
predispose older obese adults to falls. Lower risk of hip and vertebral fracture in obesity 
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might be partly attributable to greater bone density, favourable cortical and trabecular 
microarchitecture and greater bone strength. Greater soft tissue thickness may also 
afford protection at central sites. The greater risk of ankle and proximal humerus fracture 
in obesity, despite greater bone density, favourable microarchitecture and greater bone 
strength at all sites measured, may be attributable to the effects of poor physical function 
on fall frequency and diferences in fall kinetics in obese individuals. There may be less 
protection afforded by greater soft tissue thickness at these sites in obesity. Low vitamin 
D does not appear to adversely affect skeletal metabolism or physical function in obesity. 
 
These findings suggest that the most appropriate direction for fracture prevention to take 
in obesity might be to develop improved fall prevention strategies which recognise 
impaired physical performance in obese individuals. Although bone strength in obesity 
is not commenurate to greater body weight when investigated in a linear fashion, it is 
likely that bone is sufficiently adapted to habitual loading forces in those with high BMI. 
To further reduce the risk of fracture attributable to skeletal determinants, obese 
individuals may need to achieve a phenotype which is sufficiently adapted to fall forces 
rather than habitual loading forces, which is likely to be unattainable and would not be 
maintainable physiologically. Vitamin D supplementation may be unlikely to benefit the 
musculoskeletal system in obesity. 
 
How the Study was Unique 
This is the first study to investigate associations between obesity and vBMD and bone 
microarchitecture in both younger and older, men and women against a matched control 
group of non-obese individuals. Since this study began, others have studied the effects 
of obesity on vBMD and microarchitecture in specific groups of younger obese women 
(269), younger obese men (268), younger and older obese and non-obese women 
matched on age (261) and younger and older men and women who were not specifically 
obese or non-obese (267). By studying younger and older adults it has been possible to 
identify potential differences in the relationship between obesity and bone metabolism in 
younger and older adults, and allude to the possible mechanisms by which obesity may 
exert protective effects on the skeleton. 
 
This study has investigated a range of possible mechanisms by which obesity may affect 
bone density and microstructure, including the role of various body fat compartments 
determined by imaging and anthropometry, associations with bone turnover and 
biochemical factors.  
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This is the first study to investigate differences in SPPB score in an obese group against 
a group of individually matched non-obese controls. Others have investigated the effect 
of adiposity by BMI on physical performance (472, 645). However, the design of the FAB 
study ensured a good representation of obese individuals, a group which can be 
underrepresented in population based studies. Having matched normal BMI and obese 
adults by height and age was a further strength. Controlling for such factors is important 
to be able to draw conclusions regarding the effect of adiposity on physical performance 
outcomes.  
 
25OHD3 by LC-MS/MS has not previously been determined in an obese population. This 
study is the first to investigate the free fraction of 25OHD in obese individuals compared 
to matched normal BMI controls. Determining the free fraction of 25OHD provides a 
better understanding of the biological availability of 25OHD and may be considered more 
physiologically relevant than total 25OHD. This was also the first study to measure free 
25OHD, rather than use calculated free 25OHD in relation to BMI. Measuring free 
25OHD is advantageous, as calculating free 25OHD may incur measurement error from 
the total 25OHD, albumin and DBP assays and makes assumptions about the binding 
affinities of these proteins for 25OHD which may be inaccurate. This combined error 
most likely explains the difference observed in free 25OHD determined by measured and 
calculated free 25OHD methods. This is the first study to investigate free 1,25(OH)2D 
levels in obesity. 
 
Future Work 
Further research is required to confirm the mechanisms by which obesity is protective 
against hip and vertebral fracture. Following the identification of leptin as a potential 
mechanism by which subcutaneous abdominal fat might affect bone resorption and 
ultimately bone density and microstructure, an interventional study of weight change 
would be valuable to investigate how changes in the subcutaneous fat compartment 
affect leptin expression and concentration, bone resorption and bone microarchitecture. 
Others have shown that bariatric surgery induced weight loss leads to cortical bone loss 
(47), decreases in adipocyte size (646) and changes leptin expression which are 
associated with bone resorption (434), but which may be disproportionate to the loss of 
fat mass, possibly linked to a nonlinear relationship between adipocyte volume and leptin 
expression (647, 648). A single study linking weight loss, body composition analysis, 
bone microarchitecture, bone turnover, leptin and E2 levels may help to confirm whether 
the mechanisms identified in this work are indeed causal mechanisms by which obesity 
affects bone metabolism. Future research may involve the study of leptin administration 
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to prevent weight loss induced bone resorption which may drive cortical bone loss. 
Although an initial study has shown this may not be successful, further research is 
warranted (649). 
 
Further studies are needed to understand how locomotor characteristics, plantar 
pressures, static postural stability and dynamic balance in obesity influence gait and fall 
kinematics in obese adults. Better understanding of fall kinematics and kinetics in obesity 
are needed to improve current FE models by developing more realistic models based on 
true fall patterns in obesity. This could help to better explain the site-specific fracture risk 
in obesity. The building of more sophisticated FE models from which bone strength can 
be estimated and fracture risk predicted is an area which warrants further research. Such 
models would be particularly useful for predicting ankle fractures, where fractures most 
commonly occur as a result of torsion rather than a vertical compression which is the 
action simulated by current FE models. Generating FE models which do not assume 
uniformity of bone is likely to be more complex but would also be beneficial for accurate 
fracture prediction. Others have begun to developing FE models which take into account 
soft tissue padding at sites of impact (274). Standing hip width at the level of the greater 
trochanter has been measured in all participants in the FAB study to determine soft tissue 
thickness at the hip and will be incorporated into in-house FE models to provide a more 
realistic estimate of fracture risk than is achievable using present models. 
 
More research is required to characterise the role of ligament ossification and muscle-
tendon unit stiffness in ankle fracture in obesity. Understanding the role of ligaments and 
tendons in physical performance and associations with falls may facilitate such 
properties to be incorporated into finite element models. Again, this would be particularly 
beneficial for FE models of the ankle. 
 
Muscle fat infiltration will be studied in this study population to try to better understand 
why physical performance and muscle function are lower in obesity despite greater 
muscle mass. Further research is needed to clarify the role of brown fat and bone marrow 
fat compartments in obese adults compared to normal BMI populations. 
 
Whether weight history, or duration of obesity, affects associations between obesity and 
bone density, structure and strength is unclear and warrants further research.  
 
Further research is required to quantify 24,25(OH)2D in obese adults compared to those 
with a normal BMI to determine associations between obesity and the catabolism of 
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1,25(OH)2D. Further research to investigate whether leptin affects renal 1α-hydroxylase 
expression in humans, as has been shown in mice, is warranted to better understand 
the causes of low 1,25(OH)2D in obesity. 
 
Limitations 
The main limitation of this work is the cross-sectional, observational study design. 
Differences observed between obese and normal BMI individuals are associated with 
obesity rather than caused by obesity.  
 
The smaller sample of young adults compared to that of older adults was a result of 
difficulty in recruiting eligible adults from this age group. Employment, use of hormonal 
contraceptives, childcare commitments and lower levels of health engagement were the 
key factors for lower recruitment rates in this group. Most recruitment of older adults was 
done through GP practices, with small catchment areas. As a result, highly selective 
matching based on postcode could be employed for older adult pairs. However, young 
adults were typically university and hospital staff and visitors, often living within a large 
radius. This made postcode matching of younger adults difficult. Alternative methods of 
adjusting for socioeconomic status may have been better suited to the young adult group. 
 
Although visits 1 and 2 were completed within 28 days, it is acknowledged that serum 
samples were not collected at the same time point as bone imaging. However, most 
participants attended for visit 2 within 1 to 2 weeks of their first visit and it is unlikely that 
a 28 day interval would lead to discrepancies in measurements. Biochemical data from 
the vitamin D sub-study were related to imaging data taken up to 2 years prior. It was 
not possible to repeat imaging due to radiation constraints. 
 
I was unable to analyse the hip QCT scans due to difficulties in trimming soft tissue from 
the image prior to quantification of the bone. This meant reliance on hip aBMD which 
may be affected by greater soft tissue thickness, rather than vBMD, and the inability to 
determine bone microstructural properties at the hip. 
 
Assessments of physical performance in this study were chosen as they as are 
established components of a previously determined physical performance battery. More 
sophisticated motion analysis techniques might have enabled a more detailed 
understanding of movement patterns in obese individuals and may help to better 
understand fall patterns in obesity. Motion capture can be troublesome in obese 
individuals due to cutaneous marker error from soft tissue movement. Some simple 
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exercises might have given further insights into physical performance in obesity in 
relation to falls; testing reaction times and postural sway for example. Incorporating a 
measure of lower body strength may have been valuable in the context of falls during 
habitual activity.  
 
Fall history was only collected for the six months prior to the first study visit. One year 
fall history might have given more generalisable data, although there are limitations 
associated with participant recall over longer periods. None of the participants had 
fractured in the year before recruitment and so none of the falls reported in the six months 
prior to recruitment resulted in fracture. Excluding individuals with fracture may have 
limited the findings to an extent, as obese individuals who experience more falls but are 
seemingly protected against fracture at most sites were eligible, while normal BMI 
individuals at greater risk of fracture at most sites may have been more frequently 
excluded. To have determined fracture site, fracture cause and perceived fall direction 
of those who were ineligible due to prior fracture might be have been interesting. 
 
Due to the large number of participants to recruit to the vitamin D sub-study and 
requirement for serum sampling to be done in the fasted state with control for circadian 
variation, the sub-study had to be run over two roughly one-month periods either side of 
the winter. As recruitment to the main study was more rapid in the older group, the 
majority of the participants entering the first vitamin D sub-study period were in the older 
age group. Weekly sunlight hours were shown to be similar during the two study periods 
(Appendix 3). The assessment of sun exposure did not take into account sun exposure 
received from holidays abroad due to difficulties quantifying the UVB exposure 
accurately especially with respect to SPF habits.  
 
The free 25OHD assay used has not been widely validated to date. However the results 
were comparable to those attained using the calculated method and the discrepancy 
between measured and calculated free 25OHD was similar to that reported by others 
(560). 
 
There may be alternative causes of low 25OHD in obesity which were not investigated, 
such as faster metabolic clearance of 25OHD, altered enzymatic activity, or decreased 
hepatic 25-hydroxylation (626). Shorter 25OHD half-life in obesity could explain lower 
circulating 25OHD. However, lower 1,25(OH)2D in obesity, despite higher PTH, might 
suggest that the metabolic clearance of 25OHD is not increased.  
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The findings of this work may not be applicable to children, peri-menopausal or 
menopausal women, or to elderly adults. 
 
Conclusion 
Obese adults have a lower risk of hip and vertebral fracture which might be explained by 
greater aBMD, vBMD, favourable bone microarchitecture and greater bone strength at 
these sites. Greater BMD and bone microarchitecture appear to be a consequence of 
lower bone resorption, mediated by the effects of leptin and oestrogen on bone 
resorption. The greater risk of ankle and proximal humerus fracture in obesity might be 
explained by poor physical function in obesity despite greater LM compared to individuals 
with a normal BMI. Poor physical function may contribute to greater fall frequency and 
affect fall kinematics in obese individuals which may predispose to a greater risk of 
fracture, despite greater BMD, favourable bone microarchitecture and greater bone 
strength at all sites measured. Low 25OHD due to greater volumetric dilution in obesity 
and lower supplementary vitamin D intake does not appear to exert negative 
consequences on bone density, structure and strength, nor does it affect physical 
function.  
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Appendix 
1) Sunlight Questionnaire 
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2) Quantification of UVB Exposure: the Rule of Nines 
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3) Sunlight Hours 
 
Average number of hours of intense sunlight (irradiance measurement >120 w/m2) in 
Sheffield over the duration of the vitamin D sub-study visits.  
 
Data kindly provided by Weston Park Weather Station, Sheffield.  
  
Week beginning Mean daily hours of sunlight 
17/09/12 3.9 
24/09/12 2.7 
01/10/12 5.3 
08/10/12 3.7 
15/10/12 5.4 
22/10/12 1.1 
01/04/13 5.7 
08/04/13 1.9 
15/04/13 6.6 
22/04/13 4.9 
29/04/13 7.2 
06/05/13 6.1 
13/05/13 5.7 
Total 4.6 
 
